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Abstract  
Rifampicin-resistant TB in Botswana: barriers and risk factors influencing patient outcomes, case detection, 
and linkage to effective care and treatment 
Background: Botswana reports high treatment success for rifampicin-resistant tuberculosis (RR-TB), but many 
challenges remain. Case detection is lower than expected and varies by year, and mortality rates are high. 
Research aims included identifying: factors associated with mortality, access to culture and drug susceptibility 
testing (DST) for patients at risk of RR-TB, access to first- and second-line DST among RR-TB patients, time to RR-
TB treatment, and patient and provider experiences with RR-TB management.  
Methods: Retrospective data (multiple cohorts across 2006-2014) were extracted from Botswana national 
registers and information systems, with additional data collected by standardized, qualitative interviews (2017). 
Data analyses (Cox proportional hazards regression, survival and hazards curves, logistic regression) were 
conducted to describe significant associations. A systematic review and meta-analysis was conducted. Thematic 
analysis was performed for qualitative research.  
Results: There was low access (42%) to culture testing among patients at risk of RR-TB (previously-treated TB 
patients); particularly associated with rural residence and having previous successful TB treatment, compared to 
previous treatment failure. While confirmation of first-line drug resistance was available for 85% of patients 
initiating RR-TB treatment, access to second-line DST was poor (24%), impacted by limited in-country laboratory 
capacity.  
Genotypic DST by Xpert MTB/RIF at peripheral laboratories was associated with faster time to treatment from 
diagnosis compared to phenotypic DST at the centralized national lab, 5 versus 22 days (median, p<0.001), 
consistent with systematic review findings of time to RR-TB treatment.  
Risk factors for mortality during treatment included unconfirmed RR-TB (aHR 2.9), Pre/XDR-TB (aHR 2.5), HIV 
positivity without ART (aHR 3.6) and receiving treatment at two (of five) specific facilities (aHR 2.6 and 2.3).  
Qualitative interviews confirmed inconsistent adherence to national policies and identified additional challenges 
including frequent medication and reagent stock-outs, misperceptions about disease transmission from both 
providers and patients, and inadequate national level support for the RR-TB program.  
Conclusion: Several clinical and demographic factors negatively influencing case detection and RR-TB mortality 
in Botswana were identified. General health system dysfunction and poor political commitment to the RR-TB 
program also contributed. Recommendations include increased focus on: early diagnosis through universal DST, 
consistent access to effective drugs, and overall adherence to policies.  
4 
 
Conference Proceedings 
2015 The Union World Conference on Lung Health, Cape Town International Convention Center, Cape Town,  
South Africa. 
Poster: Evaluation of the use of Xpert®MTB/RIF to Diagnose and Treat MDR-TB under Routine Program 
Conditions in Botswana 
2016 The Union World Conference on Lung Health, Arena and Convention Center, Liverpool, United Kingdom. 
 Oral Presentation: Evaluation of Access to DST for Previously Treated Patients in Botswana 
2018 The Union World Conference on Lung Health, The World Forum, The Hague, The Netherlands. 
 Poster: Increased mortality during rifampicin-resistant TB treatment associated with inadequate  
laboratory testing 
  
5 
 
Acknowledgements  
Many people supported me in this work, and I am grateful. First, I would like to thank the people of Botswana 
making me feel at home for the 7 years that I lived and worked there. Living in the relatively small and sparsely 
populated country of Botswana was very different from life in my home country of the United States; however, 
Botswana became my home and a place that I feel strong loyalty to and love for due to the amazing people that 
I met there. I was motivated by the compassion and fun loving nature of my Batswana friends and colleagues.  
Many thanks to my UCT supervisor, Helen Cox, who provided patient and thoughtful guidance and support 
throughout the PhD process, from development of the research proposal and data collection tools to many 
reviews of the thesis drafts. Her experience, knowledge and passion about TB and the people affected by TB 
were very influential in my approach to this research.  
Dr. Chawanga Modongo was my main counterpart in Botswana and is the leading expert on drug-resistant TB in 
the country. I feel very honored to have worked with her and am grateful for all of the advice and support she 
provided me along the way. Dr. Modongo loves her country of Botswana, and her dedication and love of people 
affected by drug-resistant TB gave me hope when dealing with some harsh realities of this research.  
I would like to thank my colleagues at the Botswana Ministry of Health and Wellness and especially Dr. Botshello 
Kgwaadira who was the program manager of the Botswana National TB Program during the time of my research. 
He was very involved in and excited about this research and was always very interested in hearing about results. 
I’m very thankful for his support and trust in accessing health facilities, patients and data.  
Several colleagues at CDC Botswana were supporting and mentoring throughout the process. I am grateful to 
them for teaching me about the country and the health system and for sharing their expertise about TB in the 
country. I’d especially like to thank Unami Mathebula, a senior study coordinator, who provided valuable input 
while I was planning my research, and she also served as an interpreter during qualitative interviews. I would 
also like to thank Motlalepula Letsholathebe who assisted with translating and transcribing qualitative 
interviews. I am also very grateful to my employers at CDC Atlanta who were supportive of my PhD studies and 
provided helpful guidance and support throughout the process.  
I want to thank my family and friends who believed in me and gave me encouragement along the way. Thank 
you for the motivation and for giving me an outlet to unwind and refresh my brain when needed. Thanks to my 
niece and nephew for being part of this journey, giving me encouragement, the right amount of distraction 
when needed and excitement about the celebration which will come when this is finished. A very special thank 
you to my parents for letting me hide out in their house away from all other distractions in the last weeks of 
6 
 
writing this thesis. I’m thankful for the example they are in my life, their unconditional love, their interest in my 
research and the bottomless cup of coffee that kept appearing on the desk where I worked.  
This thesis is dedicated to my parents, Jim and Carol Boyd.   
7 
 
Table of Contents 
List of tables and figures ......................................................................................................................................... 10 
List of abbreviations ............................................................................................................................................... 12 
Chapter 1: Introduction .......................................................................................................................................... 14 
1.1 Chapter overview .......................................................................................................................................... 14 
1.2 Rationale and context ................................................................................................................................... 14 
1.3 Key definitions .............................................................................................................................................. 14 
1.4 Hypotheses, aims and objectives ................................................................................................................. 15 
1.4.1 Overall research hypothesis ................................................................................................................... 15 
1.4.2 Specific hypotheses, aims and objectives .............................................................................................. 15 
Chapter 2: Background and literature review ....................................................................................................... 17 
2.1 Chapter overview .......................................................................................................................................... 17 
2.2 Botswana – general statistics and description of health system ................................................................ 17 
2.2.1 Botswana general statistics .................................................................................................................... 17 
2.2.2 Botswana health system......................................................................................................................... 18 
2.3 TB and RR-TB globally and in Botswana ...................................................................................................... 20 
2.3.1 TB Epidemiology ..................................................................................................................................... 20 
2.3.2 RR-TB epidemiology ............................................................................................................................... 21 
2.3.3 TB and RR-TB diagnosis .......................................................................................................................... 22 
2.3.4 TB and RR-TB treatment ......................................................................................................................... 26 
2.3.5 Barriers to TB and RR-TB diagnosis and accessing treatment ................................................................ 27 
2.3.6 Delays and time to treatment ................................................................................................................ 28 
2.3.7 Mortality and risk factors ....................................................................................................................... 29 
2.3.8 Models of care for RR-TB treatment ...................................................................................................... 31 
2.3.9 Patient experiences with RR-TB treatment ............................................................................................ 33 
2.3.10 Timeline of key events .......................................................................................................................... 34 
Chapter 3: Data sources and methodology ........................................................................................................... 36 
3.1 Chapter overview .......................................................................................................................................... 36 
3.2 Description of existing data sources ............................................................................................................ 36 
3.2.1 Existing data sources .............................................................................................................................. 36 
3.2.2 Access to existing data sources .............................................................................................................. 38 
3.2.3 New data collection ................................................................................................................................ 38 
3.3 Development of study databases................................................................................................................. 39 
3.4 Ethical review ................................................................................................................................................ 42 
8 
 
Chapter 4 - Assessment of RR-TB case detection in Botswana ............................................................................. 43 
4.1 Chapter overview .......................................................................................................................................... 43 
4.2 Hypotheses, aims and objectives ................................................................................................................. 43 
4.3 Background/Policy review ............................................................................................................................ 43 
4.4 Section 1: Assessment of culture and first-line DST among previously treated TB patients in Botswana 46 
4.4.1 Methods (Section 1) ............................................................................................................................... 46 
4.4.2 Results (Section 1) .................................................................................................................................. 48 
4.4.3 Discussion (Section 1) ............................................................................................................................. 61 
4.5 Section 2: Confirmation of drug resistance profile for patients initiating second-line treatment ............ 65 
4.5.1 Methods (Section 2) ............................................................................................................................... 65 
4.5.2 Results (Section 2) .................................................................................................................................. 66 
4.5.2 Discussion (Section 2) ............................................................................................................................. 73 
Chapter 5: Risk factors for mortality during treatment of rifampicin-resistant TB in Botswana ........................ 76 
5.1 Chapter overview .......................................................................................................................................... 76 
5.2 Hypotheses, aim and objectives ................................................................................................................... 76 
5.3 Background/Policy review ............................................................................................................................ 76 
5.4 Section 1: Mortality among RR-TB patients initiating treatment 2006-2014 ............................................. 78 
5.4.1 Methods (Section 1) ............................................................................................................................... 78 
5.4.2 Results (Section 1) .................................................................................................................................. 80 
5.5 Section 2: Mortality among RR-TB patients initiating treatment 2012-2014 ............................................. 97 
5.5.1 Methods (Section 2) ............................................................................................................................... 97 
5.5.2 Results (Section 2) .................................................................................................................................. 99 
5.6 Discussion .................................................................................................................................................... 108 
Chapter 6: Time to treatment for rifampicin-resistant tuberculosis: a systematic review and meta-analysis 
(published) ............................................................................................................................................................ 115 
6.1 Chapter overview ........................................................................................................................................ 115 
6.2 Hypothesis, aim and objective ................................................................................................................... 115 
6.3 Summary ..................................................................................................................................................... 115 
6.4 Background ................................................................................................................................................. 116 
6.5 Methods ...................................................................................................................................................... 116 
6.6 Results ......................................................................................................................................................... 118 
6.7 Discussion .................................................................................................................................................... 129 
Chapter 7: Utilization of Xpert MTB/RIF (Xpert) and the impact on time to second-line treatment ................ 132 
7.1 Chapter overview ........................................................................................................................................ 132 
7.2 Hypotheses and aim ................................................................................................................................... 132 
9 
 
7.3 Background/Policy review .......................................................................................................................... 132 
7.4 Methods ...................................................................................................................................................... 134 
7.5 Results (Section 1)....................................................................................................................................... 137 
7.6 Results (Section 2)....................................................................................................................................... 141 
7.7 Discussion .................................................................................................................................................... 144 
Chapter 8: When policy and practice do not align: a qualitative study of patient and provider experiences with 
RR-TB diagnosis and treatment in Botswana. ..................................................................................................... 147 
8.1 Chapter overview ........................................................................................................................................ 147 
8.2 Hypothesis and objective ........................................................................................................................... 147 
8.3 Context and update .................................................................................................................................... 147 
8.4 Methods ...................................................................................................................................................... 148 
8.5 Results ......................................................................................................................................................... 150 
8.6 Discussion .................................................................................................................................................... 168 
Chapter 9: Conclusions ......................................................................................................................................... 173 
9.1 Chapter overview ........................................................................................................................................ 173 
9.2 Key findings and implications ..................................................................................................................... 173 
9.3 Recommendations ...................................................................................................................................... 178 
Appendix A: BNTP Diagnositic Algorithm (2016) ................................................................................................. 181 
Appendix B: Qualitative Questionnaires and Consents ...................................................................................... 183 
Appendix C:  Systematic Review Protocol and Study Screening Form ............................................................... 199 
References ............................................................................................................................................................. 202 
 
 
  
10 
 
List of tables and figures 
Figure 2.1. Location and map of Botswana3 ............................................................................................................ 17 
Figure 2.2. Health districts of Botswana .................................................................................................................. 19 
Figure 2.3 TB Notification Rate and HIV Prevalence among Adult Pregnant Women in Botswana, 1990 – 200916. 
Sources: BNTP Annual Reports and ANC Sentinel Surveillance Reports ................................................................. 21 
Figure 2.4. Results from drug resistance surveys, Botswana18 ............................................................................... 22 
Figure 2.5. Standardized MDR-TB treatment regimen in Botswana16 .................................................................... 27 
Figure 2.6. Catchment area of RR-TB treatment facilities in Botswana, as of 2010 ............................................... 31 
Figure 2.7. Schematic Flow of drug-resistant TB patients, Botswana16 .................................................................. 32 
Table 2.3. Timeline of key events related to TB and RR-TB in Botswana ................................................................ 35 
Figure 4.1. Diagnosis and treatment cascade for previously treated patients in Botswana registered 2013-2014 49 
Table 4.1. Patient characteristics and sample submission, previously treated TB patients, 2013-2014 ................ 50 
Figure 4.2. Culture and/or smear testing among previously treated TB patients in Botswana, 2013-2014, N=2053
 ................................................................................................................................................................................. 51 
Table 4.2. Logistic regression: factors associatied with sample submission among previously treated TB patients 
in Botswana 2013-2014 ........................................................................................................................................... 52 
Figure 4.3. Proportion of previously treated TB patients with sample submission per district – and comparison 
maps of population density and road systems ....................................................................................................... 54 
Figure 4.4. Proportion of previously treated TB patients with first-line DST results available per district – and 
comparison maps of population density and road systems.................................................................................... 55 
Table 4.3: Characteristics of districts in Botswana .................................................................................................. 56 
Figure 4.5. Testing results of previously treated patients (2013-2014) with samples submitted to the NTRL and/or 
Xpert facility ............................................................................................................................................................ 58 
Table 4.4. Comparison of Xpert results to the NTRL culture results, 2013-2014 .................................................... 59 
Table 4.5. Univariate and multivariate analysis for culture positivity ..................................................................... 60 
Figure 4.6. RR-TB patients registered and TB case notification by year ................................................................. 66 
Figure 4.7. Diagnosis cascade for patients registered for RR-TB treatment 2006-2014 ......................................... 67 
Table 4.6. Characteristics of patients in the RR-TB treatment register, 2006-2014 ............................................... 69 
Figure 4.8. Number of registered RR-TB patients with confirmed first-line drug resistance profile, by year ........ 70 
Figure 4.9. Number of registered RR-TB patients with confirmed of second-line drug resistance profile, by year 70 
Figure 4.10. Time from treatment initiation to second-line DST results available, Kaplan Meier .......................... 71 
Figure 4.11. Pre-XDR or XDR-TB patients and timing of second-line DST ............................................................... 72 
Table 5.1. Patient characteristics RR-TB patients initiating treatment 2006-2014 ................................................. 81 
Table 5.2. Time to treatment outcome for patients initiating RR-TB treatment, 2006-2014 ................................. 82 
Figure 5.1. Proportion of patients per treatment outcome by year, N=704 ........................................................... 82 
Figure 5.2. Survival of patients on second-line treatment, Kaplan Meier .............................................................. 83 
Table 5.3. Univariate and multivariate analysis of risk factors for mortality among patients initiating RR-TB 
treatment, 2006-2014 ............................................................................................................................................. 85 
Figure 5.3. Mortality by HIV status and baseline smear result, adjusted survival curves ....................................... 86 
Figure 5.4. Mortality by age group, adjusted survival curve ................................................................................... 87 
Figure 5.5. Mortality by registration category and baseline radiology, adjusted survival curves .......................... 88 
Table 5.4. Proportion of patients with missing information by facility*** ............................................................. 89 
Figure 5.6. Mortality by drug resistance profile, adjusted survival curve ............................................................... 90 
Figure 5.7. Mortality by treatment facility, adjusted survival curve ....................................................................... 91 
Table 5.5 Select patient characteristics per treatment facility ............................................................................... 92 
Figure 5.8. Mortality by year of registration, adjusted survival curve .................................................................... 92 
11 
 
Figure 5.9. Cumulative hazard of mortality over time among RR-TB patients on second-line treatment ............. 93 
Table 5.6. Logistic regression for mortality within six months of treatment initiation and after six months of 
treatment initiation ................................................................................................................................................. 96 
Table 5.7. Definitions used to characterize side effects .......................................................................................... 98 
Table 5.9. Time to treatment outcome for patients initiating RR-TB treatment, 2012-2014, N=176 .................. 101 
Table 5.10. Mortality by characteristics of disease severity among patients initiating RR-TB treatment, 2012-2014
 ............................................................................................................................................................................... 101 
Table 5.11. Proportion of RR-TB patients with reported side effects and mortality per side effect, 2012-2014 . 103 
Table 5.12. Proportion of RR-TB patients with reported comorbidities and mortality per comorbidity, 2012-2014
 ............................................................................................................................................................................... 103 
Table 5.13. Univariate and multivariate analysis of risk factors for mortality among patients initiating RR-TB 
treatment 2012-2014 ............................................................................................................................................ 104 
Figure 5.10. Mortality by characteristics of disease severity, adjusted survival curve ......................................... 105 
Figure 5.11. Mortality by drug resistance profile, adjusted survival curve ........................................................... 106 
Figure 5.12. Mortality by side effects and comorbidities, adjusted survival curve............................................... 107 
Figure 6.1. PubMed search strings (unpublished) ................................................................................................. 117 
Figure 6.2. Study selection process flowchart ....................................................................................................... 119 
Table 6.1. Study characteristics and results .......................................................................................................... 122 
Figure 6.3. Time to treatment initiation by model of treatment provision .......................................................... 124 
Figure 6.4. Time to treatment initiation by laboratory drug susceptibility testing methods ............................... 125 
Figure 6.5. Trends in mean time to treatment initiation over time ...................................................................... 126 
Figure 6.6. Mean time to treatment (days) over time (unpublished) ................................................................... 126 
Figure 6.7. Time to treatment initiation by proportion initiating treatment ........................................................ 127 
Table 6.2. Combination of interventions and time to treatment initiation .......................................................... 128 
Figure 7.1. Location of Xpert devices in Botswana in 2013-201431 ....................................................................... 133 
Figure 7.2. Xpert testing results, total tests, 2013-2014 (no deduplication conducted) ...................................... 137 
Figure 7.3. Management of patients with an RR result by Xpert, 2013-2014 (all data de-duplicated) ................ 139 
Figure 7.4. Management of patients with an RR indeterminate result by Xpert, 2013-2014 (all data de-
duplicated) ............................................................................................................................................................. 140 
Table 7.1. Patient characteristics of the cohorts ................................................................................................... 141 
Table 7.2. Time to diagnosis and second-line treatment, 2013-2014 ................................................................... 142 
Figure 7.5. Cumulative proportion of patients initiating second-line treatment after RR-TB result available, Xpert 
and NTRL cohorts, 2013 – 2014 (Xpert cohort N = 65, NTRL cohort N= 63) ......................................................... 143 
Figure 7.6. Cumulative proportion of patients initiating second-line treatment after RR-TB specimen collection, 
Xpert and NTRL cohorts, 2013 – 2014  (Xpert cohort N = 65, NTRL cohort N= 63) ............................................... 143 
Table 8.1. Characteristics of interviewed patients ................................................................................................ 151 
Figure 8.1. Map of patient home villages in relation to RR-TB treatment facilities .............................................. 152 
 
  
12 
 
List of abbreviations 
 
AFB Acid-fast bacilli 
aHR Adjusted harzard ratio 
aOR Adjusted odds ratio 
ART Antiretroviral therapy 
BNTP Botswana National Tuberculosis Program 
CHE Current health expenditure 
CI Confidence intervals 
CMS Central Medical Stores 
CTCAE Common Terminology Criteria for Adverse Events  
CXR Chest X-ray 
DHMT District Health Management Teams 
DOT Directly observed therapy 
DRS Drug resistance surveys 
DR-TB  Drug-resistant tuberculosis 
DST Drug susceptibility testing 
EPTB Extrapulmonary tuberculosis 
ETR Electronic TB registry 
GDP Gross domestic product 
HR Hazard ratio 
IQR Interquartile range 
IUATLD International Union Against Tuberculosis and Lung Disease 
LIS Laboratory Information System 
LJ Lowenstein-Jensen solid media 
LPAs Line probe assays 
MDR-TB Multidrug-resistant tuberculosis  
MeSH Medical subject headings 
MGIT Mycobacteria growth indicator tube 
13 
 
MoHW Ministry of Health and Wellness 
MSF Médecins Sans Frontières 
NTM Non-tuberculosis mycobacteria 
NTRL National Tuberculosis Referral Laboratory 
OR Odds ratio 
PCR  Polymerase chain reaction 
PPA Patient-pathway analysis 
Pre-XDR TB Pre-extensively drug-resistant tuberculosis 
PRISMA Preferred Reporting Items for Systematic Review and Meta-Analyses 
PTB Pulmonary tuberculosis 
RMR-TB Rifampicin  mono-resistant tuberculosis 
RR-TB Rifampicin-resistant tuberculosis 
RR-TB Rifampicin-resistant tuberculosis 
TB Tuberculosis 
TTT Time to treatment 
U.S. CDC U.S. Centers for Disease Control 
WHO World Health Organization 
WMD Weighted mean differences 
XDR-TB Extensively drug-resistant tuberculosis 
Xpert MTB/RIF Xpert 
XPRES Xpert Package Rollout Evaluation Study 
   
14 
 
Chapter 1: Introduction  
 
1.1 Chapter overview 
Chapter one describes the rationale and context for the development and conduct of this doctoral research 
project, key definitions, and the hypotheses, aims and objectives of this research. 
1.2 Rationale and context 
The concept of this thesis was developed after living and working in Botswana for three years. I initially moved 
to Botswana in 2010 in a position as a public health advisor in the TB Research Division of the U.S. Centers for 
Disease Control and Prevention (U.S. CDC), based in the capital city of Gaborone. In this position, I worked very 
closely with the Ministry of Health and Wellness (MoHW) planning and conducting tuberculosis (TB) operational 
research projects and clinical trials. In my collaborations with the MoHW and the Botswana National TB Program 
(BNTP), I developed a strong interest in learning more about the management of rifampicin-resistant 
tuberculosis (RR-TB) in Botswana, and my colleagues at the BNTP expressed interest in having more research 
conducted to increase awareness and understanding of the successes and challenges of the RR-TB management 
program. The concept and research questions for this thesis were developed in consultation with colleagues at 
the BNTP and aimed to address issues and questions of the most interest to the program. Throughout the next 
four years in Botswana, I continued to work at the U.S. CDC office in Gaborone while also working on data 
collection and analysis for this doctoral research project in close collaboration with BNTP colleagues. During the 
final year of thesis writing, I had moved back to the U.S. but remained in close contact with BNTP colleagues. 
The primary supervisor for this doctoral work was Associate Professor Helen Cox (University of Cape Town). 
Technical support was provided by medical officers at the BNTP and the U.S. CDC Office in Botswana.  
1.3 Key definitions  
Key definitions are explained throughout the thesis as the concepts are introduced. It is important early on to 
define the terms related to the categorization of drug-resistant tuberculosis. Multidrug-resistant TB (MDR-TB) is 
defined as resistance to at least isoniazid and rifampicin, the two most potent drugs used for treating TB1. 
Extensively drug-resistant TB (XDR-TB) is defined as resistance to at least isoniazid and rifampicin plus resistance 
to any fluoroquinolone and at least one of three injectable second-line drugs1. Pre-XDR TB is defined as MDR-TB 
with resistance to a fluoroquinolone or an injectable second-line drug, but not both2. Rifampicin-resistant TB 
(RR-TB) is defined as resistance to at least rifampicin1. Rifampicin mono-resistant TB (RMR-TB) is defined as 
resistance to rifampicin and susceptibility to isoniazid1. The term RR-TB encompasses MDR-TB, XDR-TB and RMR-
TB1. 
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1.4 Hypotheses, aims and objectives 
1.4.1 Overall research hypothesis  
In Botswana, there are identifiable barriers and risk factors influencing RR tuberculosis case detection, linkage to 
effective care and treatment and patient outcomes.  
1.4.2 Specific hypotheses, aims and objectives 
Chapter 2 includes background information and a literature review, while chapter 3 describes methods. 
Subsequent chapters will investigate the following specific hypotheses, aims and objectives. 
Assessment of RR-TB case detection in Botswana (chapter 4) 
Hypothesis 1: Case detection of RR-TB is suboptimal in Botswana 
Aim: Conduct an assessment of access to TB culture and first-line drug susceptibility testing (DST) according to 
global and national guidelines  
Objectives:  
To determine the proportion of previously treated TB patients, registered in 2013-2014, with samples submitted 
for culture and first-line DST within 1 month of first-line TB treatment initiation 
To identify risk factors associated with not having a sample submitted for culture and first-line DST for 
previously treated TB patients 
Hypothesis 2: There are gaps in confirmed diagnosis of patients initiating second-line treatment in Botswana 
Aim: Conduct an assessment of first and second-line DST for patients initiating second-line treatment 
Objective: 
To determine the proportion of patients registered for RR-TB treatment from 2006 to 2014 with first-line and 
second DST results available.  
 
Risk factors and time to mortality among RR-TB patients initiating second-line treatment in Botswana (chapter 5) 
Hypothesis 1: Mortality among patients initiating RR-TB treatment is associated with identifiable risk factors, 
some of which are modifiable 
Hypothesis 2: Time to mortality is affected by specific risk factors. 
Aim: To identify and determine risk factors for mortality among RR-TB patients in Botswana 
Objectives: 
To describe the proportion of cases initiating treatment who have died and risk factors for mortality 
To describe time to mortality and factors associated with early and late mortality 
To describe the frequency of co-morbidities and side effects and their impact on mortality 
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Time to treatment for rifampicin-resistant tuberculosis: a systematic review and meta-analysis (published Nov 
2017, chapter 6) 
Hypothesis 1: Time to treatment is influenced by diagnostic methods and model of care provided in various 
setting.  
Aim: To conduct a systematic review and meta-analysis assessing time to treatment for RR-TB and variability by 
diagnostic testing methods and treatment delivery approach. 
Objectives: 
To assess treatment delay in terms of DST methods, access to ambulatory treatment compared to hospital 
based treatment, and the proportion of patients who initiate treatment. 
 
Utilization of Xpert MTB/RIF (Xpert) and the impact on time to second-line treatment (chapter 7) 
Hypothesis 1: Xpert improves time to treatment as compared to DST conducted at the centralized laboratory. 
Hypothesis 2: There are gaps in confirmatory testing for patients initially tested by Xpert. 
Aim: To assess patient management and linkage to care for patients with RR detected or RR indeterminate 
results by Xpert in 2013 to 2014. 
 
When policy and practice do not align: a qualitative study of patient and provider experiences with RR-TB 
diagnosis and treatment in Botswana (chapter 8) 
Hypothesis 1: There are gaps in the diagnosis and treatment process in Botswana that can be identified by 
patients, providers and government staff. 
Aim: To identify and describe common themes through analysis of individual interviews with patients, health 
care providers, and national level government staff. 
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Chapter 2: Background and literature review 
 
2.1 Chapter overview 
Chapter 2 describes the country of Botswana and the context of TB and RR-TB, globally and in Botswana. More 
specific policy and background information is summarized at the beginning of each analysis chapter throughout 
the thesis. This section will include a high-level literature review of topics relevant to the development of the 
research plan for this thesis. Each chapter throughout the thesis will also include a detailed discussion section, 
describing literature in the context of the findings of this current research.  
2.2 Botswana – general statistics and description of health system 
2.2.1 Botswana general statistics 
Botswana is a landlocked country in sub-Saharan Africa sharing boundaries with the Republic Of South Africa, 
Namibia, Zambia and Zimbabwe3 (Figure 2.1). Botswana gained independence from Great Britain in 1966 and 
has remained politically stable since then4. The people of Botswana are referred to as Motswana (singular) or 
Batswana (plural). Ethnic groups include Tswana (67%), Kalanga (15%) San (1%), Ndebele (2%), Herero (1%), 
Afrikaner (1%) and other (13%)3. Botswana’s economy is driven primarily by mineral extraction (principally 
diamonds) as well as tourism, and the country has a reputation of being one of the most stable economies in 
Africa4. Table 2.1 describes general statistics about Botswana.  
 
Figure 2.1. Location and map of Botswana3 
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Description Measurement 
Land area5 582,000 square kilometers  
Population (2011)6  2,024,904 
Rural population (2017)7  42% of total population 
GDP (2017)4 $17.41 billion U.S. dollars 
GDP per capita (2017)4 $7,595.60 U.S. dollars 
Current Health Expenditure (2015)8 6% of GDP 
Life expectancy (2016)7  66 
Literacy rate (2014)9  88% 
Unemployment rate (2013)9  18% (male); 22% (female) 
Estimated HIV incidence per 100,000 (2016)7  444 
Estimated ART coverage (2016)7  83% 
Estimated TB incidence per 100,000 (2016)7 356 
 
Table 2.1. General statistics, Botswana 
2.2.2 Botswana health system 
The Botswana health system is composed of public facilities, private facilities and traditional medicine, with 98% 
of the facilities in the public sector10. Nearly all Batswana seek health care in the public sector11. Health services 
in the public sector are decentralized to the district level; services are delivered through a network of health 
facilities. All health facilities are managed by District Health Management Teams (DHMTs)12. Botswana has 24 
health districts as shown in Figure 2.2.  
Table 2.2 describes the number public health facilities in the country. In addition to the health facilities listed in 
Table 2.2, there are 900 mobile health posts operating in Botswana. Most of the population (95% of the total 
population, 89% of the rural population) lives within 8 km of a health facility12. Patients move from lower 
facilities to hospitals through a referral system. Primary health care facilities are mainly staffed by nurses and 
midwives, and doctors visit health posts through a routine schedule as well as clinics which do not have their 
own doctors on staff. In addition to doctors, nurses and midwives, all hospitals have pharmacy, laboratory and 
radiology personnel. Referral hospitals have specialized care services. All health facilities have ambulance 
services for referrals and emergency calls12. 
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Figure 2.2. Health districts of Botswana 
Health Facility Type Number 
Referral Hospitals 3 
General Hospitals 15 
Primary Hospital 17 
Clinics 289 (181 w/out bed) 
Health Posts 350 (13 w/out nurse) 
  
Total public health facilities 674 
 
Table 2.2. Public health facilities in Botswana (2012)12 
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2.3 TB and RR-TB globally and in Botswana 
2.3.1 TB Epidemiology 
Tuberculosis (TB) is a major global health problem. In 2017, the World Health Organization (WHO) estimated 
that 10 million people developed TB, and 1.6 million died from the disease, including 300,000 deaths among 
HIV-positive people13. The majority of individuals with TB worldwide in 2017 were in the South-East Asian (44%), 
African (25%) and Western Pacific (18%) regions13. Estimated TB incidence rates at the country level differ 
substantially, with 204 cases per 100,000 population in India, around 300 or more cases per 100,000 population 
in South Africa, Pakistan and Nigeria, and fewer than 25 per 100,000 population in parts of the Americas, Japan, 
Australia, New Zealand and several countries in Western Europe13. An estimated 9% of the 10 million people 
who developed TB globally in 2017 were HIV-positive13. Over half of these cases were in the African Region. For 
2017, the WHO estimated TB incidence in Africa was 237 per 100,000 population and, specifically in Botswana, 
was 300 per 100,000 population13. The Botswana Ministry of Health and Wellness (MoHW) reported that 59% of 
all notified individuals with TB were HIV positive in Botswana in 201414. As of 2017, an estimated total of 
380,000 adults and children in Botswana were living with HIV; the estimated HIV prevalence among adults was 
23%15. 
Prior to 1990, Botswana had shown success in controlling TB. Annual risk of infection surveys conducted in 
Botswana showed a decline from 5.8% in 1956 to 0.1% in 198916. TB notification rates declined from 506 per 
100,000 in 1975 to 199 per 100,000 by 198916. However, in 1990 notification rates began to increase and peaked 
at 623 per 100,000 in 20023. Based on studies of TB and HIV co-infection, it has become clear that the increase in 
TB was a result of the increasing prevalence of HIV in Botswana, as shown in Figure 2.3, and that the recent 
decline may be the result of high antiretroviral therapy (ART) coverage in Botswana16.  
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Figure 2.3 TB Notification Rate and HIV Prevalence among Adult Pregnant Women in Botswana, 1990 – 200916. 
Sources: BNTP Annual Reports and ANC Sentinel Surveillance Reports 
2.3.2 RR-TB epidemiology 
RR-TB has emerged as a global epidemic with approximately 558,000 cases and 230,000 deaths estimated to 
occur in 201713. RR-TB data from drug resistance surveys (DRS) and continuous surveillance among notified TB 
cases suggest that, globally, 3.6% of newly diagnosed TB patients and 18% of those previously treated for TB had 
RR-TB in 201213. A total of 160,684 patients with RR-TB were notified globally in 201713, and 139,114 were 
reported to be started on second-line treatment. This represents only 25% of the 558,000 estimated cases 
globally in 201713. In Botswana, 41% (87) of the estimated 210 RR-TB cases were detected and started on 
treatment in 201713.  
Botswana has conducted periodic, national anti-TB DRS in 1995-1996, 1999, 2002 and 2007-2008. A new survey 
is planned for 2019. In the 2007-2008 DRS in Botswana, resistance to isoniazid, rifampicin, ethambutol and 
streptomycin continued to rise among new TB patients compared to previous surveys17, 18. The proportion of 
new patients with any isoniazid or rifampicin resistance increased 1.7-fold since 2002, and MDR-TB increased 
3.1-fold since 200217, 18. The percentage of new, previously untreated patients with MDR-TB increased from 0.8% 
in the 2002 DRS to 2.5% in the 2007-2008 DRS, a statistically significant increase18. Although the percentage of 
previously treated patients with MDR-TB decreased from 10.4% in 2002 to 6.6% in 2007-2008, this change was 
not statistically significant (P=0.29)18. In the 2007-2008 DRS, any resistance to rifampicin was reported for 3.6% 
of new TB patients and 13% of previously treated TB patients17, 18 in line with the current estimates from the 
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WHO for Botswana13. Drug-resistant TB appears to be increasing in Botswana. The trends of MDR-TB, over the 
four national drug resistance surveys suggest this, particularly the proportion among new patients who have not 
previously received TB treatment17, 18 (Figure 2.4).  
 
Figure 2.4. Results from drug resistance surveys, Botswana18  
2.3.3 TB and RR-TB diagnosis 
Summary of available diagnostics for TB 
Diagnosis of TB has historically relied on smear microscopy and culture testing, but advances in TB diagnosis 
have led to more options in recent years19. The technique of detecting acid-fast bacilli (AFB) using smear 
microscopy is a TB diagnostic tool developed over 100 years ago13, and while it is simple, quick and 
inexpensive20, the sensitivity of smear microscopy ranges from 20-60%21. Xpert MTB/RIF (Xpert) is the only point 
of care, rapid molecular test for TB currently recommended by the WHO; rapid line probe assay tests (HAIN) are 
laboratory based tests and are also recommended by WHO13. Culture testing for TB (using solid or liquid media) 
is still considered the reference standard for the diagnosis of TB and RR-TB; culture based methods require more 
developed laboratory capacity, and can take as much as 12 weeks for results to be available13.   
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Drug susceptibility testing 
Testing for drug resistance is also recommended for patients diagnosed with TB; the WHO recommends 
universal drug susceptibility testing (DST) for all patients with signs and symptoms of TB13. While culture based 
DST, where bacteria are cultured in the presence of the drug to test for resistance, is the reference standard for 
DST, there are several other methods available as well. Xpert is a genotypic test which simultaneously tests for 
TB and for specific mutations known to confer resistance to rifampicin, the most effective first-line TB drug13. 
Rapid line probe assays (LPAs) are also genotypic tests available for both first and second-line DST. First-line 
LPAs were first recommended by the WHO in 2008 and test for resistance to isoniazid and rifampicin, and 
second-line LPAs were recommended by the WHO in 2016 and test for resistance to fluoroquinolones and 
injectable anti-TB drugs13.  
Xpert MTB/RIF 
Xpert is a relatively new and improved diagnostic test that has been shown to have an impact on RR-TB 
diagnosis and linkage to care22, 23. The rapid molecular test simultaneously detects presence of M. tuberculosis 
and rifampicin drug resistance (RR) in sputum samples with high sensitivity and specificity24, and results are 
available within 2 hours. In 2010, the WHO endorsed the use of Xpert as the initial diagnostic test for persons 
with presumed RR-TB or HIV-associated TB25. By 2017, 9449 testing machines and 34.4 million test cartridges 
had been procured by 130 of the 145 countries eligible for concessional prices13.  
After the initial endorsement of Xpert in 2010, the WHO policies regarding Xpert use were updated in 2013, 
taking into account the available body of evidence26. More than 85 peer-reviewed, published papers reporting 
on Xpert use were reviewed and summarized as part of this update. Xpert, when used as an initial diagnostic 
test, achieved overall pooled sensitivity and specificity of 88% and 99% respectively26. Among smear- and 
culture-positive TB, the pooled sensitivity was 98%, compared to 68% for smear-negative, culture-positive TB26. 
For people living with HIV, the pooled sensitivity was 79%, compared to 86% for people without HIV infection26. 
For detecting rifampicin resistance, Xpert achieved a pooled sensitivity of 95% and pooled specificity of 98%26. 
Xpert was initially recommended (in 2010) for the diagnosis of pulmonary TB in adults; the 2013 policy update 
expanded this recommendation to include use in children and to diagnose specific forms of extrapulmonary 
TB26.  
Given the WHO recommendation for universal DST, defined as rapid DST for at least rifampicin27, Xpert can be 
utilized by programs to achieve universal DST. In regards to confirmatory DST, the WHO recommends that 
patients at high risk of MDR-TB with a diagnosis of RR-TB by Xpert should immediately have follow-up DST for at 
least isoniazid, fluoroquinolones and second-line injectables28. For patients at low risk of MDR-TB with a 
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diagnosis of RR-TB by Xpert, the WHO recommends a second Xpert test; in the event the second test is also 
positive for RR, the WHO recommends follow-up DST to confirm rifampicin resistance as well as susceptibility 
testing for isoniazid, fluoroquinolones and second-line injectables13.  
Since the introduction of this rapid TB diagnostic, research has been published to describe the implementation 
of Xpert. Research has indicated that it is feasible to use Xpert in resource-limited settings. A study reporting on 
Xpert use in decentralized testing locations in South Africa, Peru, Indian, Azerbaijan, Uganda and the Philippines, 
reported that Xpert could be effectively utilized in these settings with accurate and early diagnosis29. Theron, et 
al reported that Xpert can be accurately utilized by nurses in clinic settings in South Africa and resulted in more 
patients with a same day diagnosis and treatment30. A study in Botswana also indicated that Xpert 
implementation was feasible at both point of care sites and at district level laboratories31. As well as being 
feasible to implement, research also confirms that Xpert provides accurate diagnosis. A systematic review of 27 
studies reported that Xpert, used as an initial diagnostic test, is sensitive (89%) and specific (99%) among both 
HIV positive and negative patients32. The same systematic review reports high sensitivity (95%) and specificity 
(98%) for the detection of rifampicin resistance32.  
Several studies have reported on challenges with Xpert implementation. Inconsistent access to both cartridges 
and required maintenance have been reported by several studies33-35. Xpert has been adopted quickly in many 
settings, however national guidelines and testing algorithms are not always updated and disseminated as quickly 
to align with new testing recommendations35, 36. The requirement for consistent power supply has been 
reported as a barrier for Xpert implementation36, and in Botswana, one in five error results by Xpert were 
attributed to power supply31.  
Despite the challenges observed during Xpert implementation, the benefits of Xpert for RR-TB diagnosis and 
linkage to care have been well documented. Whereas results from culture based DST are available after weeks 
or months29, Xpert testing results are available the same day. Therefore, many studies have reported on 
shortened time to initiation of treatment as a result of Xpert implementation37-41. Research also indicates that 
Xpert can increase RR-TB case detection42-44 and lead to less empiric treatment45. A systematic review has been 
published recently indicating that Xpert may have a population-level impact by decreasing mortality, particularly 
among people living with HIV22. 
Diagnosis of TB and RR-TB in Botswana 
In Botswana, all health facilities in each health district have the capacity to collect and transport sputum or other 
specimens (i.e. gastric aspirate, bronchial alveolar lavage, etc.) for TB testing; all hospitals and some clinics have 
the capacity to conduct lumbar punctures to collect cerebrospinal fluid. Specimens from patients presumed to 
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have TB are submitted from health facilities to peripheral laboratories for smear microscopy. Peripheral 
laboratories (36 in total) with the ability to conduct smear microscopy are available throughout the country. For 
patients in whom it is indicated (to be described more fully in relevant chapters), specimens are submitted to 
the National Tuberculosis Reference Laboratory (NTRL), through the peripheral laboratories, for mycobacterial 
culture and DST.  
The NTRL is the only laboratory facility in Botswana with the capacity to conduct TB culture and phenotypic DST, 
and is located in Gaborone. The NTRL has been conducting culture testing since approximately 2000, and first-
line solid media DST was introduced in the early 2000s (exact date unknown). During the time of this research, 
the majority of culture and DST was performed using Mycobacteria growth indicator tube (MGIT) or Lowenstein 
Jensen (LJ) solid media. The NTRL has suffered several closures in recent years. In 2011, the laboratory closed for 
renovations and once these were completed in 2012, capacity remained limited due to lack of reagents. The 
NTRL was fully opened by 2013 but was closed again from the end of 2014 through 2016. The closure in 
December 2014 resulted from a laboratory evaluation, which discovered a malfunction with the airflow system, 
creating positive pressure in the laboratory. This required a significant renovation, and the laboratory re-opened 
in 2016. There was an additional TB research laboratory, which was owned and managed by US CDC until 2017, 
used for research study-related testing. This research laboratory was a separate containerized TB laboratory co-
located with the NTRL, and was not routinely used for testing non-study participants. In 2017, this research 
laboratory was transferred to the NTRL and continues to be used for research as well as a backup laboratory as 
needed.  
Xpert was first introduced in Botswana in 2012 through an operational research study, the Xpert Package Rollout 
Evaluation Study (XPRES), conducted by the U.S. CDC in Botswana in collaboration with the Botswana Ministry of 
Health and Wellness. The study aimed to compare the sensitivity of microscopy-based and Xpert-based 
pulmonary TB diagnostic algorithms in diagnosing sputum culture-positive TB and to evaluate the impact of 
Xpert and intensified case finding on all-cause, 6-month, adult antiretroviral therapy (ART) mortality46. During 
this time, thirteen Xpert devices were placed throughout the country in district laboratories or in TB/HIV clinics 
(point of care), further described in Chapter 7. The study enrolled and followed up all HIV positive persons 
initiating ART with symptoms of TB seeking treatment at 22 participating TB/HIV clinics from 2012 to 201446. The 
devices were also used by the government of Botswana for routine testing of patients with presumed TB at the 
participating clinics.  
After the XPRES study ended and follow-up was complete (2015), the Xpert devices were donated to the MoHW. 
The MoHW subsequently installed additional devices as well, bringing the total Xpert devices in use to 34 by 
2015. Xpert was not fully incorporated into the National TB Program in Botswana until 2016, when the 
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diagnostic algorithm including Xpert (Appendix A) was finalized and distributed. While Xpert was used prior to 
2016, it was not intended to replace routine practices in the country, described in the first paragraph. Any 
patient who would have had a sample sent to the NTRL for testing should still have had a sample sent to the 
NTRL, regardless of Xpert result. Additionally, the government specifically released guidance to all facilities 
utilizing Xpert, instructing that any patient with an Xpert test indicating RR-TB should have confirmatory DST 
conducted at the NTRL and should be initiated on second-line treatment while waiting on results of 
confirmatory culture and DST. Guidance also indicated that any test with an RR indeterminate result by Xpert 
should have a repeat Xpert test and follow-up testing at the NTRL if warranted based on the second test or other 
recommendations for routine testing. This guidance was sent to health facilities as a savings gram (official 
government communication) from the Botswana National TB Program (BNTP) in 2012 when XPRES started 
introducing Xpert devices. 
Throughout this thesis, reference is made to confirmatory testing and confirmatory DST, which includes 
confirmation of empirical diagnosis as well as confirmation of rifampicin resistance diagnosed by Xpert, along 
with inclusion of additional testing (e.g. isoniazid resistance).  Given the low level of RR-TB among TB patients in 
Botswana, it is important and recommended to conduct confirmatory testing for all empiric and Xpert diagnosed 
RR-TB patients.   
2.3.4 TB and RR-TB treatment 
Effective medications for the treatment of tuberculosis were first developed in the 1940s13. Currently, the 
recommended regimen for drug-susceptible TB is a six month regimen of four first-line drugs: rifampicin, 
isoniazid, ethambutol and pyrazinamide13. The treatment for RR-TB is longer and requires more toxic 
medications13. Patients with RR-TB are treated with a combination of second-line drugs, usually for 18 months or 
more13. A shorter, 12 month, regimen was conditionally recommended by the WHO in 2016, recommended only 
under specific conditions (no previous second-line treatment, no resistance to fluoroquinolones or second-line 
injectable drugs)47.  
In Botswana, based on the most recent national guidance (2011 TB Program Manual and 2009 National 
Guidelines for Management of DR-TB), all RR-TB patients are placed on a standardized RR-TB regimen composed 
of amikacin, levofloxacin, ethionamide, cycloserine, pyrazinamide and P-aminosalicylic acid (PAS) (Figure 2.5)16, 
48. Prior to 2009, the standardized second-line regimen consisted of fewer TB drugs: amikacin, ethionamide, 
pyrazinamide, and ciprofloxacin49. An adjustment of treatment is considered based on DST results or if adverse 
events are documented warranting a change. The recommendations that remain in place suggest the duration 
of second-line treatment in Botswana is 18 months after culture conversion48. More detailed information about 
RR-TB treatment in Botswana is provided in Chapter 5. 
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Figure 2.5. Standardized MDR-TB treatment regimen in Botswana16 
2.3.5 Barriers to TB and RR-TB diagnosis and accessing treatment 
Barriers to accessing effective TB and RR-TB diagnosis and treatment are likely to be present at many levels. 
Barriers to TB diagnosis at the healthcare system level can include lack of awareness about program testing 
guidelines and protocols among providers, limited supplies, unreliable transport and no specimen tracking 
methods50 . At the patient level, socioeconomic barriers are often barriers to seeking care and treatment51. 
Additionally at the patient level, age, distance to care and treatment centers and male gender have been 
associated with treatment delays52. Specific groups, such as individuals with substance use disorders and 
subsistence farmers have experienced delays in diagnosis and treatment53 . The WHO reports that one of the 
barriers countries face for access to treatment for RR-TB is reliance on centralized, hospital-based models of 
care, and recommends the use of outpatient models of care; this will be discussed further in section 2.3.8.  
Many TB programs are developed from the top down and focus on where health system capacities currently 
exist, rather than where patients actually present for care54. As part of the End TB Strategy, the WHO includes 
patient centered-care as a core principle, focusing on ensuring universal access to TB services with increased 
attention to vulnerable and hard to reach populations. Hansen, et al described the patient-pathway analysis 
(PPA) approach which was developed for programs to better understand the association between patient care 
seeking behaviors and availability of TB services54. The PPA can be used at national and subnational levels and 
includes the following indicators, by health facility level and sector, to assist in understanding the patient-
pathway: 1) initial care seeking (the proportion of patients who initiate care); 2) diagnostic coverage (the 
proportion of health facilities with diagnostic services); 3) diagnostic access (the proportion of patients who 
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initiate care in a facility with TB diagnostic services); 4); treatment coverage (the proportion of health facilities 
that have TB drugs or that can provide treatment supervision); 5) treatment access (the proportion of patients 
who initiate care in a facility that has TB drugs available); 6) notification location (the location of case 
notification for cases notified to the WHO); 7) treatment outcome (treatment outcomes among cases notified to 
the WHO)54. A report of five countries which implemented the PPA indicate that it is a useful tool for programs 
to understand where they may find TB patients who are currently being missed55. Among the five countries 
(Kenya, Ethiopia, Philippines, Indonesia and Pakistan), 76% of patients initially sought care in a TB care facility 
which did not have capacity for TB diagnosis. Other findings included insufficient referral processes, facilities 
with strong diagnostic capacity but low proportions of patients initiating care (particularly centralized hospitals) 
and limited engagement of the private sector55. Treatment availability appeared to be more aligned with patient 
care-seeking55. All five countries reported differences in the patient-pathways within the country, indicating that 
subnational assessments are important to fully understand where patients are seeking TB care in different 
regions55.  
To further understand how to best address barriers to diagnosis and treatment, research has examined what 
makes certain programs successful. A program analysis of three successful RR-TB programs reported on six areas 
that were common among each program56. First, each program conducted baseline and repeat qualitative 
assessments to identify areas needed for program improvement. Second, each program identified and 
emphasized relationships with key collaborators, such as those involved in policy making, laboratory services 
and drug procurements. Third, programs identified where patients initially seek TB care. Fourth, all programs 
worked to minimize costs to the patients. Fifth, each program identified vulnerable populations at increased risk 
of RR-TB and/or increased risk of poor treatment outcomes, and interventions were developed (i.e. universal 
screening among mine workers, support for patients with substance abuse issues). Lastly, all programs received 
significant technical assistance from an external partner (Partners In Health), in their early development, and all 
receive funding from both government and Global Fund56.  
2.3.6 Delays and time to treatment  
For the minority of RR-TB patients who are appropriately diagnosed and receive second-line treatment, delays 
to treatment initiation are often many months in some settings.37, 57-61 Such delays are likely to increase 
mortality and loss to follow-up while waiting for treatment,62, 63 in addition to potentially contributing to poorer 
treatment outcomes among those who do start treatment.64 Long delays to treatment are also likely to 
contribute substantially to transmission, in both community and nosocomial settings.65-67 Given that the majority 
of RR-TB patients in high burden settings are likely due to direct transmission,68 scale up of diagnosis and rapid 
initiation of effective treatment are required to improve patient outcomes and reduce ongoing transmission.69 
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Chapter 6 provides a systematic review of literature reporting on factors influencing time to treatment for RR-TB 
patients. 
Qualitative research has explored factors that contribute to delays in diagnosis and/or treatment. A study in 
Vietnam reported findings from focus groups and in-depth interviews with MDR-TB providers. Challenges to 
MDR-TB detection and linkage to treatment included inadequate screening capacity at district hospitals, 
inconsistent training and poor communication and implementation of policy changes; updates regarding policy 
changes were not always communicated at all levels of the health system70. Other research has indicated that 
inadequate sample transportation systems contribute to delay, as well as inefficient systems for tracking and 
referring patients to treatment71.  
A study in Cape Town, South Africa identified both enablers and barriers to early MDR-TB diagnosis and 
treatment72. Patients diagnosed by Xpert attributed their rapid linkage to treatment to the new technology72. 
Patients who had previous TB episodes and recognized the symptoms reported seeking health care early, while 
those who thought the symptoms had another cause, delayed seeking care72. Patient perceptions of poor 
services in the public sector contributed to delays72. Health system delays were present, including lack of testing 
at initial health contact, poor adherence to testing algorithms, unavailable results and delays in recalling patients 
when results are available72. 
2.3.7 Mortality and risk factors 
In addition to reducing ongoing transmission of disease, a key goal of treatment is to reduce mortality. In the 
absence of treatment, the mortality rate from TB is very high. Tiemersma, et al described the natural history of 
tuberculosis and mortality among HIV negative individuals with untreated pulmonary tuberculosis73. This study 
reported on patients who were diagnosed before drug treatments became available (from research published 
between 1900 and 1966). Seventy percent of patients with untreated smear positive TB died within 10 years, 
and the 10-year case fatality rate among patients with smear-negative culture-positive TB was estimated to be 
20%73.  
Given the greater risk of receiving ineffective treatment, compared to drug sensitive TB, the risk of mortality is 
higher among patients with RR-TB; a study in Peru reported that patients with RR-TB had significantly higher 
probability of death compared to drug sensitive TB patients74. Globally, mortality as a treatment outcome 
among RR-TB patients who initiated treatment in 2015 is reported as 15%; success (cured or completed 
treatment) among this same cohort is reported as 55%, and the remaining have outcomes of treatment failure 
(8%), lost to follow-up (14%) or no outcome information (7%)13. In comparison, Botswana has reported mortality 
as a treatment outcome for 17%, treatment success for 78%, lost to follow-up for 2% and treatment failure for 
2% among the cohort included in this research (those initiating second-line treatment 2006-2014). 
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Past studies show a range of risk factors for mortality after diagnosis of RR-TB, including clinical and social 
factors. A 13 year retrospective study in Beijing showed that chronic obstructive pulmonary disease and 
hypertension are both independent risk factors associated with death among patients on second-line 
treatment75. In Lithuania, a retrospective national cohort study (all MDR/XDR-TB patients 2002-2008) showed 
that older age, alcohol use, lower education levels, unemployment, cavitary disease, being smear positive at the 
time of diagnosis and HIV positivity were associated with poorer survival76. In a study in Latvia, 20% of patients 
were underweight (BMI ˂ 18.5) and these patients were significantly more likely to have clinical evidence of 
advanced disease and had a greater risk of death77. A South African study has also shown that lower baseline 
weight is associated with a higher hazard of death78. It should be noted that low BMI and baseline weight are 
most likely to be indicators of advanced clinical disease.  
High death rates among HIV-infected RR-TB patients have been well documented, especially in high HIV burden 
settings78-80. A systematic review assessing treatment outcomes among HIV-RR-TB co-infected patients reported 
a mortality rate during treatment of 38% in adults and 11% in children; compared to HIV negative RR-TB 
patients, mortality was higher particularly among adults81. Several studies have reported that HIV is 
independently associated with mortality. Studies have reported HIV as an independent risk factor for mortality 
among MDR-TB patients initiating treatment in South Africa in the early 2000s, prior to ART access78, 80. Even 
after the availability of ART, research continues to show HIV as an independent risk factor for mortality82. A 
study in Eastern Europe, among RR-TB patients registered for treatment in 2009, reported median survival after 
treatment initiation of 5.9 years in patients with RR-TB; in patients co-infected with HIV survival reduced to 1.9 
years83. However, some studies highlight this increased risk of mortality during RR-TB treatment only among HIV 
positive persons not on ART84. In particular, patients with a low CD4 count have been shown to have a higher 
risk of mortality while on RR-TB treatment. A case-control study of MDR-TB patients in South Africa who died 
within two years of diagnosis showed that mortality was associated with a greater degree of 
immunosuppression (CD4 count ≤ 50 and 51-200 cells/mm3) and drug resistance (resistance to all six drugs 
tested)85. In Nigeria, mortality has also been linked to low CD4-counts among HIV-positive patients86. A previous 
study in Botswana reported a two fold increase in mortality among HIV positive persons with baseline CD4<100, 
compared to HIV negative persons87.  
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2.3.8 Models of care for RR-TB treatment 
Historically, global recommendations for management of RR-TB included hospitalization for up to 8 months; 
however, the WHO has recommended ambulatory models of care since 201188, and systematic reviews suggest 
that hospitalization is not associated with better outcomes compared to ambulatory treatment89, 90. The 2017 
Médecins Sans Frontières (MSF) Out of Step Report indicated that fewer countries now require hospitalization 
for DR-TB treatment initiation, and none of the nine countries from Sub-Saharan Africa surveyed for the Out of 
Step report required hospitalization for treatment91. It should be noted however that the report is based on 
current country policies, but how these policies are actually implemented in practice was not reported. The 
WHO also recommends models of care that include directly observed therapy (DOT) (second-line treatment 
given by DOT throughout the entire course of treatment) and active contact tracing88.  
RR-TB in Botswana is managed at specialized facilities with both inpatient and outpatient care. RR-TB care has 
been decentralized from two referral hospitals in 2009 to five facilities by 2010 (a sixth facility was added in 
2017 but was not operating during the time period covered by this research). The five facilities, and the 
catchment areas which they serve, are shown in Figure 2.6. These five centers are managed by a team including 
physicians and nurses trained in RR-TB care. Based on the 2011 national TB guidelines, all presumptive and 
bacteriologically confirmed RR-TB patients are referred to one of five specialized government RR-TB treatment 
centers located around the country.  
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Catchment area of RR-TB treatment facilities in Botswana, as of 2010 
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According to the Botswana National 2011 TB Program Manual and the 2009 National Guidelines for 
Management of DR-TB, most RR-TB patients receive treatment as outpatients16, 48. Figure 2.7 from the 2011 TB 
Program Manual shows the flow of patients from primary clinics to an RR-TB treatment facility for treatment 
initiation (isolation in this figure refers to hospitalization). For ambulatory treatment, patients come with the TB 
coordinator or treatment adherence partner to one of the MDR-TB treatment centers and are reviewed on a 
monthly basis throughout treatment. Hospitalization during the intensive phase of treatment (until culture 
conversion or clinical stability) is recommended only for certain groups of people who the program considers to 
be at high-risk because of clinical characteristics, non-adherence, or are thought to be at high risk of infecting 
others. The program considers the following patients to be at high risk of clinical complications during treatment 
and therefore recommends they are hospitalized until clinically stable: confirmed and presumptive XDR-TB 
patients, clinically unstable patients, patients with severe adverse events, and patients with failure to culture 
convert after four months of treatment. Patients who have demonstrated poor adherence, based on reports 
from treatment monitors, are also recommended to be hospitalized for close monitoring to promote adherence 
to the treatment regimen. The program also recommends hospitalization for patients with no options for 
isolation in home (defined as a separate space in the home where the patient can be isolated from other 
members of the household), particularly those with children; the program considers these patients at high risk 
of infecting others48. The 2017 updated national guidelines for management of drug-resistant TB (still in draft, 
2019) retained these recommendations92.  
  
Figure 2.7. Schematic Flow of drug-resistant TB patients, Botswana16 
National policies also address DOT and contact tracing. Guidelines suggest that RR-TB patients should receive 
DOT, provided by health facilities (hospitals, clinics, health posts) or by trained community volunteers. 
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Throughout the entire course of treatment, patient treatment cards are supposed to be signed every day by a 
DOT provider to record adherence48. Regarding contact tracing, national guidelines indicate that all close 
contacts of RR-TB patients, including household members, co-workers and schoolmates who have close contact 
with the source case, should be screened for signs and symptoms of TB48.  
2.3.9 Patient experiences with RR-TB treatment 
Treatment for RR-TB is lengthy, up to two years for many patients, and is challenging for patients93, 94.  Receiving 
daily injections, the high pill burden and the long duration of treatment have been reported as challenges for 
patients94. The toxic medication and harsh side effects are also very challenging for patients94; some report the 
side effects are unbearable95. 
Psychological challenges have been reported by patients, including depression, stigma and discrimination96.  
Patients have reported losing their sense of identity because they cannot work and are socially isolated97.  Fear 
is a common feeling reported by RR-TB patients, fear of death or fear that it would be hard to find or pay for 
medication97. 
Patients also report economical hardships96. Economic hardships are often a result of losing a job due to the 
prolonged illness or not being allowed to work because of the perceived risk from their workplace97.  Patients 
who work manual labor jobs or farm their own land have reported not being able to do so because of the effects 
of the medicine and losing income due to this97. Patients living in rural areas have reported economic hardships 
and selling their assets due to centralized care and having to travel to treatment sites98. 
Many studies indicate that patients prefer ambulatory care for RR-TB treatment95, 99, 100.  Patients report they 
feel they are able to recover better at home, have better psychosocial support from family members and 
friends, and have time for other activities such as social interactions or having small jobs100.  Patients also report 
being afraid of contracting other infections while at the hospital100. Patients have expressed frustration with 
delays in diagnosis and long pathways to care72, 101, as previously described in Section 2.3.6. 
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2.3.10 Timeline of key events 
Table 2.3 describes the timeline of key events related to TB and RR-TB in Botswana. Data for this timeline was 
collected through reviews of all annual reports and TB program manuals produced for the past 20 years, as well 
as through personal communication with members of the BNTP and NTRL.  
YEAR(S)  
1910 TB is thought to be introduced in Botswana by miners returning from South Africa102 
1956 Annual risk of TB infection in Botswana = 5.8%16 
1970s Documented resistance to isoniazid, streptomycin and thioacetazone in Botswana103 
1975 National TB Program Established16 
1986 Rifampin first used in Botswana104 
1989 Annual risk of TB infection = 0.1%16 
1990 TB cases began to rise again16 
1995 Introduction of first fully oral regimen (2EHRZ/4HR)16 
1995 Adopted DOTS Strategy16 
1995 1st DRS conducted16 
1995 9 patients with MDR-TB notified – first documented account48 
1996 First guidelines for management of TB in lab setting produced105 
1996 
First national guidelines for management of MDR-TB developed but not finalized or 
distributed105 
1999 2nd DRS conducted16 
1999 
Program review conducted. Identified priorities: 1) MDR-TB Guidelines: develop and 
disseminate; 2) Ongoing surveillance of DR-TB105 
1999 Funding provided by CDC to construct the NTRL106 
~2000 Culture testing began at the National Health Lab (limited basis)106 
~2002 1st line solid media DST validated106 
2002 3rd DRS conducted16 
2006 Routine screening and treatment of RR-TB patients begun104 
2006 NTRL opened104 
2008 4th DRS conducted16 
2008 3 XDR-TB cases confirmed48 
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2009 Guidelines for management of drug-resistant TB finalized and disseminated48 
2010 Liquid culture (MGIT) validated at the NTRL106 
2011-12 
Interrupted/Limited laboratory (NTRL) services  
(renovations and limited reagent availability)14 
2012 LPA validated106 
2012 1st line liquid DST validated106 
2012 Xpert implementation pilot study introduced – limited use 
2014 2nd line liquid DST validated106 
2014-2016 
The NTRL closure – Evaluation discovered positive pressure; complete renovation 
needed11 
2016 Xpert algorithm finalized and disseminated11 
2016 2nd line solid DST validated106 
2017 Draft Guidelines for MDR-TB Management developed92 
 
Table 2.3. Timeline of key events related to TB and RR-TB in Botswana 
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Chapter 3: Data sources and methodology 
3.1 Chapter overview 
This chapter will describe the data sources used for this research, both existing national datasets and new data 
collected for this research. The chapter will further describe the methods used to develop the final databases 
used for this research, including verifying data in existing data sources, combining data from multiple data 
sources and adding new data collected. This chapter will also describe ethical review of the research. Specific 
analytical methods will be described in the relevant chapters.  
3.2 Description of existing data sources 
3.2.1 Existing data sources 
I. Electronic TB Registry (ETR) 
The ETR includes data on all patients initiating first-line TB treatment in Botswana. Traditionally, information 
about TB patients in Botswana has been reported to the national level through a routine paper-based TB 
recording and reporting system, based on the World Health Organization (WHO) guidelines38. In 1996 Botswana 
introduced a case-based electronic TB registry (ETR) designed in Epi Info. The Botswana National Tuberculosis 
Program (BNTP) transitioned the ETR to a Windows based version of the ETR called ETR.net in 2004. The ETR.net 
is a Microsoft.net–based computer software program, based on the WHO and the International Union Against 
TB and Lung Disease (IUATLD) recording and reporting formats. The ETR.net was developed and is managed by 
WAM Technology, a South African software development and support company. The ETR.net is a stand-alone 
system with Access back end and .net front end. The server for the system is located at the BNTP in Gaborone. 
From 2006 to present, the data in the ETR has been considered complete and reliable, according to the BNTP11. 
Data flow involves paper forms at the facility level that are transported to the district level. This should occur on 
a monthly basis but is not always the case. Also on a monthly basis, data entry staff or TB coordinators at the 
district level are to enter data into the database and forward to the national level.  
Individual TB patient records are entered from a standard manual facility TB Register into a District-based (Local 
Service Area-/Sub-district-based) data entry program that provides interactive guidance and support. The 
program then generates different patient listings, with a management and supervision function (i.e. a list of 
patients lost to follow-up, etc.), and standard quarterly and annual reports on case finding, sputum conversion, 
and treatment outcome. In addition to the report tables, the program also provides graphs (time trends) and 
maps (geographic distribution) on important TB indicators. These reports are also used to provide feedback to 
the districts. The ETR includes data on patient identifying information, demographics and clinical information; 
37 
 
this includes name, national identity number, date of birth, age, HIV status, treatment dates, smear results, 
health care facility and home district. Patients are identified as new or previously treated for TB in the ETR. 
II. RR-TB registry 
While Botswana does have a web-based RR-TB registry (OpenMRS), it is not used consistently due to limited 
internet connectivity at treatment facilities; therefore, this registry is considered incomplete. There are plans to 
improve the usability of this sytstem. However, in the meantime, the best source of RR-TB registry data is an 
offline electronic database at each facility. This is in the form of an Excel file in which RR-TB clinicians enter data 
directly from patient charts or laboratory reports. Clincians update this file each time new information is 
reported about a patient. Updates are sent from facilities and compiled at least biannually at the national level 
where the master RR-TB register is held. The data from this registry are used for surveillance, to develop 
national annual reports and has been used for previous publications of the RR-TB cohort in Botswana87, 107-112. 
This Excel file RR-TB registry wil be referred to as the RR-TB registry in this thesis. The RR-TB registry inclues data 
on all patients who were referred to an RR-TB treatment center; some patients did not initiate treatment (died 
before treatment initiation or clinical decision not to initiate treatment) and are identified as not initiating 
treatment in the RR-TB registry. The RR-TB registry includes patient identifying information, demographics and 
clinicial information. The RR-TB registry has been in use since 2006.  
III. The National Tuberculosis Reference Laboratory (NTRL) laboratory database 
The Laoratory Information System (LIS) used by the NTRL is the DisaLab system113. The DisaLab system is a 
windows based system which interfaces multiple workstations and testing instruments through the network. 
The server, workstations and testing instruments are all co-located in the NTRL. Data is entered directly into the 
LIS by laboratory technicians or is imported directly from laboratory equipment (eg. mycobacteria growth 
indicator tube [MGIT]). Patients are given a unique laboratory number which automatcially links the patient with 
the result from the laboratory equipment. The LIS using DisaLab was first implemented in 2009 and includes 
patient identifying information and laboratory data per patient (specimen details and results).  
IV. Patient medical records  
Medical records are kept in paper format at the RR-TB treatment facilities. All patient information, including 
patient history from the referring facility, testing results and treatment information is kept in a folder at the 
treatment facility. At each patient visit (monthly while on treatment), the RR-TB clinican types clinic notes 
describing any updates in the patient condition. These typed notes are printed and kept in the patients medical 
records. The RR-TB treatment card is also kept in the patient files.  There were some patients for whom paper 
charts were unavailable, and it is not clear why this is. These were collected directly from the RR-TB treatment 
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facilities, so it is likely this was impacted by poor filing and retention practices.  
V. Xpert MTB/RIF data sets 
Each Xpert testing instrument is accompanied by a computer. The GeneXpert Dx System software is installed on 
the computers, and this software automatically archives all test results as .gxx files on the computer. Data 
included in the archived Xpert files includes patient identifying information and testing results data. This data is 
stored at each testing facility and backed up by the NTRL staff (or CDC staff during the CDC study) on CDs or 
hard-drives during lab monitoring visits. Backed up records are stored at the NTRL. 
3.2.2 Access to existing data sources 
A data sharing agreement was developed with the BNTP, specifically for this research, to ensure that data was 
collected in agreement with program policies and procedures. This data sharing agreement was incorporated 
into the protocol and approved by ethical review boards as well. Additionally, the Program Manager of the BNTP 
provided an official letter to all facilities visited as part of this research to ensure facilities were aware of the 
approval for access to data.  
Based on the data sharing agreement, data was provided to the researcher as follows. The ETR data, covering 
the years of 2013-2014, were exported to an Excel file and provided to the researcher on an encrypted USB 
drive. The RR-TB Registry, covering patients registered for treatment in the years 2006-2014, was provided to 
the researcher on an encrypted USB drive. The LIS data, covering the years of 2013-2014, were exported to an 
Excel file and provided to the researcher on an encrypted USB drive. The Xpert data (.gxx files), covering the 
years 2013-2014, were extracted from archived files directly from the Xpert instruments. These files were 
extracted and placed on an encrypted USB drive by the researcher or by a collaborator from the MoHW. Xpert 
software version 4.0 was used to access and combine test results at a central location, and results were 
exported to an Excel spreadsheet. Additional data was extracted directly from paper patient files and entered 
into a password protected database. All files were password protected, as was the computer on which they 
were stored. 
3.2.3 New data collection 
Data from qualitative interviews were captured in both written and verbal recording formats. Recordings were 
stored on the researcher’s computer, and written interview notes were transferred into word documents and 
stored on the researcher’s computer. All files were password protected, as was the computer on which they 
were stored. 
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3.3 Development of study databases 
This section will describe how existing data were used to create the databases for this research. Each study 
database has been given a name in this section and will be referred to by this name throughout the thesis. The 
methods for creating the database for the published systematic review are included in the systematic review 
chapter. 
Previous TB treatment database 
The previous TB treatment database was created from three existing data sources: the ETR, the LIS and the 
Xpert datasets. Initially, all previously treated TB patient data was extracted from the ETR to create a database 
of previously treated patients only, registered January 1, 2013 to November 30, 2014. The cutoff of November 
30, 2014 is due to a lab closure at this time, which interrupted submission of samples for testing at the NTRL. 
The ETR extraction of previously treated patients was reviewed for duplicates, and any duplicates were 
removed. Each data source had the following patient identifying information: name (first and last name) and 
omang (national identity number); date of birth (DOB) was available for the ETR and the LIS. The ETR data were 
manually matched against the national LIS records and the Xpert dataset by national identity number, name 
and, where available, by date of birth to determine if the patient had a sample submitted for culture or Xpert 
testing. Manual methods included using spelling variations for names in searching for matches; any names 
identified by a spelling variation were confirmed by another variable as well (date of birth or omang). Any 
discrepancies between the databases were resolved; if two databases had the same data and one differed, the 
data confirmed by two would be retained. If this could not be resolved by majority, the data from the ETR was 
retained as it was determined by the researcher to be more complete and accurate. Only data from samples 
submitted for testing within the following timeframe were considered: within three months prior to first-line TB 
treatment initiation and up to one month after treatment initiation. The rationale for the time frame is 
described in Chapter 4. The testing results data from the LIS or Xpert datasets were merged into the previous 
treatment database. Results data included test results as well as dates (date of sample receipt at lab [LIS only], 
date of test conducted and date of result reviewed). In instances when multiple results were available per 
patient, all results were included in the merge and were reviewed manually. For analysis, when more than one 
sample was submitted per patient during the specified time frame, all results were reviewed for completeness, 
i.e. both culture and DST results. For example, in the LIS if one sample had only culture results available and 
another sample for the same patient was also submitted, during the time frame for analysis, with both culture 
and DST results available, the results and date of sample submission for the latter sample would be included in 
analysis. The main outcome of the analysis this database was used for was having a sample submitted for 
culture; however DST results were also described in this analysis making it important to include the most 
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complete information for each patient. Xpert data was also reviewed for duplicate tests per patient, and no 
duplicate results were identified. A unique study ID was assigned by the researcher to each patient; once all 
matching was complete, all identifying information was deleted from the database.  The coded age variable, 
calculated from date of birth, and the district of residence remained in the database.  All analyses were 
conducted on the de-identified database. RR-TB patient database  
The RR-TB patient database was created from four existing data sources: the national RR-TB registry, the LIS, 
patient medical records (paper) and the Xpert dataset. The national RR-TB registry formed the base of the study 
database, and additional data was added to this database from the other three sources. Each data source had 
the following patient identifying information: name (first and last name) and omang (national identity number); 
date of birth (DOB) was available for the RR-TB registry, patient medical records and the LIS.  Matching methods 
described in the previous section were also used in the development of this database. Each data source was 
reviewed for quality and completeness. In review of the data, the researcher did identify missing data for some 
variables (radiology results, smear results, etc.) and some illogical dates. These are highlighted as limitations in 
the respective chapters. It was clear that some dates were entered in different formats. Some dates were 
entered in the MM/DD/YY format, while others were entered in the DD/MM/YY format. These were manually 
corrected to all be in the same format, and where available these dates were checked against the LIS records 
(however, LIS was only available for the years 2012-2014). Specific data definitions and analytic methods are 
described in detail in the respective chapters. This database was used in Chapter 4 to describe confirmation of 
drug resistance patterns; data for this analysis came mainly from the RR-TB register and the Xpert dataset which 
did not have specimen collection date data; therefore these findings are presented in terms of when the test 
result was recorded in these data sources (result available date). This database was also used in Chapter 5 and 
additional data cleaning and merging were conducted to make the database useful for the sub-analysis of 
patients initiating treatment between 2012 and 2014. For these patients, matching with the LIS and Xpert 
datasets was conducted to confirm testing data. Additionally, patient charts were reviewed for these patients 
and variables were added for the data from these reviews (weight, side effects, etc.). A unique study ID was 
assigned by the researcher to each patient; once all matching was complete, all identifying information was 
deleted from the database. The coded age variable, calculated from date of birth, and the district of residence 
remained in the database.  All analyses were conducted on the de-identified database. 
Xpert database 
The Xpert database was created from the original Xpert datasets (.gxx files directly from testing instruments), 
the LIS and the RR-TB registry. The Xpert dataset formed the base of this study database and included the results 
from all tests conducted by Xpert in 2012-2014. Tests conducted for quality assurance or training purposes were 
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identified in the dataset and were excluded from the study database. A broad analysis was conducted on the full 
Xpert database to describe all testing conducted in the study time period.  
Further data cleaning and matching was conducted for a subset of this database. This subset included all tests 
with a result of rifampicin resistance detected or rifampin resistance indeterminate.  For all tests with a result of 
rifampicin resistance or rifampicin resistance indeterminate by Xpert, these were reviewed by name and omang 
(national ID number) for duplicates, and all duplicates were removed. Some patients had multiple tests 
performed within the same week. If there were multiple tests for the same patient, only one result was retained 
for the analysis. In the case that the result was the same, the date of the first result was retained. In the case 
that results were different, any positive result was retained. Manual matching, using name and omang was 
conducted with the LIS for NTRL test results for this subset of the database. Data was organized by patient, and 
results from the LIS (results and dates of results) were added to the data for the corresponding patients. The RR-
TB register was also matched with this subset of the database, and data was added for corresponding patients. 
The data from the RR-TB register included demographic data (sex, age) and treatment data (start date, 
outcome). Any patient with a result of RR-TB by Xpert who was not located in the RR-TB registry was followed 
up further. The researcher called the RR-TB facilities to determine why the patient was not started on 
treatment, and this information is included in Chapter 7.  
Additional data was added to this database for patients who initiated RR-TB treatment based on results from the 
NTRL. This data was added as a comparison group to patients who initiated RR-TB treatment based on Xpert, to 
compare time to treatment among these two groups. To add this data, the RR-TB registry was matched with the 
LIS to confirm testing dates and results for patients who had initiated treatment in 2012-2014. Any patient who 
initiated treatment without a test result available at the time of treatment initiation was excluded. Data for 
patients who did initiate treatment based on results from the NTRL was added to the database, including patient 
characteristics (gender and age), treatment information (start date and outcome) and testing data (result data 
and dates of specimen collection and result available date). The specific data definitions and analyses are 
described in Chapter 7. A unique study ID was assigned by the researcher to each patient; once all matching was 
complete, all identifying information was deleted from the database. The coded age variable, calculated from 
date of birth, and the district of residence remained in the database.  All analyses were conducted on the de-
identified database. 
Qualitative data 
Qualitative data was collected using standardized interviews (Appendix B). Interviews were recorded, 
transcribed and translated into word documents. Interview transcripts were read through to identify patient and 
provider experiences with RR-TB treatment, themes were uncovered and transcribed on to note cards which 
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included specific quotes, participant ID numbers and thematic codes. Summarized themes and quotations were 
entered into an Excel database for further organization and review.  A unique study ID was assigned by the 
researcher to each patient; all identifying information was deleted from the database. The coded age variable, 
calculated from date of birth, and the GIS coordinates for village of residence (not unique to any one patient) 
remained in the database.  All analyses were conducted on the de-identified database.  Specific methods for 
data collection (Section 8.4), review and analysis are described in Chapter 8.  
Data analysis: 
Specific methods for data analysis are described in individual chapters.  Common to all analyses, efforts were 
made to reduce type 1 errors.  The p-value set for significance was 0.05.  In addition, factors included in models 
were carefully selected and minimized, only including factors with clinical or public health reasons to suspect 
there may be an association, increasing the confidence that type 1 errors were minimized.   
3.4 Ethical review 
Ethical approval for this research was given by the University of Cape Town, Faculty of Health Sciences, Human 
Research Ethics Committee; U.S. Centers for Disease Control and Prevention; and Botswana Ministry of Health 
and Wellness. Informed consent was provided by each of the study participants participating in the qualitative 
interviews (Appendix B).  Informed consents were translated into Setswana and Basarwa verbally at the time of 
the interview.  Back translations of the consents, as well as any questions and responses were performed 
verbally and recorded (written and verbal recordings).   
 
  
43 
 
Chapter 4 - Assessment of RR-TB case detection in Botswana 
4.1 Chapter overview 
Two main analyses will be described in this chapter. The first section will describe an assessment of culture 
testing and first-line DST for previously treated TB patients registered January 1, 2013 to November 30, 2014 in 
Botswana. The second section will describe an analysis of first- and second-line DST for patients registered for 
RR-TB treatment from January 1, 2006 to December 31, 2014. The chapter begins with a background and 
overview of current policies regarding case detection in Botswana, relevant to both sections.  
4.2 Hypotheses, aims and objectives 
Hypothesis 1: Case detection of RR-TB is suboptimal in Botswana 
Aim: Conduct an assessment of access to TB culture and first-line drug susceptibility testing (DST) according to 
global and national guidelines  
Objectives:  
To determine the proportion of previously treated TB patients, registered January 1, 2013 to November 30, 
2014, with samples submitted for culture and first-line DST within 1 month of first-line TB treatment initiation 
To identify risk factors associated with not having a sample submitted for culture and first-line DST for 
previously treated TB patients 
Hypothesis 2: There are gaps in confirmed diagnosis of patients initiating second-line treatment in Botswana 
Aim: Conduct an assessment of first and second-line DST for patients initiating second-line treatment 
Objective: 
To determine the proportion of patients registered for RR-TB treatment from 2006 to 2014 with first-line and 
second DST results available.  
4.3 Background/Policy review 
The WHO has published recommendations to address improvements in case detection of RR-TB27. The WHO 
recommends universal access to DST for all patients with signs and symptoms of TB and defines universal access 
to DST as rapid DST for at least rifampicin27. The WHO guidance acknowledges the difficulty of accomplishing 
this in certain settings and suggests that, at a minimum, patient groups with the highest risk of RR-TB should 
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receive culture DST. These high risk groups include previously treated TB patients, contacts of RR-TB patients, 
and those patients who do not culture convert after three months of TB treatment114.  
Globally, 3.5% of new TB patients and 18% of previously treated TB patients are estimated to have RR-TB13. 
Based on the last drug resistance survey (DRS) for Botswana conducted in 2008, 2.5% of new TB patients and 
6.6% of previously treated TB patients were estimated to have MDR-TB (confirmed resistance to isoniazid and 
rifampicin)17. Any resistance to rifampicin (with or without isoniazid resistance) was reported for 3.6% of new TB 
patients and 13% of previously treated TB patients in 200817, in line with the current estimates from the WHO 
for Botswana13. The first section of this chapter assesses culture and DST among previously treated patients in 
Botswana as a group at risk of developing RR-TB. Previously treated TB patients were selected as the major 
group to monitor testing among high risk groups, because it is large and easily identifiable.  
Ideally, all patients initiating RR-TB treatment should also have second-line DST for at least fluoroquinolones 
(which are used in the country) and at least one of the three second-line injectable agents114. The second section 
of this chapter assesses the first and second-line DST practices for patients initiating RR-TB treatment in 
Botswana. 
There is one laboratory facility in Botswana with the capacity to conduct TB culture and phenotypic DST, the 
National Tuberculosis Reference Laboratory (NTRL), located in Gaborone. Laboratory capacity has been affected 
by two NTRL closures. In 2011, the laboratory closed for renovations and once complete in 2012, capacity 
remained limited due to lack of reagents. The NTRL fully opened by 2013 but was closed again from the end of 
2014 through 2016. With the exception of these closures, the NTRL has been conducting culture testing since 
approximately 2000, and first-line solid DST was introduced in the early 2000s (exact date unknown). There was 
an additional TB research laboratory established in 2011, which was owned and managed by the US CDC until 
2017, used for research study related testing. This research laboratory was a separate containerized TB 
laboratory collocated with the NTRL, and was not routinely used for testing non-study participants. In 2017, this 
containerized laboratory was transferred to the MoHW; it continues to be used for TB research as well as 
serving as a backup for the NTRL. 
During the time of the analyses described in this chapter, culture and first-line DST were primarily performed 
with Mycobacteria growth indicator tube (MGIT) or Lowenstein-Jensen solid media (LJ), with a low proportion of 
samples tested using line probe assays (LPA). Samples were processed with GB Mycoprep (Becton Dickinson, 
Sparks, Maryland, United States of America) which consists of 1% N-acetyl-L-cysteine (NALC), 4% sodium 
hydroxide and 2.9% sodium citrate. Routine practice at the NTRL was to conduct first-line DST for all culture 
positive samples, including those submitted for monitoring purposes. LPAs were first introduced in 2012 but 
were not routinely used for all patients during the time of these analyses. The capacity for second-line DST was 
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not available in Botswana during the time of these analyses. From 2006 to 2010, samples were sent to South 
Africa for second-line DST. However, this stopped almost completely after 2010, and the country did not 
develop capacity for second-line DST until 2014. 
Citing costs and limited capacity, the Botswana National TB Program does not recommend culture and DST for 
all TB patients in Botswana16. However, culture and first-line DST is recommended for patient groups in whom 
there is a higher risk of drug resistance or lower sensitivity of smear microscopy16. These patient groups are 
listed together in the 2011 TB Program Manual as follows; they are not separated by their reasons for testing 
(i.e. risk of drug resistance or lower sensitivity of smear microscopy):  
• HIV positive individuals with presumptive TB with 2 negative sputum smear results  
• New TB patients who remain or become smear positive at month 3 of treatment  
• All previously treated TB patients regardless of reason (failure, relapse, or loss to follow-up)  
• All children < 5 years of age with presumptive TB 
• Patients who develop TB during or after isoniazid preventive therapy 
• Symptomatic individuals at higher risk of MDR-TB: laboratory workers, MDR-TB contacts, health care 
workers 
According to the 2009 National Guidelines for Management of DR-TB, all patients microbiologically diagnosed 
with RR-TB and initiating second-line treatment and those initiating treatment empirically should have a 
baseline culture and first-line DST48. Patients with presumptive or laboratory confirmed RR-TB are placed on a 
standardized second-line TB regimen. Additionally, patients are to be monitored throughout second-line 
treatment with monthly smear and culture testing48.  
There is inconsistent guidance regarding second-line DST. While the most recent TB program manual (2011) 
states that all confirmed MDR patients should receive second-line DST16, the 2009 National Guidelines for 
Management of DR-TB states that only those who remain culture positive after four months of treatment should 
receive second-line DST48. Both were current guidelines in use during the time of the study; while it is possible 
that these were inconsistent because the guidelines were changing over time, it is unclear which guidelines were 
meant to be adhered to. 
Xpert was first introduced in Botswana through an operational research study (XPRES), which was being 
conducted within the programmatic setting of TB care in Botswana from the years 2012-2014. Some patients 
included in these analyses received Xpert testing through this study; however, national policies regarding Xpert 
use were not fully developed and implemented until 2016. While Xpert was used during the time of this 
research, it was not intended to replace routine practices in the country. Any patient who would have had a 
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sample sent to the NTRL for testing should still have had a sample sent to the NTRL, regardless of Xpert result. 
During the time of this study, any patient with a positive Xpert test should have received confirmatory culture 
and first-line DST performed at the NTRL.  
TB diagnosis and care is managed through a network of health facilities at six levels: national referral hospitals 
(3), general district hospitals (15), primary hospitals (17), clinics (288), health posts (350) and mobile clinics 
(900)12. All facilities in a health district are overseen by District Health Management Teams (DHMTs). All facilities 
have the capacity to collect and transport sputum for TB testing. Peripheral laboratories (36) are available 
throughout the country and have the capacity to conduct smear microscopy testing. Sputum samples are sent to 
the NTRL by all facilities via the peripheral laboratories throughout the country. However, based on personal 
communication from members of the national TB program, poor coordination of transportation from some 
health posts and particularly from mobile clinics limits the ability of these facilities to collect and submit sputum 
for TB testing11. The program reports 100% geographical coverage of the WHO recommended Directly Observed 
Therapy Short Course (DOTS) for drug sensitive TB treatment, and direct observation is provided at local health 
facilities (hospitals, clinics, health posts) or through community volunteers16. Because mobile posts are not open 
every day, they do not provide DOT but do support the community volunteers providing DOT in these areas.  
4.4 Section 1: Assessment of culture and first-line DST among previously treated TB 
patients in Botswana 
4.4.1 Methods (Section 1) 
Study population 
The study population included all patients initiating first-line TB treatment registered as previously treated 
patients in the Electronic TB Registry (ETR) in 2013 and 2014. All analyses use data for patients registered 
between January 1, 2013 through November 30, 2014. This did not extend beyond November 2014 because of a 
laboratory closure in December 2014, which would have affected sample submission and testing. The methods 
for development and description of this database are included in the Chapter 3. Previously treated patients 
included the following categories16: 
• Retreatment after previous successful treatment: A patient previously treated for TB who has been 
declared cured or treatment completed, and is diagnosed with TB. 
• Retreatment after treatment failure: A patient who is started on a retreatment regimen after having 
previous treatment failure.  
• Retreatment after loss to follow-up: A patient who is started on a retreatment regimen following 
interruption of treatment for two or more consecutive months.  
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• Smear-negative PTB and EPTB patients are also classified as new and retreatment after relapse, failure 
and loss to follow-up. 
Measured variables 
This analysis aims to assess if previously treated patients are being monitored for drug resistance as 
recommended. In order to be monitored for drug resistance, patients must have a sample submitted for culture 
testing. Therefore, this analysis measures the proportion of patients with a sample submitted to either the NTRL 
or an Xpert testing facility. Sample submission is used as a marker for recommended monitoring. For the 
purpose of this analysis, patients are considered as having samples submitted for monitoring if they had a 
sample submitted at treatment initiation (defined as within three months before and up to one month after 
first-line TB treatment initiation). Specimens submitted within three months before treatment initiation were 
classified as pre-treatment samples. Patients were considered as being monitored as recommended if a sample 
was submitted, regardless of whether or not results became available or were positive. Having a sample 
submitted does not necessarily mean that first-line DST would have been conducted. DST may or may not have 
been conducted for samples submitted for culture depending on initial culture result. In addition to describing 
sample submission for culture testing, DST will be described separately.  
Data analysis 
Proportions, medians and interquartile ranges were produced to describe patient characteristics, sample 
submission and testing results. Univariate and multivariate logistic regression were used to analyze associations 
between collected variables and sample submission (as the dependent variable). Univariate and multivariate 
regression were also used to identify factors related to culture positivity. Odds ratios, 95% confidence intervals 
(CI) and p-values were calculated for all variables included in the univariate and multivariate regressions. P-
values of <.05 were considered statistically significant. 
All analyses were conducted using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY: IBM Corp) or Excel for basic charts and graphs.  
ArcGIS was used to create maps, displaying spatial variation in sample submission and availability of DST results 
by health district. A separate map displaying population density by health district was created. Population 
density was calculated for each health district using the following formula: 
Population density = population of the district / square kilometers of the district 
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Population by district was obtained from the 2011 national census6, and square kilometers were obtained from 
the shape files of each district115. All maps displaying results per district were created using shape files provided 
by the Botswana National Statistics Office115.  
Additional district level data was compiled. Health facilities per district were obtained from the 2012 Ministry of 
Health and Wellness Health Facilities Report12. Health facilities per population was calculated using the 2011 
census population data6.  
4.4.2 Results (Section 1) 
Among 13,411 registered TB patients between January 1, 2013 and November 30, 2014, 2,053 (15%) were 
recorded as previously treated. The 2,053 patients represent the total after the duplicates (n=16) were 
removed. Figure 4.1 describes the testing and diagnosis cascade for the 2,053 previously treated TB patients. 
Only 855/2,053 (42%) patients had a sample submitted at treatment initiation; 70 of these had samples 
submitted for Xpert testing only. Only 425 patients had at least one culture positive for MTB and/or Xpert 
positive result; representing 21% of the entire cohort of previously treated patients. Among the entire cohort, 
387/2,053 (19%) had a DST result available from samples submitted at treatment initiation (between 3 months 
prior to treatment initiation and up to one month after treatment initiation). Each level of the cascade is 
explored in two main sections of results:  
A. Sample submission  
B. Testing results (culture positivity and DST results)  
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* Sample submitted to the NTRL or district level Gene Xpert laboratory for testing 
** DST refers to rifampicin resistance testing at a minimum 
 
Figure 4.1. Diagnosis and treatment cascade for previously treated patients in Botswana registered 2013-2014 
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A. Sample submission 
Table 4.1 describes the characteristics of previously treated patients and the proportion of patients with a 
sample submitted per characteristic.  
 Total previously 
treated patients 
Sample submitted at 
treatment initiation 
  N =2053 N = 855 
Factors n n (% per characteristic) 
Gender 
Female 820 357 (44%) 
Male 1233 498 (40%) 
Age Group 
≤18 92 35 (38%) 
19-29 270 117 (43%) 
30-44 853 371 (43%) 
45+ 838 332 (40%) 
Median (IQR) 41 40 (32-52) 
Urban/Rural (Diagnosing facility) 
Urban 485 291 (60%) 
Rural  1568 564 (36%) 
Facility type 
Clinic 1301 576 (44%) 
Health Post 555 210 (38%) 
Hospital 179 62 (35%) 
Unknown 18 7 (39%) 
HIV Status 
Negative 635 254 (40%) 
Positive 1277 541 (42%) 
Unknown 141 60 (43%) 
Smear Status 
Negative 425 183 (43%) 
Positive 977 463 (47%) 
Not done 651 209 (32%) 
Treatment Category 
Previous successful treatment 1836 765 (42%) 
Previous treatment failure 77 44 (57%) 
Previous treatment lost to 
follow-up 
140 46 (33%) 
Year of registration 
2013 1149 464 (40%) 
2014 904 391 (43%) 
 
Table 4.1. Patient characteristics and sample submission, previously treated TB patients, 2013-2014 
  
51 
 
Multivariate analysis 
Given the overall low level of sample submission among prevously treated patients, both univariate and 
multivariate analyses were conducted to further assess if certain clinical or demographic factors were associated 
with having a sample submitted (Table 4.2). Factors which were significantly associated with increased likelihood 
of sample submission included any smear result (positive or negative) compared to no smear conducted. Of all 
previously treated patients, 756 (37%) had a smear test only (at the diagnosing facility), 646 (31%) had both 
smear and culture testing, 209 (10%) had culture testing only, and 442 (22%) had neither smear nor culture 
testing (Figure 4.2). Patients with a smear positive result (aOR 1.9) were slightly more likely to have a sample 
submitted than those with a smear negative result (aOR 1.5). Living in an urban area and a previous TB outcome 
of treatment failure were also significantly associated with increased likelihood of sample submission. Being 
diagnosed in an urban area had the largest effect on sample submission; those in an urban area were almost 
three times more likely to have a sample submitted than those diagnosed in a rural area.  
Compared to being diagnosed at a health post, being diagnosed at a clinic was associated with increased 
likelihood of having a sample submitted in the univariate model but not in the multivariate model. 
Crosstabulations revealed an association between living in an urban area and being diagnosed at a clinic. Urban 
patients were more likely to be diagnosed in a clinic (93%), compared to rural patients (54%).  
 
Figure 4.2. Culture and/or smear testing among previously treated TB patients in Botswana, 2013-2014, N=2053 
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  Total 
N=2053 
Sample 
submitted 
N=855 
 
Univariate analysis 
   
Multivariate analysis 
Factors N n % p-value OR 
CI 
Lower 
CI 
Upper   
P-
value aOR 
CI 
Lower 
CI 
Upper 
Facility type 
Health Post 555 210 38% reference   reference 
Clinic 1301 576 44% 0.010 1.305 1.065 1.600   0.742 0.964 0.773 1.202 
Hospital 179 62 35% 0.441 0.871 0.612 1.238   0.475 0.877 0.612 1.257 
Unknown 18 7 39% 0.928 1.045 0.399 2.739   0.854 1.098 0.406 2.969 
HIV Status 
Negative 635 254 40% reference   reference 
Positive 1277 541 42% 0.323 1.103 0.908 1.338   0.299 1.113 0.910 1.361 
Unknown 141 60 43% 0.576 1.111 0.768 1.608   0.391 1.183 0.806 1.735 
Smear Status 
Not done 651 209 32% reference   reference 
Positive 977 463 47% 0.000 1.905 1.549 2.343   0.000 1.876 1.514 2.324 
Negative 425 183 43% 0.000 1.599 1.242 2.059   0.002 1.515 1.166 1.969 
Urban/Rural 
Rural  1568 564 36% reference   reference 
Urban 485 291 60% 0.000 2.670 2.167 3.291   0.000 2.717 2.162 3.415 
Gender 
Female 820 357 44% 0.157 1.138 0.952 1.361   0.137 1.156 0.955 1.399 
Male 1233 498 40% reference   reference 
Age Group 
≤18 92 35 38% 0.316 0.798 0.513 1.241   0.788 .938 0.589 1.495 
19-29 270 117 43% 0.963 0.993 0.754 1.309   0.916 1.016 0.760 1.357 
30-44 853 371 43% reference   reference 
45+ 838 332 40% 0.106 0.852 0.702 1.035   0.917 0.989 0.806 1.214 
Category 
Previous 
treatment 
success 
1836 765 42% reference   reference 
Previous 
treatment failure 77 44 57% 0.008 1.867 1.177 2.959   0.020 1.768 1.095 2.855 
Previous 
treatment lost to 
follow-up 
140 46 33% 0.042 0.685 0.476 0.987   0.282 0.811 0.554 1.188 
Year of registration 
2013 1149 464 40% reference   reference 
2014 904 391 43% 0.191 1.125 0.943 1.343   0.205 1.126 0.937 1.353 
 
Table 4.2. Logistic regression: factors associatied with sample submission among previously treated TB patients 
in Botswana 2013-2014  
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Spatial analysis 
Examining the data spatially highlights wide variation in sample submission throughout the 24 health districts in 
the country. Figure 4.3 displays the proportion of patients with samples submitted per health district, an overall 
proportion of 42%, ranging from as low as 6% to 78% per district. Maps showing population density and road 
systems in Botswana are included for comparison. Figure 4.4 displays the proportion of patients with first-line 
DST results available per health district, an overall proportion of 19% ranging from 2-36% per district. Both maps 
(Figures 4.3 and 4.4) indicate that lower rates are concentrated on the eastern side where population density is 
higher. Because this is the opposite of what would be expected, additional district level factors were explored in 
an attempt to identify factors influencing sample submission rate.  
The NTRL is located in Gaborone in the southeastern corner of the country. While Gaborone has the highest 
percent of sample submission at 78%, it appears there are additional factors beyond distance from the NTRL, 
contributing to the variation in sample submission and availability of DST results. Table 4.3 describes 
characteristics of each district listed in order from lowest to highest rates of sample submission. Six out of 24 
total health districts have a sample submission rate ≤ 30%. The following characteristics are summarized for 
each district to determine if any may have an effect on sample submission: population, TB case notification rate, 
number of TB laboratories (defined as having at least smear microscopy capability), number of health facilities, 
and health facilities per population.  
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Figure 4.3. Proportion of previously treated TB patients with sample submission per district – and comparison 
maps of population density and road systems  
 
 
Botswana Road System 
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Figure 4.4. Proportion of previously treated TB patients with first-line DST results available per district – and 
comparison maps of population density and road systems 
Botswana Road System 
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Districts Sample 
submitted 
Population 
6 
TB Case 
Notification 
14* 
TB 
Labs 
12** 
Referral 
hospital 
12 
General 
hospital 
12 
Primary 
hospital 
12 
Clinics 
12 
Health 
Posts 
12 
Mobile 
Posts12 
Total 
Health 
Facilities¥
12 
Population 
per health 
facility6, 12 
KGATLENG 6% 91660 333  0   1   14 16 33 31 2957 
GOODHOPE 13% 6362 302  1     1 10 25 14 36 177 
CHOBE 23% 23347 243  1     1 3 12 2 16 1459 
KWENENG WEST 24% 47797 271  0     1 8 16 26 25 1912 
BOTETI 26% 66907 356  3   1 2 12 12 66 27 2478 
MABUTSANE 29% 2386 428  0       4 5 3 9 265 
SOUTHERN 30% 189019 222  1   1   13 21 13 35 5401 
BOBIRWA 34% 71936 196  0     2 8 13 22 23 3128 
SEROWE/PALAPYE 35% 180500 309  2   1 1 22 31 53 55 3282 
NORTH EAST 35% 60264 223  1     1 12 25 12 38 1586 
NGAMILAND 35% 149755 267  1   2   14 20 73 36 4160 
TUTUME 36% 150975 233  3     2 12 18 21 32 4718 
FRANCISTOWN 37% 98961 314  3 1     25 13 19 39 2537 
MAHALAPYE 38% 118875 228  2   1 1 15 28 27 45 2642 
KWENENG EAST 39% 256752 370  3   2 1 18 21 42 42 6113 
LOBATSE 40% 29007 345  2 1 1   10 1 4 13 2231 
OKAVANGO 41% 2529 223  1     1 11 17 30 29 87 
JWANENG 42% 18008 520  0   1   7 5 12 13 1385 
KGALAGADI NORTH 44% 20476 517  1     1 2 13 3 16 1280 
KGALAGADI SOUTH 49% 30016 438  1     1 6 16 14 23 1305 
SELEBI PHIKWE 50% 49411 228  1   2   11     13 3801 
SOUTH EAST 52% 85014 302  2   1   7 2 36 10 8501 
GHANZI 60% 43355 800  1     1 7 15 362 23 1885 
GABORONE 78% 231592 284  6 1 1   37 5 13 44 5263 
*TB Case Notification – per 100,000 population (2014); **TB laboratory = smear microscopy capability at minimum; ¥Total health facilities includes 
hospitals, clinics and health posts 
Table 4.3: Characteristics of districts in Botswana
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B. Testing results 
Figure 4.5 describes the overall testing results of the samples submitted for this cohort. Of 855 patients with 
samples submitted to any laboratory, 785 had samples submitted directly to or transported to the NTRL, and 
111 had samples submitted to an Xpert testing facility; samples were submitted to both the NTRL and an 
Xpert facility for 41 patients. DST results were available for 326 patients with samples submitted to the 
NTRL, and these results are from a combination of LJ solid media DST, MGIT liquid media DST and LPA DST 
(Figure 4.5). Some patients had samples tested by more than one method, therefore there is overlap; any 
patient with an RR positive result by any one method was considered as diagnosed with RR-TB. Thirty-five 
patients with RR-TB were identified among samples tested at the NTRL. Because Xpert testing is inclusive of 
testing for RR, all Xpert positive patients (n=63) are considered to have a first-line DST result available. Two 
patients with RR were identified among all samples tested by Xpert. One of these patients identified with 
Xpert as having RR-TB, was also identified through a sample submitted to the NTRL. Therefore, the total 
number of patients with RR-TB identified was 36, representing 4.6% of all patients with samples submitted. 
Samples were not submitted for testing for 1,198 patients.  
An estimation of the number of patients potentially missed due to inadequate monitoring can be made 
based on past DRS data for Botswana. Based on the most recent DRS (2008), 13% of previoulsy treated 
patients in Botswana have RR-TB17. Using this estimate, one would expect to diagnose 266 RR-TB patients 
among this cohort of 2053 previously treated patients included in this analysis. In contrast, only 36 (2% of 
the total 2053) RR-TB patients were identified through the monitoring efforts described in this analysis 
indicating that over 200 RR-TB patients may have gone undiagnosed.  
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* Table 4.4 describes testing results for the patients with samples submitted to both the NTRL and Xpert facility 
** No result indicates no culture result was entered into the LIS 
¥DST conducted by solid LJ method (207), by MGIT liquid method (110), and/ or by LPA (37) 
¥¥The total patients with RR identified is 36 (one patient had RR results at both Xpert facitily and the NTRL) 
 
Figure 4.5. Testing results of previously treated patients (2013-2014) with samples submitted to the NTRL and/or 
Xpert facility   
Total previously 
treated patients 
2053 
Sample submitted 
to NTRL 
785 
Total patients 
with samples 
submitted 
855 (42%) 
Sample submitted 
to Xpert facility 
111 
41 patients had samples submitted 
to both NTRL and Xpert* 
Culture 
Negative 
253 
(32%) 
Culture 
Positive 
487 
(62%) 
Contaminated 
31 (4%) 
No Result** 
14 (2%)  
MTB 
375 
(77%) 
NTM 
83 
(17%) 
No 
Species ID 
29 (6%) 
RR 
35 (11%) 
Xpert 
MTB 
Negative
44 (40%) 
Xpert 
MTB 
Positive 
63 (56%) 
Xpert 
Error 
Result 
4 (4%) 
DST result available 
63 (100%) 
DST result available¥ 
326 (87%) 
RR 
2 (3%) 
No sample submitted 
1198 
Total patients with 
RR identified  
36¥¥/855 (4.2%) 
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Table 4.4 describes a comparison of Xpert testing results to results from the NTRL. Of the 63 total Xpert MTB 
positive tests, 44 (70%) had no sample submitted to the NTRL for culture and DST. Because of the small numbers 
submitted to the NTRL and the fact that these tests are not from the same sample or necessarily the same day, 
limited conclusions can be drawn about correlation of tests.  
 Xpert testing results (N=111) 
  Xpert MTB 
(No RR) 
n=61 
Xpert 
MTB+RR 
n=2 
Xpert 
Negative 
n=44 
Xpert Error 
n=4 
NTRL testing results 
    
MTB, Rifampicin Susceptible 9 0 0 2 
MTB, DST not conducted 2 1 0 0 
MTB+RR 0 1 0 0 
NTM* or no species test 
conducted 2 0 5 0 
Negative 4 0 12 0 
Contaminated 0 0 2 1 
No culture or DST 44 0 25 1 
      * Non-tuberculosis mycobacteria 
Table 4.4. Comparison of Xpert results to the NTRL culture results, 2013-2014 
Assessment of culture positivity rates 
To assess if any factors (such as transport time) were influencing culture positivity and therefore ability to 
conduct DST, Table 4.5 explores culture positivity rates and factors for possible association with culture 
positivity. This analysis includes only samples submitted to the NTRL and does not include samples tested by 
Xpert only. Having a salivary sample was associated with lower culture positivity in the univariate analysis but 
not in the multivariate analysis. Additionally, smear status (smear negative), from smear tests conducted at the 
NTRL, was significantly associated with lower culture positivity. Those with a smear positive sample were 33 
times more likely to have a positive culture compared to smear negative samples. It is surprising that neither 
having a sample submitted post treatment or transport time over one week significantly affected culture 
positivity. 
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Total 
N= 
785 
Culture 
positive 
N=487 
Culture 
negative 
N=253 
Contaminated 
N=31 
 
Univariate analysis 
   
Multivariate analysis 
    n %     n % p-
value 
Odds 
Ratio 
CI 
Lower 
CI 
Upper 
  P-
value 
Odds 
Ratio 
CI 
Lower 
CI 
Upper 
Time of sample submission                                 
Pre-treatment 246 143 58% 85 35% 14 6% reference   reference 
Post-treatment (within 1 month) 539 344 64% 168 31% 17 3% .113 1.287 .942 1.759   .513 1.147 .761 1.730 
Smear status at the NTRL                                 
Smear negative 370 122 33% 217 59% 26 7% reference   reference 
Smear positive 356 334 94% 16 4% 4 1% .000 33.263 20.15
8 
54.88
9 
  .000 33.452 20.132 55.585 
Not recorded 59 31 53% 20 34% 1 2% .000 2.940 1.622 5.331   .000 3.226 1.758 5.919 
Sputum appearance                                 
Salivary 154 81 53% 62 40% 8 5% reference   reference 
Mucoid 83 61 73% 19 23% 2 2% .003 2.480 1.375 4.472   .036 2.244 1.054 4.776 
Mucopurulent 497 315 63% 154 31% 18 4% .018 1.563 1.081 2.261   .119 1.463 .907 2.362 
Blood stained 34 20 59% 12 35% 1 3% .486 1.313 .610 2.830   .357 1.568 .603 4.081 
Not recorded 17 9 53% 6 35% 2 12% .937 .960 .352 2.622   .238 2.000 .632 6.329 
Time to specimen receipt at lab                                 
More than 7 days 116 82 71% 26 22% 7 6% reference   reference 
Within one week (7 days) 547 339 62% 181 33% 19 3% .089 .682 .439 1.059   .893 1.041 .579 1.872 
Not recorded 122 66 54% 46 38% 5 4% .019 .521 .302 .898   .964 .984 .481 2.009 
 
Table 4.5. Univariate and multivariate analysis for culture positivity 
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4.4.3 Discussion (Section 1) 
This study revealed a low rate of monitoring for drug resistance among previously treated TB patients in 
Botswana; only 42% of patients had samples submitted for culture and fewer still had DST conducted, leading to 
low RR-TB case detection. Factors which were associated with lower monitoring for drug resistance included not 
having a smear test at the diagnosing facility, living in a rural area and having a treatment category of previous 
treatment success. A wide variation in sample submission rates was seen among health districts. However, none 
of the measured factors completely explain the low access to recommended testing. Poor compliance with the 
guidelines appears to be the main contributor to inadequate monitoring for this group of at-risk patients.  
Sputum culture is the most sensitive test for TB and detects more cases than smear microscopy116. Because 
culture is more costly and time-consuming than microscopy and requires a specialized laboratory and skilled 
personnel, it is not routinely recommended for all patients20. However, culture is essential for certain patient 
groups in whom the risk of drug-resistance is high or the sensitivity of sputum smear microscopy is low13. The 
Botswana national guidelines do recommend culture testing for high-risk patients, and all previously treated 
patients should have had a sample submitted for culture and DST16. This analysis showed that a low proportion 
of patients had samples submitted for culture and DST; furthermore, 442 (22%) had neither smear nor culture 
testing. This analysis highlighted that not having a smear test done was associated with a significantly lower rate 
of having a sample submitted for culture and DST, indicating that for many patients no sample was collected. 
Reasons for that may include health care workers not prioritizing the collection of sputum for some patients (i.e. 
not following recommended guidelines) or patient inability to produce sputum.  
All patients in this analysis had previously been treated for TB. Among these, previous successful TB treatment 
was significantly associated with a lower likelihood of having a sample submitted for culture and DST, as 
compared to unsuccessful treatment outcomes. Those with a previous treatment outcome of treatment failure 
were more likely to have a sample submitted for testing, indicating that many clinicians wait for treatment 
failure before monitoring for drug resistance. However, even among those with previous treatment failure, 43% 
were not monitored for drug resistance. A study in Peru showed that 94% of patients with TB treatment failure 
had MDR-TB117, making this a very important group to monitor for drug resistance. 
Receiving TB treatment in a rural setting was significantly associated with lower likelihood of having a sample 
submitted for culture and DST. This was potentially due to logistical difficulties in transportation of samples to 
laboratories. The health districts in Botswana are large, and most contain both rural and urban settings. Other 
district level factors should also be explored, including training of health staff, support from the national level 
(financial and mentoring), and overall performance of district health management teams.  
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Given the wide variation in drug resistance testing among districts as highlighted by the spatial analysis, this 
analysis investigated factors that may explain this variation including: road systems, laboratory and clinical 
infrastructure, population density and TB case notification rate. None of these factors clearly explained the rates 
of drug resistance monitoring per district. Population is most concentrated on the eastern side of the country, 
and in general there are lower rates of drug resistance monitoring along the eastern side of the country (with 
the exception of the smaller urban districts such as Gaborone and Selebi Phikwe). This is the opposite of what 
one would expect, and this was also not explained by exploring whether or not there was adequate 
infrastructure per population. There also appear to be adequate roads for sample transportation throughout the 
eastern side of the country. Areas with less road infrastructure were able to achieve medium to high rates of 
sample submission (Okavango, Ghanzi, Hukuntsi and Kgalagadi South).  
Of the six districts with sample submission rates below 30%, three had no TB laboratory, which was likely a 
contributor. The two districts with the lowest rates of sample submission, Kgatleng and Goodhope, are rural 
districts. Particularly Kgatleng appears to have limited infrastructure (laboratories and health facilities) in 
comparison to other districts with similar population levels, such as Francistown and South East. However, there 
were other districts with low or high submission rates with no clear correlation to population, road systems or 
infrastructure. Therefore, the spatial and district analysis unfortunately did not provide clarity into this variation 
among districts. The districts of Gaborone and Ghanzi have the highest rates of sample submission. It should be 
noted that two large TB research studies were being conducted in these districts during the time of this current 
analysis; therefore it is possible that these districts have higher compliance to the recommended testing 
because of the research studies and the additional research staff who were placed in these districts.  
A positive culture test is needed in order to perform phenotypic DST. Therefore, to determine if there were any 
areas to improve culture positivity rates (i.e. time to specimen receipt, NTRL practices), an assessment was 
conducted to determine if any modifiable factors were associated with culture positivity. The culture positivity 
rates observed in this analysis were consistent with the rates observed in the most recent DRS17 (2008), as well 
as the WHO reports. The WHO mycobacteriology laboratory manual118 reports that more than 90% of smear 
positive samples should be culture positive. In the most recent DRS, culture positivity was presented separately 
for smear negative and smear positive previously treated patients. Among smear positive patients from the DRS, 
87% were culture positive17 consistent with the findings of this analysis, which reported, culture positivity 
among 94% of smear positive patients. Among smear negative patients from the DRS, 28% were culture 
positive17, consistent with this analysis’ finding that 33% of smear negative patients were culture positive. A 
study in Uganda also reports low culture positivity (23%) among smear negative HIV positive TB patients119. 
Smear negative pulmonary TB disease has been documented to be more prevalent among HIV infected patients 
in sub-Saharan Africa120 and is harder to diagnose121. Culture positivity rates among this cohort were what would 
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be expected, and among those that were culture positive, 91% had DST. Time to specimen receipt in the lab or 
the NTRL sample preparation and testing practices do not seem to contribute to the low case detection 
observed in this analysis. 
In the whole WHO African region, only 43% of previously treated TB patients are tested for rifampicin 
resistance13. Some African countries are able to monitor over 50% of previously treated patients, including 
Congo (57%), Kenya (52%), Nigeria (61%) and South Africa (68%). Outside of Africa, other high burden countries 
are shown to monitor high rates including India (82%) and Philippines (83%)13. Other research reports a wide 
range of monitoring for drug resistance among previously treated TB patients. In Nepal, RR-TB is also poorly 
detected, and a study revealed that only 15% of previously treated patients had samples submitted for culture 
and DST122. In Sri Lanka, 79% of previously treated TB patients had samples submitted for culture and DST123.  
The most recent 2017 TB country profile for Botswana indicated that only 5% of previously treated patients are 
monitored for RR-TB, indicating that the problem in Botswana may be getting worse. Botswana is an upper-
middle income country with an overall small population and presumably should be able to achieve monitoring 
similar to other upper-middle income countries. However, the 19% of previously treated patients with DST in 
this analysis (and the even lower proportion (5%) of patients in the most recent WHO report) is lower than other 
countries with the same income status, including South Africa (68%), China (69%) and Gabon (40%)13. In Algeria 
and Equatorial Guinea (upper middle income countries), 14% and 29%, respectively, of previously treated 
patients are estimated to have RR-TB; both countries achieve 100% monitoring for RR-TB among previously 
treated patients13. It is surprising that Botswana’s rate of monitoring is so low and appears to be worsening, 
given the implementation of Gene Xpert machines in Botswana. However, Chapter 8 will highlight challenges 
being experienced with the Xpert implementation in Botswana as well as ongoing challenges of the NTRL 
closures.  
As a result of inadequate monitoring for drug resistance, patients with drug resistance are likely to remain 
undiagnosed. These patients may be detected with TB drug resistance during subsequent TB treatment 
episodes, but in the meantime they are likely to develop more severe disease, and remain infectious for 
longer117 possibly transmitting drug-resistant tuberculosis in the community and at the health centers where 
they are seeking care. However, many patients, particularly those with HIV infection are likely to die during TB 
treatment if their TB drug resistance remains undiagnosed. Among patients receiving first-line TB treatment in 
Botswana in 2014, a total of 9% died; among HIV negative patients, 6% died, compared to 10% of HIV positive 
patients and 15 % of patients with unknown HIV status14. Some of these patients may have been diagnosed later 
after treatment failure, but this may lead to resistance amplification124 as well as higher risk of mortality125. It 
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should also be noted that the last DRS in Botswana was conducted in 2008; it is possible that drug resistance has 
increased, and the gap in case detection may be underestimated.  
None of the factors investigated in this analysis clearly explain the low rates of sample submission, and it 
appears that poor compliance with the guidelines may be the main contributor. A previous study in Botswana 
reported that guidelines for diagnosing smear negative pulmonary TB disease were not well followed in 
Botswana126. Clinicians were interviewed as part of this previous study and reported reasons for non-adherence 
to guidelines including inability of patients to produce sputum and frustration with long laboratory delays in 
releasing sputum results126. The current TB guidelines in Botswana were last updated in 2011, and there is lack 
of clarity in some of the guidance. For example, the recommendations for who should receive culture and DST 
include a list of patient groups who are ‘at risk’ and does not separate or identify the reasons for testing these 
groups of patients (i.e. risk of drug resistance or lower sensitivity of smear microscopy). Mohr, et al identified 
missed opportunities for early diagnosis of RR-TB due to noncompliance with diagnostic algorithms; specifically, 
this study reported that 18% of patients were screened incorrectly at some point while seeking care in the 6 
months before the eventual RR-TB diagnosis127. Other research highlighting noncompliance with guidelines 
suggests that inconsistencies with training and distribution of guidelines contributes to noncompliance70.  
The study did have limitations. Some important information that may influence adherence to guidelines was not 
available including staffing levels at facilities, training of staff in districts, availability of guidelines in the facilities 
and other indicators of district level performance. Submission of samples was determined by matching two 
databases, the electronic TB registry and the national laboratory information system. Matching was done 
manually by name and ID number, and it is possible that some matches were missed due to mis-entering of 
names or ID numbers in either database. This analysis only examined one group of patients at increased risk of 
drug resistance, and it would be important to assess performance of recommended testing among other groups 
of at risk patients. 
To address the low rate of monitoring for drug resistance and the wide range of variability among districts, it is 
crucial that the TB program focus on disseminating clear education and guidance to health facilities at all levels 
(from hospitals to mobile posts) regarding testing for this and other high-risk groups of patients. Program 
supervision and monitoring are needed to ensure guidelines are followed consistently. Ensuring adequate 
resources at all facilities in the districts (rural and urban) is essential. Greater access to Xpert through 
decentralized laboratories has the potential to reduce gaps and improve RR-TB case detection if it could be 
implemented effectively and if the high priority groups are targeted for testing with Xpert.  
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4.5 Section 2: Confirmation of drug resistance profile for patients initiating second-line 
treatment 
4.5.1 Methods (Section 2) 
Study population 
The study population included all patients registered for second-line treatment in the RR-TB register between 
January 1, 2006 and December 31, 2014. Patients registered for treatment more than once were considered as 
separate patients. The full methods for development and description of this database are included in the 
Methods chapter.  
Definitions 
The primary outcome of this analysis is confirmation of drug resistance profile. Confirmation of first-line drug 
resistance profile is defined for this analysis as having DST results (for at least rifampicin) available in the RR-TB 
treatment register. Confirmation of second-line drug resistance is defined as having second-line DST results (for 
at least fluoroquinolones and/or injectable drugs) available in the RR-TB treatment register. While the DST 
results are recorded in the RR-TB treatment register, it is not always known if the result is from a baseline 
sample (specimen collection date is not recorded). Therefore, for this analysis the resistance profile categories 
were not assumed to be from baseline DST. Patients are considered to have confirmation of drug resistance if 
they have a DST result recorded in the treatment register, regardless of date of DST. Patients with Xpert DST 
results only were included as having confirmation of first-line drug resistance. Patients were categorized as 
presumptive RR-TB patients if they never had a confirmed first-line drug resistance profile recorded in the 
register throughout treatment.  
Data analysis  
For patient characteristics and primary outcome data, categorical variables were summarized using frequencies 
and proportions, and continuous variables were summarized using median values and interquartile ranges (IQR). 
A graph was created to describe confirmation of drug resistance over time among this cohort.  
Using the date that second-line DST was recorded in the RR-TB register (defined as the date the result is 
available), time to second-line DST from treatment initiation was calculated, producing median and IQR. Patients 
with second-line DST results available before treatment initiation were given a time to DST of 0 days. A Kaplan 
Meier curve was created for time to second-line DST; patients were censored at date of DST or date of 
treatment end. Time to second-line DST result was defined as time from second-line treatment initiation to the 
time a second-line result was reviewed at the laboratory.  
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All analyses were conducted using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY: IBM Corp) or Excel (for basic charts and graphs).  
4.5.2 Results (Section 2) 
Figure 4.6 displays the number of RR-TB patients registered by year and the TB (drug sensitive) case notification 
by year. The TB case notification rate has declined over the study time period. On the other hand, the number of 
patients registered as RR-TB patients has been variable over time with no clear trend.  
 
Figure 4.6. RR-TB patients registered and TB case notification by year 
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Of 785 patients in the treatment register, 665 (85%) had a first-line DST result available and were therefore 
bacteriologically confirmed RR-TB patients. Among these 665 patients 190/665 (29%) had a second-line DST 
result available in the RR-TB treatment register (Figure 4.7).  
 
Figure 4.7. Diagnosis cascade for patients registered for RR-TB treatment 2006-2014 
Patient characteristics 
Table 4.6 describes the characteristics of patients included in the RR-TB treatment register between January 1, 
2006 and December 31, 2014 and the proportion of patients with confirmed drug resistance profiles per 
characteristic. Overall, 85% of patients had confirmation of first-line drug resistance but this was much lower 
among younger patients, particularly those aged 5 years and under. Confirmation of first-line drug resistance 
profile was also lower among patients with no previous TB treatment, those with unknown HIV status and those 
with extrapulmonary TB (including those with both pulmonary and extrapulmonary disease). Overall, only 24% 
of patients had confirmation of second-line drug resistance profile, and this was particularly low in recent years. 
There were no patients with confirmation of second-line drug resistance profile who did not also have 
confirmation of first-line drug resistance profile.  
Of the 785 registered patients, 120 (15%) had no confirmation of first or second-line drug resistance profile and 
are classified as presumptive RR-TB patients. Among these 120 patients, 41 (34%) were female, 73 (61%) were 
HIV positive, and the median age was 38 (IQR 19-51). 
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Characteristic  Total 
Cohort  
First-line DST results 
available among entire 
cohort 
Second-line DST results available 
among those with first-line DST 
 
 
n  n (%)  n (%) 
TOTAL 785 665 (85%) 190 24% 
Age           
≤5 20 5 25% 1 20% 
6 to 18 53 39 74% 8 21% 
19-29 164 152 93% 56 37% 
30-44 328 290 88% 78 27% 
45+ 202 165 82% 47 28% 
Not recorded 18 14 78% 0 0% 
Median (IQR) 36 (28-46)         
Gender           
Female 361 320 89% 98 31% 
Male 424 345 81% 92 27% 
HIV Status           
HIV negative 254 210 83% 56 27% 
HIV Positive on ART* 449 389 87% 131 34% 
HIV Positive not on ART 37 30 81% 3 10% 
HIV Positive ART unknown 34 28 82% 0 0% 
HIV status unknown 11 8 73% 0 0% 
Smear at treatment start           
Negative 220 179 81% 40 22% 
Positive 427 372 87% 140 38% 
Not recorded 138 114 83% 10 9% 
Baseline radiology           
Non-cavitary 285 243 85% 65 27% 
Cavitary 252 216 86% 78 36% 
Not recorded 248 206 83% 47 23% 
Registration Category           
New TB (no previous TB 
treatment) 65 49 75% 9 18% 
Previous cure or completed 
treatment 15 14 93% 4 29% 
Treatment after failure 622 536 86% 170 32% 
Not recorded 83 66 80% 7 11% 
TB site           
Pulmonary 695 601 86% 169 28% 
Extrapulmonary and both 73 55 75% 21 38% 
Not recorded 17 9 53% 0 0% 
Treatment facility           
NRH 230 205 89% 61 30% 
LIIMH 64 52 81% 14 27% 
GPH 57 49 86% 13 27% 
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PMH 341 281 82% 89 32% 
SMH 93 78 84% 13 17% 
Year of registration           
2006 18 14 78% 2 14% 
2007 68 59 87% 29 49% 
2008 95 81 85% 34 42% 
2009 156 137 88% 46 34% 
2010 131 104 79% 55 53% 
2011 67 48 72% 17 35% 
2012 61 51 84% 1 2% 
2013 103 93 90% 3 3% 
2014 83 78 94% 3 4% 
Year not recorded 3 0 0% 0 0% 
 
Table 4.6. Characteristics of patients in the RR-TB treatment register, 2006-2014 
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Confirmation of first and second-line drug resistance over time 
Figure 4.8 describes the number of patients in the treatment register with a confirmed first-line drug resistance 
profile per year, and Figure 4.9 describes the proportion of patients with a confirmed second-line drug 
resistance profile per year. These figures do not represent a diagnostic cascade; rather they display the gap that 
exists between empiric treatment and diagnostic confirmation.  Overall, the proportion of patients with first-line 
DST results is 85% and this has remained consistent throughout the years. On the other hand, the proportion of 
patients with second-line DST results has been consistently low and has dropped in recent years.  
 
Figure 4.8. Number of registered RR-TB patients with confirmed first-line drug resistance profile, by year 
 
Figure 4.9. Number of registered RR-TB patients with confirmed of second-line drug resistance profile, by year 
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Time to second-line DST 
A total of 190 patients had second-line DST results available in the RR-TB register; 14 (7%) had no date of DST 
result in the RR-TB register and were excluded from the time to DST analysis. Of the 176 patients with a second-
line DST result and date, the median time to second-line DST results from initiation of second-line treatment was 
63 days (IQR 0-174). Patients with DST results available before treatment initiation were given a time to DST of 0 
days. Figure 4.10 displays the curve for time from treatment initiation to second-line DST result (event of 
interest). All patients who initiated treatment and had a known date of event or date of treatment stop were 
included in this analysis (704), and patients were censored at time of event (DST result available) or treatment 
stop. Patients remained in the analysis until time of event or treatment stop. At day 500 after treatment 
initiation, 295 patients remained in the analysis, at day 600, 190 patients remained, and at day 700, only 25 
patients remained in the analysis. Among these 25 patients, two received subsequent second-line DST due to 
treatment failure, explaining the rise in the curve at this point.   
 
 
Figure 4.10. Time from treatment initiation to second-line DST results available, Kaplan Meier  
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Second-line DST results for patients with confirmed Pre-XDR or XDR-TB 
Of the 190 patients with second-line DST results, a total of 60 (32%) patients had laboratory confirmed Pre-XDR 
or XDR-TB, and 53 had a known second-line DST result date. Among these 53, 11 (21%) had second-line DST 
results available at the time of second-line treatment intiiation, while 42/53 (79%) had second-line DST results 
available after inititiating second-line treatment (Figure 4.11). These results were available a median of 118 days 
after treatment initiation; this time extended beyond 1 year for 6 of these patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patients with 
confirmed Pre-XDR 
or XDR-TB 
60/190 (32%) 
Confirmed Pre-XDR or XDR- 
TB and a recorded date of 
second-line DST result 
53/60 (88%) 
Date of second-line DST 
result not recorded for 7 
patients 
Second-line DST result 
available before treatment 
initiation* 
11 (21%) 
Second-line DST result 
available after treatment 
initiation 
42 (79%) 
Median time to second-
line DST result after 
treatment initiation 
118 days (IQR 22-209) 
Patients with 
second-line DST 
conducted 
190 
* Patients with DST results available before treatment initiation were given a time to DST of 0 days 
Figure 4.11. Pre-XDR or XDR-TB patients and timing of second-line DST 
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4.5.2 Discussion (Section 2) 
RR-TB case registration has varied considerably over time. For patients initiating RR-TB treatment, the first-line 
drug resistance profile was confirmed for 85%, and this proportion has remained consistent over time. There 
were 120 patients with presumptive RR-TB, who received second-line treatment with no information about 
resistance available at any point during treatment. Notably, many younger patients did not have access to first-
line DST, likely due to the challenges of sample collection from younger patients128, 129. Second-line DST was 
available for few patients (24%) and has been impacted by changing practices (not sending samples to South 
Africa for testing) and no in-country laboratory capacity.  
There is a range of laboratory confirmation of RR-TB patients reported for other countries. In the Middle East 
where drug-resistant TB cases are underreported, a study reports that limited laboratory capacity leads to 
under-diagnosis of drug-resistant TB; in Iran 48/53 (91%) patients started on MDR-TB treatment were laboratory 
confirmed, and this was well under the total estimated MDR-TB cases (131) in the country130. A study in India 
reported that 45/58 (78%) HIV positive, presumptive MDR-TB patients on treatment were confirmed131. Based 
on the WHO country profiles of high burden TB countries, many countries appear to achieve laboratory 
confirmation for most or all of the RR-TB patients. For example, Angola reports laboratory confirmation for 
100% of patients initiating treatment, Mozambique reports laboratory confirmation for 95% of patients initiating 
treatment, and South Africa reports laboratory confirmation for more patients than have initiated treatment 
(15,986 patients with laboratory confirmation, with 10,259 patients initiating treatment)13. It should be noted 
that for many countries this is still well under the estimated RR-TB cases in the country, and for countries like 
South Africa there appear to be challenges with linking bacteriologically confirmed patients to care42. However, 
for the purposes of comparing the proportion of RR-TB patients on treatment with laboratory confirmation, it is 
clear that with the 85% of RR-TB patients with laboratory confirmation in Botswana, many countries are 
performing much better than Botswana.  
The effect of interrupted laboratory services was highlighted in this analysis. In 2011 and 2012, the national 
laboratory had limited capacity overall due to renovations (2011) and limited reagent availability (2012), 
therefore all diagnosis numbers dropped during these years. Testing for some priority patients with known or 
presumed RR-TB was still conducted with the assistance of the US CDC TB research laboratory in Gaborone. 
However, the research laboratory was not able to cover all testing needs during this time frame, and only select 
patients identified by the government as high priority received testing. While the proportion of patients with 
confirmed RR-TB did not decrease during this time, the overall numbers of patients identified with rifampicin 
resistance did decrease. Many patients are likely to have been missed during these years and may have died or 
entered treatment very late leading to increased transmission risk in the communities.  
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Additionally, laboratory infrastructure for second-line DST testing suffered a major interruption after 2010. Until 
2010, Botswana followed guidelines to send samples to South Africa for second-line DST. In 2010, the country 
began to move forward with plans to develop laboratory capacity to locally conduct second-line DST. However, 
due to laboratory interruption and lengthy validation processes, the country did not have the local capacity to 
conduct second-line DST until 2014. During this gap, 2010-2014, few samples were sent to South Africa for 
testing, per personal communication11. As a result, patients with Pre-XDR or XDR-TB may have not been 
identified, and consequently many patients may have received ineffective second-line treatment.  
Examining time to second-line DST is important to understand how long patients may be on ineffective therapy 
if additional second-line resistance is present. For the patients with second-line DST, the results were available a 
median of 63 days after second-line treatment initiation. Among those who were eventually confirmed to have 
Pre-XDR or XDR-TB, these confirmatory results were available a median of 118 days after treatment initiation, 
with a delay of more than one year for some patients; therefore, it is difficult to discern whether second-line 
resistance was present at treatment start or developed during treatment. The low proportion of patients with 
access to second-line DST and the delay among some of those who do have access contributes to potentially 
ineffective regimens for many patients.  
This study had limitations. Firstly, DST results were reported in the RR-TB register, but the timing of specimen 
collection was not reported; only the date the DST result is recorded in the RR-TB register is available. Therefore, 
this analysis used a definition of confirmation of drug resistance profile based on results available at any point 
during treatment. Therefore, the analysis did not address when that resistance may have developed (pre-
existing or during treatment) and the length of time patients may have been receiving potentially ineffective 
treatment. The program should focus on improving data quality and also further exploration around timing of 
DST to guide treatment. Secondly, guidelines regarding second-line DST were inconsistent; while the 2011 TB 
program manual recommended second-line DST for all patients receiving RR-TB treatment, the 2009 National 
Guidelines for Management of DR-TB recommended second-line DST only for patients who remained culture 
positive after four months of treatment.  Both were current guidelines in use during the time of the study; while 
it is possible that these were inconsistent because the guidelines were changing over time, it is unclear which 
guidelines were meant to be adhered to. Therefore, the research cannot draw specific conclusions about 
compliance with guidance since the guidance is unclear. Regardless, there are clear gaps in access to both first- 
and second-line DST in Botswana. 
Several factors influence the varied case detection over time observed in Botswana, including inadequate 
screening of at risk patients identified in Section 1 of this chapter. Furthermore, once patients are identified, it is 
crucial to confirm drug resistance profile to ensure effective treatment. Recommendations for the program 
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would include ensuring updated guidance is clear and fully disseminated to all health facilities. The program 
should focus on consistent laboratory capacity and reducing interruptions, which affect case detection and 
confirmation.  
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Chapter 5: Risk factors for mortality during treatment of rifampicin-
resistant TB in Botswana 
 
5.1 Chapter overview  
This chapter will include two sections, describing analysis of two cohorts. The first section describes analysis of 
RR-TB patients initiating second-line treatment from 2006-2014 inclusive (Cohort 1). The Cohort 1 section 
explores risk factors for mortality over time. The second cohort is a subset of Cohort 1 for which additional 
information was collected through medical record review (Cohort 2). Cohort 2 includes patients from 2012-2014 
inclusive, and this section will add to findings of the first section by further exploring the frequency and impact 
of disease severity and drug side effects on mortality during treatment. The chapter begins with an overview of 
background and policies regarding RR-TB management in Botswana, relevant to both sections. 
5.2 Hypotheses, aim and objectives 
Hypothesis 1: Mortality among patients initiating RR-TB treatment is associated with identifiable risk factors, 
some of which are modifiable 
Hypothesis 2: Time to mortality is affected by specific risk factors. 
Aim: To identify and determine risk factors for mortality among RR-TB patients in Botswana 
Objectives: 
To describe the proportion of patients initiating treatment who have died and risk factors for mortality 
To describe time to mortality and factors associated with early and late mortality 
To describe the frequency of co-morbidities and side effects and their impact on mortality 
5.3 Background/Policy review 
Globally, mortality as a treatment outcome among RR-TB patients who initiated treatment in 2015 is reported as 
15%; success (cured or completed treatment) among this same cohort is reported as 55%, and the remaining 
have outcomes of treatment failure (8%), lost to follow-up (14%) or no outcome information (7%)13. In 
comparison, Botswana has reported mortality as a treatment outcome for 17%, treatment success for 78%, lost 
to follow-up for 2% and treatment failure for 2% among the cohort that will be described in this chapter 
(patients initiating treatment from 2006-2014). In Botswana, in contrast to other settings and globally, lost to 
follow-up and treatment failure rates are low, and mortality during treatment is the main contributor to poor 
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outcomes. Therefore, reducing mortality is the main area in which the Botswana TB program should focus 
efforts to improve treatment outcomes for RR-TB patients. Hence, this analysis was planned in collaboration 
with the Botswana National TB Program (BNTP) to try to better understand the factors associated with mortality 
and to identify modifiable risk factors for potential interventions.  
RR-TB in Botswana is managed at specialized centers with both inpatient and outpatient care. RR-TB care has 
been decentralized from two referral hospitals in 2006 to five facilities by 2010. Currently, all presumptive and 
confirmed RR-TB patients are referred to one of five specialized government RR-TB treatment centers located 
around the country16. These five centers are managed by a team including physicians and nurses who have 
received specific training in RR-TB care. All national guidance up to the most recent 2011 TB Program Manual 
suggest that all RR-TB patients are initially started on a standardized treatment regimen16, and this is retained in 
the 2017 updated national guidelines for management of drug-resistant TB (still in draft, 2019)92. Based on the 
2007 TB Program Manual, the standardized regimen at that time was composed of amikacin, ethionamide, 
pyrazinamide and ciprofloxacin132. The standardized regimen was updated by 2009 to be composed of amikacin, 
levofloxacin, ethionamide, cycloserine, pyrazinamide and P-aminosalicylic acid (PAS)48. According to the 2009 
National Guidelines for Management of DR-TB, the recommended duration of treatment is 18 months after 
culture conversion48. All national guidelines have suggested that individualized regimens may be provided for 
patients based on DST results or patients who do not culture convert after four months of treatment. As of 
2008, additional drugs available for individualized regimens included linezolid, clarithromycin, clofazimine, 
capreomycin and augmentin104. Based on the 2011 TB Program Manual, RMR-TB patients are treated with 
isoniazid, ethambutol, levofloxacin and at least two months of pyrazinamide; minimum treatment duration is 
12-18 months16. The 2017 draft (unreleased) updated national guidelines for the management of drug-resistant 
TB suggest that the program is considering moving to the short course MDR regimen for RMR-TB patients. 
General recommendations for treatment of pre-XDR or XDR-TB (i.e. use an injectable for which the strain is 
susceptible and extend duration) are included in the treatment guidelines, and providers are advised to liaise 
with national level consultants in developing the regimen for patients with Pre-XDR or XDR-TB48. 
Some patients are hospitalized for the intensive phase of treatment; and reasons for hospitalization are 
discussed further in Chapter 8. National guidelines suggest that RR-TB patients on ambulatory treatment should 
receive directly observed treatment (DOT), provided by health facilities (hospitals, clinics, health posts) or by 
trained community volunteers48. Throughout the entire course of treatment, patient-held treatment cards are 
supposed to be signed every day by a DOT provider to record adherence, and ambulatory patients are seen at 
the specialized RR-TB treatment facilities once a month for monitoring48.  
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National guidance suggests that all RR-TB patients should have a baseline culture and first-line DST48 (2009 
National Guidelines for Management of DR-TB). Patients are to be monitored throughout second-line treatment 
with monthly smear and culture testing48. There is conflicting guidance regarding second-line DST. While the 
most recent TB program manual (2011) states that all confirmed RR-TB patients should receive second-line 
DST16, the 2009 National Guidelines for Management of DR-TB states that only those who remain culture 
positive after four months of treatment should receive second-line DST48. As described in Chapter 4, capacity for 
first- and second-line DST in Botswana was affected by laboratory closures (2011-2012, 2014-2016) and changes 
in practices whereby the program stopped sending samples to South Africa for second-line DST after 2010. At 
monthly consultations, patients should also be monitored for side effects, and the 2009 guidelines provide 
recommendations for laboratory testing (frequency and type of tests)48. For example, serum creatinine is to be 
monitored at baseline and monthly while receiving an injectable drug.  
5.4 Section 1: Mortality among RR-TB patients initiating treatment 2006-2014 
5.4.1 Methods (Section 1) 
Study population and definitions 
This analysis included patients registered in the RR-TB treatment register from 2006-2014 (Cohort 1). The 
development of the study database from the RR-TB treatment register is described in detail in Chapter 3 
(Data/Methods Chapter). Patients were excluded from this analysis if they were registered but did not initiate 
treatment or if they had an unknown treatment outcome date.  
The primary outcome of this analysis was mortality during treatment (death as a treatment outcome), defined 
as death from any cause. Treatment outcomes were assigned by clinical staff in the RR-TB treatment register, 
defined based on the World Health Organization (WHO) guidelines13 as follows: 
• Cured: Treatment completed as recommended by the national policy without evidence of failure AND 
three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase. 
• Treatment Completed: Treatment completed as recommended by the national policy without evidence 
of failure BUT no record that three or more consecutive cultures taken at least 30 days apart are 
negative after the intensive phase 
• Treatment Failure: Treatment terminated or need for permanent regimen change of at least two anti-
TB drugs because of: 
o Lack of conversion by the end of the intensive phase OR 
o Bacteriological reversion in the continuation phase after conversion to negative OR 
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o Evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs 
OR 
o Adverse drug reactions 
• Death: A patient who dies for any reason during the course of treatment 
• Lost to follow-up: A patient whose treatment was interrupted for 2 consecutive months or more 
• Treatment success: The sum of cured and treatment completed 
The resistance profile for each patient was defined by DST results available at any point during treatment. If 
there was more than one resistance profile available per patient, any profile that showed resistance was 
included in the analysis. While the resistance profile was recorded in the RR-TB treatment register, it was not 
always known if the result was from a baseline sample or during treatment (as the specimen collection date is 
not recorded). Therefore, for this analysis the resistance profile categories were not assumed to be from 
baseline DST. Patients listed as presumptive RR-TB were patients that never had a confirmed drug resistance 
profile recorded in the database and were assumed to have had unknown drug resistance profile throughout 
treatment.  
Data analysis 
For patient characteristics and treatment outcomes, categorical variables were summarized using frequencies 
and proportions, and continuous variables were summarized using median values and interquartile ranges (IQR). 
Median time from treatment initiation to outcome date was calculated for each outcome. The outcome date 
was recorded by RR-TB clinicians in the RR-TB registry.  
Cox proportional hazards regression was used to determine associations between potential risk factors and 
mortality over time. Potential risk factors, including demographic and clinical characteristics and selected other 
characteristics, were used in both univariate and multivariate analyses. Unadjusted hazard ratios (HR) and 
adjusted hazard ratios (aHR) with 95% confidence intervals (CI) and p-values for time to mortality were 
calculated. A p-value < 0.05 was considered statistically significant. Cases (patients) were censored at outcome 
date. Survival curves were produced from the adjusted model and plotted by each characteristic of interest. 
Survival curves were scaled to show survival from treatment initiation to two years. Kaplan Meier curves were 
created to show overall mortality. A cumulative hazard curve was produced from the adjusted model to explore 
changes in hazard over time.  
Binary logistic regression was conducted at two time points (death within 6 months and death after 6 months) 
to separately examine risk factors for early and late mortality. Odds ratios with 95% confidence intervals and p-
values were calculated. A p-value < 0.05 was considered statistically significant. All analyses were conducted 
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using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp) or 
Excel (for basic charts and graphs).  
5.4.2 Results (Section 1) 
Of the 785 patients registered in the RR-TB treatment register from 2006-2014, 704 were included in this 
analysis. Nineteen patients were excluded because they did not initiate treatment, seven of whom died before 
treatment initiation. An additional 62 patients were excluded because they had an unknown treatment outcome 
date, of whom 20 (32%) had an outcome of death. As will be shown throughout this analysis, missing 
information for patients is common; among those excluded due to missing information, the majority of patients 
were treated at Nyangabwe Referral Hospital (NRH). Patient characteristics are described in Table 5.1 for 
patients initiating RR-TB treatment, both for those included in the analysis as well as for those excluded due to 
unknown outcome date to assess potential limitations of excluded patients for this reason. Only Table 5.1 
includes results from excluded patients; all other analyses are only presented for the 704 patients meeting the 
inclusion criteria. Of the 704 patients, 46% are female, median age is 36 (IQR 28-46), and 471 (67%) are HIV 
positive.  
 
 Included in this analysis 
N=704 
 Excluded from this analysis 
(missing outcome date) 
N=62 
  n (%/IQR)  n (%/IQR) 
Gender 
 
   
Male 379 (54%)  36 (58%) 
Female 325 (46%)  26 (42%) 
Age groups     
Median age 36 (28-46)  39 (29-47) 
≤18 66 (9%)  6 (10%) 
19-29 150 (21%)  11 (18%) 
30-44 294 (42%)  26 (42%) 
45+ 181 (26%)  17 (28%) 
Not recorded 13 (2%)  2 (3%) 
Miner     
Miner 72 (10%)  2 (3%) 
Not miner 632 (90%)  60 (97%) 
HIV ART      
HIV negative 229 (33%)  18 (29%) 
HIV Positive on ART* 423 (60%)  19 (31%) 
HIV Positive not on ART 29 (4%)  6 (10%) 
HIV Positive ART unknown 19 (3%)  14 (23%) 
HIV status unknown 4 (1%)  5 (8%) 
Smear at treatment start      
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Positive 407 (58%)  16 (26%) 
Negative 208 (30%)  4 (7%) 
Not recorded 89 (13%)  42 (68%) 
Baseline radiology      
Cavitary 243 (35%)  7 (11%) 
Non-cavitary 266 (38%)  10 (16%) 
NA 195 (28%)  45 (73%) 
Registration category      
New TB (no previous anti-TB 
treatment)¥ 59 (8%)  4 (7%) 
Previous cure or completed 
treatment¥¥ 14 (2%)  1 (2%) 
Treatment after failure¥¥ 584 (83%)  29 (47%) 
Not recorded 47 (7%)  28 (45%) 
Resistance profile      
Presumptive RR-TB 105 (15%)  12 (19%) 
Rifampicin mono-resistance 51 (7%)  8 (13%) 
MDR, second-line susceptible 129 (18%)  0 
MDR, 2nd Line DST not conducted** 360 (51%)  42 (68%) 
Pre-XDR or XDR-TB 59 (8%)  0 
Treatment facility***      
GPH 56 (8%)  0 
LIIMH 50 (7%)  13 (21%) 
NRH 196 (28%)  33 (53%) 
PMH 322 (46%)  7 (11%) 
SMH 80 (11%)  9 (15%) 
Year of registration      
2006-2008 161 (23%)  17 (27%) 
2009-2011 327 (46%)  16 (26%) 
2012-2014 216 (31%)  29 (47%) 
TB site      
Pulmonary 623 (88%)  56 (90%) 
Extrapulmonary and both 69 (10%)  3 (5%) 
Not recorded 12 (2%)  3 (5%) 
* ART at treatment initiation 
¥ New TB = No previous history of first or second-line treatment 
¥¥ Outcome from first-line treatment 
** Includes Xpert only 
*** NRH = Nyangabwe Referral Hospital (Francistown), LIMH = Letsholathebe Memorial Hospital (Maun), GPH = 
Ghanzi Primary Hospital (Ghanzi), PMH = Princess Marina Hospital (Gaborone), SMH = Sekgoma Memorial 
Hospital (Serowe)  
 
Table 5.1. Patient characteristics RR-TB patients initiating treatment 2006-2014 
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Treatment outcomes 
Table 5.2 shows median time to outcome for patients initiating RR-TB treatment, by outcome category. Overall, 
17% of patients initiating treatment had an outcome of died, and median time to mortality from treatment 
initiation was 144 (IQR 57-343) days (4.7 months). Mortality among those patients who were lost to follow-up or 
had treatment failure is unknown.  
 
 
Treatment outcome 
 
n (%) 
Time to outcome 
(days) 
median (IQR) 
Completed 375 (53%) 637 (575-700) 
Cured 176 (25%) 644 (592-731) 
Treatment Success 551 (78%)  
Lost to follow-up 15 (2%) 305 (172-376) 
Treatment failure 16 (2%) 404 (172-629) 
Died 122 (17%) 144 (57-343) 
   
Total 704 (100%) 610 (468-691) 
 
Table 5.2. Time to treatment outcome for patients initiating RR-TB treatment, 2006-2014 
To assess treatment outcomes over time, Figure 5.1 displays the proportion of patients per treatment outcome 
by year. Overall, treatment success is high across the years, ranging between 70-86%. There are low rates of 
treatment failure and loss to follow-up. However, mortality remains high (19% or higher for 5 out of 9 years) 
over time, though proportionally mortality has decreased in 2013 and 2014.  
 
 
 
Figure 5.1. Proportion of patients per treatment outcome by year, N=704 
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As previously described, the median time to mortality was 144 (IQR 57-343) days. While mortality was more 
rapid in the first 3 month of treatment, patients continue to die throughout treatment, as shown in Figure 5.2. 
Risk factors for mortality during treatment will be further explored throughout this chapter, including risk 
factors for early mortality and late mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Survival of patients on second-line treatment, Kaplan Meier 
Cox proportional hazard regression 
Both univariate and multivariate survival analyses were conducted to assess if certain clinical or demographic 
factors were associated with time to mortality (Table 5.3). Factors which were significantly associated with 
increased mortality risk over time in the multivariate model included: age ≥ 45 years, HIV positive patients not 
on ART at treatment initiation, unknown HIV status, smear positive patients at treatment initiation, baseline 
radiology not recorded, registration category not recorded, unknown drug resistance profile (presumptive RR-
TB), Pre-XDR or XDR-TB, treatment at Princess Marina Hospital, treatment at Sekgoma Memorial Hospital, and 
treatment between 2009-2011. Figures 5.3-5.8 display adjusted survival curves, and each of these factors are 
further discussed along with the respective survival curves.  
  
(days) 
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  Total 
N=704 
Deceased Univariate Analysis Multivariate Analysis 
  n  n (%) p-value Unadjusted 
HR 
Lower 
CI 
Upper 
CI 
p-value Adjusted 
HR 
Lower 
CI 
Upper 
CI 
Gender                     
Male 379 78 (21%) .021 1.544 1.066 2.234 .861 1.039 .679 1.591 
Female 325 44 (14%) reference Reference 
Age groups                     
≤18 66 3 (5%) .026 .261 .080 .850 .013 .206 .059 .712 
19-29 150 16 (11%) .121 .626 .347 1.131 .178 .664 .367 1.205 
30-44 294 48 (16%) reference Reference 
45+ 181 52 (29%) .528 1.177 .709 1.956 .026 1.726 1.068 2.791 
Not recorded 13 3 (23%) .442 1.581 .492 5.079 .981 .985 .274 3.536 
Miner                     
Miner 72 25 (35%) .000 2.426 1.562 3.767 .780 1.086 .610 1.932 
Not miner 632 97 (15%) reference reference 
HIV ART                     
HIV negative 229 28 (12%) reference reference 
HIV Positive on ART* 423 78 (18%) .041 1.568 1.018 2.415 .244 1.322 .826 2.115 
HIV Positive not on ART 29 10 (34%) .000 3.695 1.794 7.612 .001 3.633 1.674 7.885 
HIV Positive ART unknown 19 2 (11%) .849 .870 .207 3.653 .163 .309 .059 1.608 
HIV status unknown 4 4 (100%) .000 43.650 14.790 128.823 .000 22.415 6.853 73.313 
Smear at treatment initiation                     
Positive 407 88 (22%) .000 2.616 1.575 4.344 .000 2.787 1.636 4.747 
Negative 208 18 (9%) reference reference 
Not recorded 89 16 (18%) .020 2.229 1.136 4.371 .299 1.547 .679 3.522 
Baseline radiology                     
Cavitary 243 37 (15%) .865 1.040 .661 1.636 .606 .883 .550 1.417 
Non-cavitary 266 38 (14%) reference reference 
Not recorded 195 47 (24%) .008 1.787 1.165 2.741 .001 2.483 1.456 4.236 
Registration category                     
New TB ¥ 59 3 (5%) reference       reference 
Previous cure or completed¥¥ 14 5 (36%) .006 7.559 1.806 31.641 .133 3.122 .706 13.812 
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Treatment after failure 584 103 (18%) .028 3.620 1.148 11.410 .138 2.425 .752 7.818 
Not recorded 47 11 (23%) .012 5.103 1.424 18.293 .009 6.655 1.591 27.831 
Resistance profile                     
Presumptive RR-TB 105 31 (30%) .000 3.301 1.755 6.209 .002 2.851 1.461 5.564 
Rifampicin monoresistance 51 4 (8%) .772 .849 .279 2.580 .659 .764 .232 2.522 
MDR, second-line susceptible 129 14 (11%) reference reference 
MDR, second-line DST not 
conducted** 360 58 (16%) .103 1.626 .907 2.915 .057 1.837 .981 3.437 
Pre-XDR or XDR-TB 59 15 (25%) .009 2.657 1.282 5.509 .019 2.468 1.163 5.241 
Treatment facility***                     
GPH 56 5 (9%) .475 .703 .267 1.850 .580 1.343 .473 3.815 
LIIMH 50 1 (2%) .072 .160 .022 1.182 .214 .278 .037 2.095 
NRH 196 23 (12%) reference reference 
PMH 322 74 (23%) .003 2.032 1.271 3.246 .001 2.594 1.463 4.600 
SMH 80 19 (24%) .029 1.972 1.073 3.623 .015 2.266 1.174 4.372 
Year of registration                     
2006-2008 161 26 (16%) reference reference 
2009-2011 327 66 (20%) .177 1.368 .868 2.155 .004 2.200 1.287 3.761 
2012-2014 216 30 (14%) .745 .917 .542 1.551 .218 1.486 .791 2.795 
TB site                     
Pulmonary 623 102 (16%) reference  reference 
Extrapulmonary and both 69 17 (25%) .134 1.481 .886 2.476 .083 1.661 .936 2.947 
NR 12 3 (25%) .305 1.824 .578 5.753 .860 1.132 .285 4.488 
* ART at treatment initiation 
¥ New TB = No previous history of first or second-line treatment 
¥¥ Outcome from first-line treatment 
** Includes Xpert only 
*** NRH = Nyangabwe Referral Hospital (Francistown), LIMH = Letsholathebe Memorial Hospital (Maun), GPH = Ghanzi Primary Hospital (Ghanzi),  
PMH = Princess Marina Hospital (Gaborone), SMH = Sekgoma Memorial Hospital (Serowe)  
 
Table 5.3. Univariate and multivariate analysis of risk factors for mortality among patients initiating RR-TB treatment, 2006-2014 
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Adjusted survival curves were produced from the Cox proportional hazards regression. This next section further 
describes risk factors for mortality along with survival curves.  
HIV and smear status both revealed associations with mortality (Figure 5.3). Being HIV positive without ART at 
RR-TB treatment initiation was associated with an almost four-fold increase in risk, as compared to HIV negative 
persons. Unknown HIV status was also associated with increased risk though the n is small (n=4, and all died 
within 6 months of treatment); HIV positive individuals on ART at RR-TB treatment initiation had a high mortality 
risk over time compared to HIV negative individuals in the univariate model only. HIV positivity with unknown 
ART status has the lowest mortality rate; however, the n is small (19), and this effect is not statistically 
significant. Being smear positive at treatment initiation was associated with a three-fold increase in risk as 
compared to smear negative, in the multivariate model.  
 
Figure 5.3. Mortality by HIV status and baseline smear result, adjusted survival curves 
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Older age, over 45, was significantly associated with a higher risk of mortality, while younger age, 18 years or 
less, was shown to be protective (Figure 5.4).  
 
 
Figure 5.4. Mortality by age group, adjusted survival curve 
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Increased mortality was associated with missing patient information for both registration category and baseline 
radiology (Figure 5.5). A result of ‘not recorded’ indicates there was no information available in the RR-TB 
registry. The RR-TB registry is completed from the patient medical records at the RR-TB treatment facilities; 
therefore, if information is missing in the registry, it can be assumed that the clinicians did not have access to 
this data to take into account for patient management.  
Missing baseline radiology results are associated with a higher risk of mortality, and a large proportion of 
patients were missing these results (195/704, 28%). It is possible that patients who are smear positive are not 
further referred for chest x-ray. Cross tabulations revealed that those with unknown radiology results were 
more likely to be smear positive (90/195, 46%) than smear negative (37/195, 19%), with 35% (68/195) having 
both missing radiology and smear results.  
Registration category refers to previous first-line TB treatment and provides information about a patient’s 
history of exposure to TB medications. Having previous TB treatment was associated with a higher risk of 
mortality in the univariate model for both those with a previous outcome of cure or completed and those with 
an outcome of treatment failure. However, in the multivariate model only those with missing data on 
registration category had a significantly higher risk of mortality.  
 
* New TB = No previous history of first or second-line treatment; ** Outcome from first-line treatment 
 
Figure 5.5. Mortality by registration category and baseline radiology, adjusted survival curves 
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Other findings also indicate that missing patient information was associated with mortality. Unknown HIV status 
was associated with a higher risk of mortality as described above (Figure 5.3), as well as unknown smear status 
(in the univariate model only) (Figure 5.3). In an effort to identify if missing patient information is more common 
at any of the treatment facilities, these results are displayed by treatment facility in Table 5.4. Nyangabwe 
Referral Hospital (NRH), in Francistown (the second largest city in Botswana) has consistently higher proportions 
of missing information than other facilities. 
 
Characteristic NRH 
N=196 
LIMH 
N=50 
GPH 
N=56 
PMH 
N=322 
SMH 
N=80 
Radiology – not recorded 77 (39%) 7 (14%) 16 (29%) 70 (22%) 25 (31%) 
Smear – not recorded 48 (25%) 4 (8%) 5 (9%) 22 (7%) 10 (13%) 
Registration – not recorded 36 (18%) 2 (4%) 0 4 (1%) 5 (6%) 
HIV positive, ART unknown 14 (7%) 2 (4%) 0 0 3 (4%) 
HIV status unknown 2 (1%) 0 0 2 (1%) 0 
*** NRH = Nyangabwe Referral Hospital (Francistown), LIMH = Letsholathebe Memorial Hospital (Maun), GPH = 
Ghanzi Primary Hospital (Ghanzi), PMH = Princess Marina Hospital (Gaborone), SMH = Sekgoma Memorial 
Hospital (Serowe) 
 
Table 5.4. Proportion of patients with missing information by facility***  
 
  
90 
 
As has just been described, missing patient information was associated with increased mortality. Further 
supporting this finding, missing drug resistance information was also associated with increased mortality. 
Missing both first and second-line DST (presumptive RR-TB) was associated with a three-fold increase in 
mortality. Additionally, having first-line DST results confirming RR but no second-line DST also suggested 
increased risk (not statistically significant) (Figure 5.6). Overall, 15% of patients were classified as presumptive 
RR-TB. Certain groups were more likely to have a presumptive RR-TB classification, including children (38%) and 
HIV positive persons with unknown ART (32%). No facility had a higher proportion of patients with presumptive 
RR-TB classification; the proportion of presumptive RR-TB per facility ranged from 11-17%  
 
Figure 5.6. Mortality by drug resistance profile, adjusted survival curve 
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Increased risk of mortality was associated with receiving treatment at two of the five treatment facilities in 
Botswana: Princess Marina Hospital (PMH) and Sekgoma Memorial Hospital (SMH) (Figure 5.7). Table 5.5 
describes select patient characteristics per treatment facility. PMH is located in the capital city (Gaborone) and 
treated the highest number of RR-TB patients. PMH appears to have received patients with more severe disease; 
there are higher rates of smear positive patients and patients with documented cavitary disease. However, LIMH 
also has high rates of cavitary disease, and there is a high rate of unreported radiology results among all sites. 
Smear and baseline radiology results were similar in Serowe compared to other facilities. There was a slightly 
higher rate of HIV positive patients not on ART in Serowe (7.5% compared to 4-5% at other sites). However, all 
of these factors were adjusted for in the multivariate model; therefore, there remain un-identified factors 
influencing mortality at these treatment facilities.  
 
* NRH = Nyangabwe Referral Hospital (Francistown), LIMH = Letsholathebe Memorial Hospital (Maun), GPH = 
Ghanzi Primary Hospital (Ghanzi), PMH = Princess Marina Hospital (Gaborone), SMH = Sekgoma Memorial 
Hospital (Serowe)  
 
Figure 5.7. Mortality by treatment facility, adjusted survival curve 
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 NRH 
N=196 
n (%) 
LIMH 
N=50 
n (%) 
GPH 
N=56 
n (%) 
PMH 
N=322 
n (%) 
SMH 
N=80 
n (%) 
HIV status      
HIV negative 41 (21%) 17 (34%) 32 (57%) 115 (36%) 24 (30%) 
HIV positive on ART 129 (66%) 31 (62%) 24 (43%) 192 (60%) 47 (59%) 
HIV positive not on ART 10 (5%) 0 0 13 (4%) 6 (8%) 
HIV positive ART uknown 14 (7%) 2 (4%) 0 0 3 (4%) 
HIV status unknown 2 (1%) 0 0 2 (1%) 0 
Smear Status      
Smear negative 47 (24%) 18 (36%) 27 (48%) 87 (27%) 29 (36%) 
Smear positive 101 (52%) 28 (56%) 24 (43%) 213 (66%) 41 (51%) 
Not recorded 48 (25%) 4 (8%) 5 (9%) 22 (7%) 10 (13%) 
Baseline radiology      
Noncavitary  62 (32%) 21 (42%) 27 (48%) 123 (38%) 33 (41%) 
Cavitary 57 (29%) 22 (44%) 13 (23%) 129 (40%) 22 (28%) 
Not recorded 77 (39%) 7 (14%) 16 (29%) 70 (22%) 25 (31%) 
 
Table 5.5 Select patient characteristics per treatment facility 
Increased mortality was significantly associated with being registered in the years 2009-2011, the time period 
with the highest number of patients (Figure 5.8). Between 2009 and 2011, 327 patients initiated treatment, 
compared to 161 (2006-2008) and 216 (2012-2014).  
 
 
Figure 5.8. Mortality by year of registration, adjusted survival curve 
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Other categories did not show significant associations with mortality. Male gender was associated with higher 
risk of mortality in the univariate analysis (HR 1.54, p-value .021), but not in the multivariate analysis. The same 
was seen for being a miner (HR 2.43, p-value .000) versus not being a miner. Cross tabulations revealed no 
differences among miners compared to non-miners in regards to HIV status, smear status, baseline radiology 
results or resistance profile. Miners were more likely to be men (71/72), most were over 45 years (61/72) and 
most were treated at PMH (63/72) (where more severe cases are referred). Miners may have had more severe 
disease. In addition, data on silicosis was not available. There were no associations with mortality by site of TB 
disease in either the univariate or multivariate model.  
Figure 5.9 displays the cumulative hazard of mortality over time for RR-TB patients on second-line treatment. 
The slope of the hazard function decreases over time; therefore the hazard of mortality appears to decrease 
over time. Specifically, for the first six months the slope is steeper, compared to after six months. Therefore, risk 
factors for mortality were explored for two time points (death within 6 months and death after 6 months) to 
separately examine risk factors for early and late mortality. 
 
Figure 5.9. Cumulative hazard of mortality over time among RR-TB patients on second-line treatment 
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Table 5.6 describes a logistic regression for mortality within the first six months of treatment and after six 
months of treatment. Of the 704 patients initiating second-line treatment, 68 (10%) died within the first six 
months of treatment; this is 56% of all patients who died at any point during treatment (68/122). Factors which 
were associated with mortality throughout treatment included smear positivity at baseline, unknown drug 
resistance profile (presumptive RR-TB), and treatment at PMH. Factors associated with mortality only in the first 
6 months include HIV positive persons not on ART, missing baseline radiology results, missing registration 
category, and year of registration of 2009-2011 or 2012-2014. Although all of the patients with unknown HIV 
results died in the first six months, the n (4) is too small to produce a significant association in this analysis. Age 
under 18 years was protective in the first six months of treatment.  
Risk factors for mortality after six months of treatment initiation were assessed for the 626 patients who 
received six or more months of treatment. Those who died in the first six months or otherwise stopped 
treatment in the first six months were not included in this analysis. Factors contributing to mortality only after 
six months of treatment included unknown smear results, Pre-XDR or XDR-TB, and receiving treatment at SMH 
(Table 5.6).  
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  Death within 6 months  Death after 6 months 
  Total 
N=704 
n 
Deceased 
N=68 
n(%) 
p-value OR Lower 
CI 
Upper 
CI 
 Total 
N=626 
n 
Deceased 
N=54 
n(%) 
p-value OR Lower 
CI 
Upper 
CI 
Gender                      
Male 379 44 (12%) .531 1.237 .635 2.410  331 34 (10%) .812 .918 .454 1.856 
Female 325 24 (7%) reference  295 20 (7%) reference 
Age groups                      
≤18 66 2 (3%) .050 .162 .026 1.000  63 1 (2%) .155 .213 .025 1.792 
19-29 150 9 (6%) .245 .578 .229 1.458  140 7 (5%) .182 .514 .194 1.364 
30-44 294 26 (9%) reference  262 22 (8%) reference 
45+ 181 29 (16%) .214 1.643 .751 3.591  150 23 (15%) .099 1.952 .882 4.320 
Age unknown 13 2 (15%) .769 .698 .063 7.714  11 1 (9%) .921 .890 .087 9.107 
Miner                      
Miner 72 14 (19%) .498 1.392 .534 3.630  57 11 (19%) .834 1.112 .412 3.002 
Not miner 632 54 (9%) reference  569 43 (8%) reference 
HIV ART                      
HIV negative 229 13 (6%) reference  212 15 (7%) reference 
HIV Positive on ART* 423 40 (9%) .329 1.461 .682 3.129  377 38 (10%) .539 1.259 .604 2.628 
HIV Positive not on ART 29 9 (31%) .000 9.740 2.951 32.151  20 1 (5%) .592 .543 .058 5.055 
HIV Positive ART unknown 19 2 (11%) .967 .954 .101 9.049  17 0 (0%) .998 .000 0.000   
HIV status unknown 4 4 (100%) .999 1.86E+10 0.000    0 - 
 
      
Smear at treatment start                      
Positive 407 48 (12%) .009 2.939 1.308 6.602  352 40 (11%) .004 3.614 1.510 8.653 
Negative 208 10 (5%) reference  196 8 (4%) reference 
Not recorded 89 10 (11%) .584 .686 .178 2.648  78 6 (8%) .045 3.816 1.033 14.096 
Baseline radiology                      
Cavitary 243 19 (8%) .954 .977 .443 2.154  219 18 (8%) .449 .753 .362 1.568 
Non-cavitary 266 17 (6%) reference  245 21 (9%) reference 
Not recorded 195 32 (16%) .000 6.031 2.495 14.579  162 15 (9%) .710 1.178 .497 2.790 
Registration category                      
New TB 59 2 (3%) reference  56 1 (2%) reference 
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Previous cure or completed 14 2 (14%) .978 1.035 .088 12.217  12 3 (25%) .105 8.198 .645 104.194 
Treatment after failure 584 55 (9%) .500 1.697 .364 7.906  520 48 (9%) .205 3.878 .477 31.542 
Not recorded 47 9 (19%) .022 11.013 1.411 85.978  38 2 (5%) .336 3.963 .240 65.420 
Resistance profile                      
Presumptive RR-TB 105 19 (18%) .042 3.096 1.042 9.199  86 12 (14%) .041 3.036 1.049 8.788 
Rifampicin monoresistance 51 2 (4%) .611 .612 .093 4.048  47 2 (4%) .648 .668 .118 3.780 
MDR, second-line 
susceptible 129 6 (5%) reference  123 8 (7%) reference 
MDR, second-line DST not 
conducted** 360 35 (10%) .182 1.964 .729 5.288  320 23 (7%) .316 1.641 .623 4.324 
Pre-XDR or XDR-TB 59 6 (10%) .404 1.761 .467 6.639  50 9 (18%) .050 3.100 .999 9.622 
Treatment facility                      
GPH 56 4 (7%) .109 3.056 .779 11.990  52 1 (2%) .757 .703 .075 6.593 
LIIMH 50 0 (0%) .997 .000 0.000    48 1 ((2%) .828 .784 .087 7.055 
NRH 196 17 (9%) reference  178 6 (3%) reference 
PMH 322 42 (13%) .006 3.561 1.451 8.741  274 32 (12%) .019 3.341 1.216 9.173 
SMH 80 5 (6%) .951 .963 .289 3.206  74 14 (19%) .000 8.307 2.696 25.597 
Year of registration                      
2006-2008 161 10 (6%) reference  149 16 11%) reference 
2009-2011 327 42 (13%) .000 7.399 2.805 19.517  281 24 (9%) .467 .736 .323 1.679 
2012-2014 216 16 (7%) .012 4.066 1.357 12.187  196 14 (7%) .210 .538 .205 1.416 
TB site                      
Pulmonary 623 57 (9%) reference  556 45 (8%) reference 
Extrapulmonary or both 69 8 (12%) .439 1.478 .549 3.974  61 9 (15%) .131 2.026 .810 5.064 
Not recorded 12 3 (25%) .617 1.574 .266 9.292  9 0 (0%) .999 .000 0.000   
* HIV Positive and on ART at RR-TB treatment initiation; ** Includes Xpert only 
 
Table 5.6. Logistic regression for mortality within six months of treatment initiation and after six months of treatment initiation 
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5.5 Section 2: Mortality among RR-TB patients initiating treatment 2012-2014 
The next section describes analyses of Cohort 2, which is a subset of the full cohort (Cohort 1) described in the 
first section of the chapter. Additional clinical information (baseline weight, drug side effects, symptoms and co-
morbidities) was obtained for patients in Cohort 2 through medical record reviews to describe the frequency of 
reported side effects, comorbidities and factors of disease severity, as well as their relative contribution to 
mortality.   
5.5.1 Methods (Section 2) 
Study population 
This analysis included patients registered in the RR-TB treatment register from 2012-2014 inclusive, using similar 
inclusion and exclusion criteria as was used for the full cohort (Cohort 1). Patients were excluded if they were 
registered but did not initiate treatment, had an unknown treatment outcome date or if their patient chart was 
not available. 
Study variables 
Characteristics which did not show a significant association in the analysis of the full cohort were excluded from 
the Cox regression for this cohort, such as gender and TB site. Some of the risk factors were combined due to 
the smaller sample size in this three-year cohort. For example, age group is limited to under 45 years and over 
45 years. For the multivariate analysis, characteristics to measure disease severity were combined into one 
composite variable including: baseline weight below 40kg, the presence of cavitary disease, smear positivity and 
shortness of breath. Likewise, side effects and comorbidities were combined into composite variables and 
analyzed by the number of events (side effect or comorbidities) reported. These variables are also described 
individually, separate from the multivariate analysis. Side effects are defined in Table 5.7 below.  
Comorbidities refer to diabetes, hypertension and cancer (HIV is included separately). Clinicians make note of 
comorbidities in the medical charts but do not include laboratory or other clinical values. The presence of a 
comorbidity was extracted from the medical charts and added to the study database per patient.  
Table 5.7 describes the definitions used to characterize side effects included in this analysis. These are the 
definitions used by clinicians to note the presence of a side effect in the medical charts. Medical charts list the 
laboratory values where relevant and/or note the presence of the side effect. These details were extracted from 
the medical charts and added to the study database per patient (with name matching) to indicate the presence 
of a side effect. Medical charts do not specify the severity of side effects based on these definitions; however, 
Table 5.7 includes an interpretation of the grade level of reported side effects based on definitions used in 
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Botswana, Common Terminology Criteria for Adverse Events (CTCAE) v4133 and normal lab ranges according to 
Merck Manuals134. All reported side effects are Grade 1 or higher.  
Side effects Definitions used by Botswana TB 
program 
 
CTCAE criteria definition 
Normal lab 
ranges 
 
Interpretation 
of reported side 
effects 
Anemia Hemoglobin < 11 g/dL Grade 1: Hgb <LLN - 10.0 
g/dL 
14-17 (men), 
12-16 
(women)* 
Grade 1 or 
higher 
Hypokalemia Potassium < 3.5 mmol/L Grade 1: K<LLN - 3.0 
mmol/L 
3.5-5 
mmol/L* 
Grade 1 or 
higher 
Hypothyroidism TSH > 9 Grade 1: Asymptomatic; 
clinical or diagnostic 
observations only 
0.5–5.0 
mcIU/mL* 
Grade 1 or 
higher 
 
Renal impairment Creatinine >104 (male) and> 90 
(female) umol/L 
Grade 1: Creatinine >ULN 
- 1.5 x ULN 
30–170 U/L* Grade 1 or 
higher 
Thrombocytopenia Platelets < 150 Grade 1: <LLN - 75.0 x 
10e9 /L 
150-350 x 
103/mcL * 
Grade 1 or 
higher 
Hepatitis ALT > 50 U/L Grade 1: >ULN – 3.0 x 
ULN 
0-35 U/L* Grade 1 or 
higher 
Hearing loss Self-reported hearing loss, 
confirmed by audiometry when 
possible. 
Grade 1: Threshold shift 
of 15 - 25 dB averaged at 
2 contiguous test 
frequencies in at least 
one ear. 
 
 
 
 
N/A 
N/A 
Tinnitus Self-reported ringing in the ears Grade 1: Mild symptoms N/A Grade 1 or 
higher 
Psychiatric 
disturbances 
Self-reported presence of one or 
more of the following: depression, 
hallucinations, suicidal attempt, 
anxiety or psychiatric 
disturbances. 
Grade 1: Mild symptoms N/A Grade 1 or 
higher 
Neuropathy Self-reported numbness, prickling 
or burning sensations 
Grade 1: Asymptomatic; 
clinical or diagnostic 
observations only; 
N/A Grade 1 or 
higher 
Gastrointestinal 
disorders 
Self-reported presence of one 
more of the following: nausea, 
vomiting, or diarrhea. 
Grade 1: Asymptomatic 
to mild symptoms 
N/A Grade 1 or 
higher 
Visual 
disturbances 
Self-reported disturbances of 
eyesight. 
Grade 1: Asymptomatic 
to mild symptoms 
N/A Grade 1 or 
higher 
Dizziness Self-reported experience of 
dizziness 
Grade 1: Mild 
unsteadiness or 
sensation of movement 
N/A Grade 1 or 
higher 
Arthralgia Self-reported pain or stiffness in 
joints 
Grade 1: Mild pain N/A Grade 1 or 
higher 
* Laboratory normal values obtained from Merck Manuals 
 
Table 5.7. Definitions used to characterize side effects  
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Data analysis 
For patient characteristics and treatment outcomes, categorical variables were summarized using frequencies 
and proportions, and continuous variables were summarized using median values and interquartile ranges (IQR). 
The median time from treatment initiation to outcome date was calculated for each outcome. The treatment 
outcome date was recorded by RR-TB clinicians in the RR-TB registry. A two proportion z test was used to 
calculate p-values for mortality among groups with reported characteristics of disease severity and side effects. 
Cox proportional hazards regression was used to determine the correlation between potential risk factors and 
mortality. Potential risk factors included demographic and clinical characteristics, and characteristics were used 
in both univariate and multivariate analyses. Unadjusted hazard ratios (HR) and adjusted hazard ratios (aHR) 
with 95% confidence intervals (CI) and p-values for time to mortality were calculated. A p-value < 0.05 was 
considered statistically significant. Cases (patients) were censored at outcome date. Survival curves were 
produced from the adjusted model and plotted by each characteristic of interest. Survival curves were scaled to 
show survival from treatment initiation to two years. Kaplan Meier curves were created to show overall survival.  
All analyses were conducted using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY: IBM Corp) or Excel (for basic graphs and charts).  
5.5.2 Results (Section 2) 
Of the 245 total patients registered in the RR-TB treatment registry from 2012 to 2014 inclusive, 176 were 
included in this analysis. During this time frame, there were no patients registered who did not initiate 
treatment. Patients were excluded if they had an unknown outcome date (29) or if they did not have a patient 
chart available (40). Of the 69 excluded participants, 14 (20%) died during treatment. A higher proportion of 
excluded patients had presumptive RR-TB (19%) and were over 45 (32%), compared to the included patients (7% 
and 18% respectively). Patient characteristics are described in Table 5.8 for patients initiating RR-TB treatment, 
both for those included in the analysis as well as for those excluded due to unknown outcome date to assess 
potential limitations of excluding patients. Only Table 5.8 includes results from excluded patients; all other 
analyses are only presented for the 176 patients meeting the inclusion criteria. Of the 176 patients, 50% were 
female, the median age was 37 (IQR 30-43), and 118 (67%) were HIV positive. Twelve (7%) had missing first and 
second-line DST and were classified as presumptive RR-TB. This proportion is smaller than the 18% presumptive 
RR-TB observed in the full cohort, and this suggests that the program improved practices for obtaining 
confirmatory DST results for patients initiating treatment in more recent years. However, there are also fewer 
patients initiating treatment in 2012-2014 as compared to preceding years suggesting patients may have been 
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missed during this time frame. Furthermore, although Xpert had not been fully implemented in Botswana at this 
time, it was in use as part of a nationwide operational research study conducted within the programmatic 
setting of Botswana. Therefore, some patients were diagnosed by Xpert during this time frame; 20/176 patients 
(11%) were diagnosed by Xpert only, and these were classified as confirmed RR-TB.  
The proportion of RR-TB patients with Pre-XDR or XDR-TB also decreased during this time period with 2% of 
patients diagnosed with Pre-XDR or XDR-TB as compared to 10% in the full cohort. Of the 136 patients with 
confirmed RR-TB, only five had second-line DST; four had Pre-XDR or XDR-TB and one was susceptible to second-
line drugs.  
 
Patient characteristics  
 
Included in this analysis 
N=176 
Excluded from this analysis 
(missing outcome date or 
patient file) 
N=69 
  n (%/IQR) n (%/IQR) 
Age Group    
Median (IQR) 37 (30-43) 37 (26-52) 
Under 45 138 (78%) 46 (67%) 
45+ 31 (18%) 22 (32%) 
Not recorded 7 (4%) 1 (1%) 
Gender  
Male 88 (50%) 36 (52%) 
Female 88 (50%) 33 (48%) 
HIV ART    
HIV negative 58 (33%) 25 (36%) 
HIV Positive on ART at RR-TB 
treatment initiation 
 
114 (65%) 
 
39 (57%) 
HIV Positive not on ART 4 (2%)* 3 (4%) 
Unknown HIV Status 0 2 (3%) 
Resistance Profile    
Presumptive RR-TB 12 (7%) 13 (19%) 
RMR 24 (14%) 7 (10%) 
RR-TB (includes Xpert only) 136 (77%)** 48 (70%) 
Pre-XDR or XDR-TB 4 (2%) 1 (1%) 
Year of registration    
2012 44 (25%) 17 (25%) 
2013 79 (45%) 24 (35%) 
2014 53 (30%) 28 (40%) 
* One person with ART unknown  
** One person with confirmed second-line susceptibility 
 
Table 5.8. Characteristics of patients initiating RR-TB treatment 2012-2014  
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Table 5.9 shows median time to outcome for patients initiating RR-TB treatment, by outcome category. Overall, 
23/176 (13%) patients initiating treatment had an outcome of died, and median time to mortality was 116 (IQR 
20-289) days in this three year cohort.  
Treatment outcome  
n (%) 
Time to outcome (days) 
median (IQR) 
Completed 124 (71%) 648 (575-713) 
Cured 20 (11%) 602 (506-648) 
Treatment success 144 (82%)  
Stopped treatment 5 (3%) 365 (14-451) 
Treatment failure 4 (2%) 378 (283-554) 
Died 23 (13%) 116 (20-289) 
   
Total 176 (100%) 609 (481-691) 
 
Table 5.9. Time to treatment outcome for patients initiating RR-TB treatment, 2012-2014, N=176 
Reviewing medical charts provided important information about disease severity, side effects and comorbidities, 
which was not present in the RR-TB registry. This additional information is described individually and then as 
part of the multivariate analysis. Table 5.10. describes mortality among individual characteristics of disease 
severity. Higher rates of mortality were observed among all characteristics used to measure disease severity in 
this analysis, compared to patients without these characteristics; the differences are statistically significant for 
low baseline weight, cavitary disease and presence of shortness of breath.  
Characteristics of Disease 
Severity 
 
Died 
 
p-value 
Baseline weight 
 
 
Below 40kgs 9/23 (39%) <.0001 
Above 40kgs 12/148 (8%)  
Baseline radiology 
 
 
Cavitary disease 9/57 (16%) .036 
Non-cavitary disease 4/79 (5%)  
Baseline sputum smear 
 
 
Smear positive 18/109 (17%) .080 
Smear negative 4/58 (7%)  
Shortness of Breath 
 
 
Yes 8/13 (62%) <.0001 
No 15/163 (9%)  
 
Table 5.10. Mortality by characteristics of disease severity among patients initiating RR-TB treatment, 2012-2014  
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The following tables describe the proportion of all patients with reported side effects and comorbidities and 
mortality among those with reported side effects and comorbidities (Tables 5.11 and 5.12). Some side effects 
are reported among a high number of patients (anemia (39%), hearing loss (44%) and gastrointestinal symptoms 
(39%)), but none of the side effects appear to be associated with mortality. Among reported comorbidities, 
hypertension and cancer have high rates of mortality but are only reported among 5% and 1% of all patients, 
respectively. No single side effect or comorbidity appears to have an association with mortality; the multivariate 
analysis will explore whether or not the number of reported side effects or comorbidities had an association 
with mortality. It should be noted that this table describes the comorbidities that are combined into a composite 
variable for the multivariate analysis. HIV is not included as part of the composite variable but is included 
separately in the multivariate analysis.  
  Number of patients Mortality per side effect 
Reported side effects N=176 N=23 p-value 
Anemia      
Yes 68 (39%) 8/68 (12%) .684 
No 108 (61%) 15/108 (14%)  
Hypokalemia      
Yes 40 (23%) 5/40 (13%) .903 
No 136 (77%) 18/136 (13%)  
Hypothyroidism      
Yes 16 (9%) 2/16 (13%) .944 
No 160 (91%) 21/160 (13%)  
Renal impairment      
Yes 35 (20%) 6/35 (17%) .424 
No 141 (80%) 17/141 (12%)  
Thrombocytopenia      
Yes 9 (5%) 1/9 (11%) .858 
No 167 (95%) 22/167 (13%)  
Hepatitis      
Yes 30 (17%) 3/30 (10%) .584 
No 146 (83%) 20/146 (14%)  
Hearing loss      
Yes 78 (44%) 8/78 (10%) .323 
No 98 (56%) 15/98 (15%)  
Tinnitus      
Yes 57 (32%) 5/57 (9%) .242 
No 119 (68%) 18/119 (15%)  
Psychiatric disturbances      
Yes 22 (13%) 4/22 (18%) .447 
No 143 (87%) 19/154 (12%)  
Neuropathy      
Yes 38 (22%) 7/38 (18%) .269 
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No 138 (78%) 16/138 (12%)  
GI symptoms      
Yes 69 (39%) 9/69 (13%) .994 
No 107 (61%) 14/107 (13%)  
Visual disturbances      
Yes 28 (16%) 0/28 (0%) .025 
No 148 (84%) 23/148 (16%)  
Dizziness      
Yes 12 (7%) 2/12 (17%) .702 
No 164 (93%) 21/164 (13%)  
Arthralgia      
Yes 53 (30%) 4/53 (8%) .154 
No 123 (70%) 19/123 (15%)  
 
Table 5.11. Proportion of RR-TB patients with reported side effects and mortality per side effect, 2012-2014  
 
  Number of patients Mortality per comorbidity 
Reported comorbidities N=176 N=23 p-value 
Diabetes      
Yes 4 (2%) 0/4 (0%) .433 
No 172 (98%) 23/172 (13%)  
Hypertension      
Yes 9 (5%) 2/9 (22%) .403 
No 167 (95%) 21/167 (13%)  
Cancer      
Yes 2 (1%) 1/2 (50%) .119 
No 174 (99%) 22/174 (13%)  
 
Table 5.12. Proportion of RR-TB patients with reported comorbidities and mortality per comorbidity, 2012-2014 
 
Both univariate and multivariate analyses were conducted to further explore risk factors for mortality among 
this cohort (Table 5.13). Factors associated with increased mortality included having three or more 
characteristics of disease severity (aHR 9.8, p-value .004) and unknown drug resistance profile (presumptive RR-
TB) (aHR 3.7, p-value .039). Age ≥ 45 years was associated with mortality in the univariate model (HR 3.8 p-value 
.002) but not in the multivariate mode. Figures 5.10-5.12 display adjusted survival curves, and each of these 
factors will be further discussed along with the respective survival curves.  
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Total N=176 Deceased (n=23) Univariate Analysis Multivariate Analysis 
  n n % p-value Unadjusted 
HR 
Lower 
CI 
Upper 
CI 
p-value Adjusted 
HR 
Lower 
CI 
Upper 
CI 
Age 
Under 45 138 13 9% reference reference 
45+ 31 10 32% .002 3.803 1.665 8.686 .177 2.080 .718 6.021 
Not recorded 7 0 0% .982 .000 0.000   .981 .000 0.000   
Side effects 
0 side effects 127 15 12% reference reference 
1-3 side effects 25 3 12% .986 1.011 .293 3.494 .744 1.243 .337 4.586 
4- 9 side effects 24 5 21% .288 1.731 .629 4.767 .100 2.524 .836 7.617 
Comorbidities 
0 165 20 12% reference reference 
1 or more 11 3 27% .161 2.382 .708 8.019 .203 2.656 .591 11.943 
HIV ART 
HIV negative 58 6 10% reference reference 
HIV Positive on ART 114 16 14% .516 1.365 .534 3.489 .762 1.166 .431 3.154 
HIV Positive not on ART* 4 1 25% .330 2.866 .344 23.857 .117 6.142 .634 59.471 
Characteristics of Disease Severity 
none 52 3 6% reference reference 
1 characteristic 60 4 7% .900 1.101 .246 4.920 .721 1.332 .276 6.433 
2 characteristics 51 9 18% .108 2.929 .791 10.855 .294 2.121 .520 8.643 
3+ characteristics** 13 7 54% .000 12.082 3.109 46.962 .004 9.801 2.058 46.665 
Resistance Profile 
Presumptive RR-TB 12 7 58% .000 7.336 2.928 18.380 .039 3.696 1.067 12.805 
RMR 24 1 4% .470 .473 .062 3.605 .693 .656 .081 5.334 
RR-TB*** 136 14 10% reference reference 
Pre-XDR or XDR-TB 4 1 25% .333 2.740 .356 21.105 .144 5.163 .570 46.764 
Year of registration 
2012 44 9 20% .086 2.810 .865 9.125 .644 1.374 .357 5.290 
2013 79 10 13% .366 1.708 .535 5.458 .866 1.116 .314 3.967 
2014 53 4 8% reference reference 
* One person ART unknown; ** One person with all 4 characteristics; died; *** One person with confirmed 2nd line susceptibility; includes Xpert only 
 
Table 5.13. Univariate and multivariate analysis of risk factors for mortality among patients initiating RR-TB treatment 2012-2014
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Characteristics of disease severity included baseline weight below 40 kgs, cavitary disease, smear positivity and 
shortness of breath. As previously described, having three or more of these characteristics was significantly 
associated with mortality in the multivariate model and was particularly associated with early mortality based 
on the curve (Figure 5.10). Having fewer than three characteristics of disease severity was not associated with 
increased mortality, but the combination of three or more has a very high risk. Of the 13 patients with three or 
more characteristics, seven (54%) died (aHR 9.8). Only one patient had all four characteristics, and this patient 
died.  
 
 
Figure 5.10. Mortality by characteristics of disease severity, adjusted survival curve 
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Similar to the findings from the 2006-2014 cohort, unknown drug resistance profile (presumptive RR-TB) was 
significantly associated with mortality (Figure 5.11). The proportion of Pre-XDR or XDR-TB patients who died was 
high (25%) but this was not statistically significant due to the small number (n=4).  
 
 
Figure 5.11. Mortality by drug resistance profile, adjusted survival curve 
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Higher rates of mortality were seen among those with one or more comorbidity (27%) and among those with 
four or more side effects (21%), but this was not a significant association (Figure 5.12). It is possible that both 
the presence of drug side effects and comorbidities were under-reported. Only four patients had a recorded 
comorbidity of diabetes (2%), and no information was included in the medical chart to confirm if others were 
tested. Comorbidities were more common in those with older age; one or more comorbidities were reported for 
16% of those over 45 compared to those under 45 years, in which 4% had one or more comorbidity reported.  
  
Figure 5.12. Mortality by side effects and comorbidities, adjusted survival curve 
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5.6 Discussion 
Botswana has had continuously high RR-TB treatment success rates, attributed to high ART coverage and close 
management of patients87. Based on personal communication with members of the national RR-TB program, 
they are very proud of their high levels of treatment success, but also concerned about the consistently high 
levels of mortality. A common sentiment among those involved in RR-TB management in Botswana is that 
‘patients are either cured or they die’11, speaking to the very low rates of treatment failure or lost to follow-up. 
Almost all patients are recorded with an outcome of either success (treatment completion or cure) or death. The 
17% average mortality rate among this cohort is slightly higher than the most recent global mortality rate of 15% 
among RR-TB patients on treatment, but is similar and even less than some high HIV settings such as Zimbabwe 
(17%), India (20%) and Mozambique (26%)13. For five years of this cohort, the mortality rate was 19% or higher. 
Although the mortality rate has dropped for the most recent two years, case detection has also declined, and 
patients are likely to be dying without being identified as having RR-TB.  
Several risk factors for mortality were identified in the analysis of the full cohort (Cohort 1), including older age, 
HIV positivity and not on ART at treatment initiation, unknown HIV status, smear positivity at treatment 
initiation, baseline radiology not recorded, registration category not recorded, unknown drug resistance profile 
(presumptive RR-TB), Pre-XDR or XDR-TB, treatment at Princess Marina Hospital, treatment at Sekgoma 
Memorial Hospital, and treatment between 2009-2011. Analysis of the three year cohort (Cohort 2) supported 
the finding that older age and unknown drug resistance profile (presumptive RR-TB) were assocated with 
mortality, although older age was only significant in the univariate model of Cohort 2. The additional elements 
which were able to be included in Cohort 2 through chart reviews also identified disease severity as associated 
with mortality. Side effects were also included in the analysis of Cohort 2 and were not shown to be associated 
with mortality.  
Many of the identified risk factors are well established. Other research has shown that older age and being 
smear positive is associated with mortality among RR-TB patients76, 135, and this was echoed in this analysis. It is 
possible that older patients are more ill in general and may have more comorbidities. The model for the full 
cohort (Cohort 1) adjusts for some indicators of disease severity (smear positivity, cavitation, HIV), but does not 
take into account other possible comorbidities and conditions that may be more common with older age such as 
hypertension, cancer and diabetes. Comorbidities were reported and analyzed in Cohort 2 (three year cohort) 
and the data support the idea that those with older age have more comorbidities. Cohort 2 also included factors 
of disease severity (low weight, cavitation, shortness of breath, and smear positivity) and identified that a 
combination of three or more indicators of disease severity was associated with mortality. Due to the small 
sample size in Cohort 2, a composite variable for disease severity was used. However, other studies have shown 
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that some of these factors are independently associated with mortality, including low baseline weight77, 78, 
cavitary disease76, 135 and smear positivity as described above, and this current analysis did show a higher 
proportion of death among these individual factors. Early diagnosis through universal DST could reduce the 
delay in treatment. If patients who do have RR-TB have DST upfront, they do not have to survive through 
ineffective first-line treatment, which may increase disease severity.  
HIV positivity has been established as a risk factor for mortality during RR-TB treatment76, 82, particularly among 
persons with low CD4 counts85-87. Other research has shown that ART is protective against mortality for those 
that are HIV positive85. This current analysis is consistent with these findings. HIV positivity was identified as a 
risk factor in the univariate analysis, and, in the multivariate analysis, HIV positive persons not on ART were 
shown to be at increased risk of mortality and were more likely to die within the first six months of treatment. 
This highlights the importance of continuing to push for high ART coverage for all HIV positive persons.  
Patients with Pre-XDR or XDR-TB had a higher risk of mortality in this analysis. The risk of mortality among these 
patients was observed after six months of treatment. Because many of the patients with Pre-XDR or XDR-TB 
were diagnosed after several months on second-line treatment as reported in Chapter 4, these patients may 
have received prolonged ineffective treatment (median time from second-line treatment initiation to diagnosis 
of Pre-XDR/XDR-TB was 153 days and over one year for some Pre-XDR or XDR-TB patients). Additionally, the 
patients may have had increased risk of resistance amplification. The newer drugs for XDR-TB treatment 
(delaminid, bedaquiline) were not routinely available and used in this time period. So although these patients 
were not dying early, the mortality is still impacted by the lack of new, more effective drugs. The proportion of 
patients with Pre-XDR or XDR-TB decreased in the three year cohort (Cohort 2) with 2% of patients diagnosed 
with Pre-XDR or XDR-TB as compared to 10% in the full cohort. Globally, the proportion of RR-TB patients with 
XDR-TB in 2017 was 8.5%13; in neighboring South Africa, 4.9% of MDR-TB patients were identified with XDR-TB in 
a recent survey (2012-2014)136. This South African survey indicates an even larger proportion have Pre- XDR-TB, 
with a total of 13% of RR-TB patients resistant to a second-line injectable and 13% resistant to a fluoroquinolone 
(ofloxacin)136. As shown in chapter 4, second-line DST drastically reduced after 2010; the lack of second-line DST 
among patients in this cohort may have led to under-diagnosis of Pre-XDR and XDR-TB. Early diagnosis, 
monitoring for increased resistance and availability of new drugs may improve the outcomes for Pre-XDR and 
XDR-TB patients. 
Botswana has suffered several major interruptions in TB laboratory services throughout the years in this 
analysis. Reasons for this include necessary but prolonged renovations and lack of reagents (Botswana TB 
report), and this is further explored in Chapter 8. The finding that patients with unknown drug resistance profile 
are more likely to die has been shown in other research137 and indicates that a proportion of patients were likely 
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to have been receiving ineffective treatment. A recent individual patient level meta-analysis, which included 
patient data from Botswana, also suggests that treatment with drugs for which there is resistance is associated 
with mortality138. Those with presumptive RR-TB are those that are clinically diagnosed; no DST results are 
available to guide treatment. They are likely to have been diagnosed and started on second-line treatment after 
first-line treatment failure, indicating late diagnosis and possibly more severe disease; others may have been 
diagnosed as contacts of other RR-TB patients. Among the full cohort (cohort 1), 83% of all patients had a result 
of treatment failure from previous first-line treatment indicating that many patients received ineffective first-
line treatment before being referred for second-line treatment. This delay in diagnosis not only has the potential 
to increase disease severity, but also increases the amount of time patients are infectious and possibly 
transmitting to others.  
The risk of mortality among presumptive RR-TB patients was very similar to those with Pre-XDR or XDR-TB. It is 
possible that some of the patients with presumptive RR-TB had undiagnosed resistance to first and second-line 
drugs and were therefore receiving ineffective treatment. A functional laboratory and adherence to the testing 
guidelines are essential elements for an effective RR-TB treatment program to ensure adequate case detection, 
known drug resistance profiles of patients on treatment and also to monitor for treatment failure. A study in 
Peru suggested that rapid DST was associated with a 54% reduction in the odds of death during RR-TB 
treatment139. As discussed in Chapter 4, Xpert has the potential to improve case detection and reduce time to 
treatment, if implemented and used according to guidelines. With the use of Xpert, confirmatory DST and access 
to second-line DST remain important.  
In addition to unknown drug resistance profile, missing other patient information (registration category and 
radiology results) were also associated with mortality. This highlights potential problems with data reporting and 
suggests poorer clinical care for these patients. Chest X-ray (CXR) is important for screening and can also help 
with diagnosing TB13. WHO recommends that CXR is used early in the TB screening and diagnosis process, along 
with other diagnostic methods140. It should be noted that missing radiology results does not necessarily mean 
that a chest x-ray was not performed for these patients. However, it does indicate that the results may not have 
been sent to the RR-TB treatment facility when patients were referred for treatment by a primary care health 
facility or may not have been recorded in the patient’s medical files. However, all RR-TB treatment facilities did 
have the capacity to conduct X-ray, and this should have been done for any patient who was referred with an 
unknown radiology result. This can be improved through education and intervention at the national level to 
monitor and identify missing data in time for corrective action. A review of missing data by treatment facility 
revealed that one facility (NRH) has consistently higher proportions of missing information than other facilities, 
warranting intervention to further understand and improve data reporting and clinical care at this facility in 
particular. It should be noted that those with missing radiology and registration category data were more likely 
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to die within the first six months; therefore, it is possible that if patients did not die, this information would have 
eventually been obtained and added to the medical charts and patient registry.  While an assumption was made 
in this analysis that missing information may be a marker of poor clinical care, it should also be noted that this 
may be artefacts of misclassification of specific factors due to missing information, leading to misclassification 
bias.  
Increased mortality was significantly associated with being registered in the years 2009-2011. More patients 
were diagnosed during this time period, so it is possible that more patients were diagnosed and started on 
treatment who otherwise would have died without diagnosis, as they may have in the other time periods. In 
2006-2008, the RR-TB program was still new, and there were only two RR-TB treatment facilities at that time; 
the three additional treatment facilities were added in 2010. In 2011 the National TB Reference Laboratory 
(NTRL) (the only culture facility in Botswana) closed which negatively impacted enrollment from 2011 through 
2012; the NTRL opened again in 2013 but was closed again from the end of 2014 through 2016. Therefore, the 
2012-2014 time period was greatly impacted by laboratory closures. Therefore, these two time periods (2006-
2008 and 2012-2014) had challenges that contributed to lower case detection and potentially patients dying 
without being diagnosed and initiated on RR-TB treatment.  
Receiving treatment at two of the five treatment facilities was associated with increased mortality. Princess 
Marina Hospital (PMH) is located in the capital city (Gaborone) and treats the highest number of RR-TB patients. 
Additionally, more severe cases are referred to PMH from other facilities for treatment; potentially explaining 
the higher mortality rate. The reasons for higher risk of mortality at SMH are not immediately clear. SMH is not a 
referral hospital, so more severe cases would not be sent to SMH to manage. Treatment at SMH is associated 
with increased mortality after six months, suggesting poor patient management, including inadequate 
identification of treatment failure. With laboratory closures and inconsistent testing to monitor patients, 
particularly for second-line drug resistance, it is possible there is more undiagnosed second-line resistance in 
this setting contributing to mortality. There are other factors that are known to contribute to mortality which 
were not addressed in this analyses and may have influenced mortality rates in specific settings; these include 
unemployment, homelessness, alcohol overuse, imprisonment135, and low CD4 counts among HIV positive 
individuals85, 87. The National TB program itself speculates that the higher rate of mortality at SMH may be 
influenced by lack of oversight and mentorship from the national level11. This lack of supervision may be 
influenced by lack of accessibility; all other RR-TB treatment facilities are located in areas with an airport. 
Because there are no flights to Serowe and it is 310 kilometers from the capital city, SMH receives much fewer 
oversight and mentoring visits from national level staff. Both facilities should be further evaluated to identify 
areas for intervention, which may include increased resources, education, monitoring and support.  
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None of the researched side effects or comorbidities showed a significant associated with mortality. One 
interesting finding is that hearing loss was reported for 44% of all patients in Cohort 2. Treatment with 
aminoglycosides (such as amikacin or kanamycin) has been shown to be associated with hearing loss141, 142. One 
study showed increased risk of severe hearing loss among patients using amikacin in comparison to 
kanamycin143. The standardized regimen in Botswana includes amikacin. A previous analysis of hearing loss 
among RR-TB patients in Botswana has been published and attributes the high rates of hearing loss to the use of 
amikacin. Modongo, et al reported that, among patients initiating RR-TB treatment in Botswana from 2006-
2012, 62% developed hearing loss110. Among those with reported hearing loss, 54% had audiometry and others 
were clinically diagnosed by the treating physician110. While the current analysis showed a slightly lower 
proportion of patients with hearing loss (44%), this remains substantial. A systematic review summarizes results 
from studies reporting hearing loss among patients receiving treatment with amikacin or kanamycin; the 
proportion of patients with reported hearing loss ranges from 23% to 64% among studies conducted in South 
Africa and Namibia141. This data is in line with what has been reported for Botswana, and highlights the need for 
incorporating new, less ototoxic drugs for the treatment of RR-TB.  
This analysis had several limitations. Firstly, there were small numbers for some of the variables leading to wide 
confidence intervals and unclear associations with mortality. Secondly, there were a high number of exclusions. 
Of patients initiating treatment, 62/766 (8%) were excluded in Cohort 1 and 69/245 (28%) were excluded in 
Cohort 2 because they had an unknown outcome date or (in Cohort 2 only) because their patient chart was not 
available for review. Factors such as older age and unknown drug resistance profile which were found to be 
associated with mortality were higher in the excluded group as compared to the included group.  Therefore, bias 
may be present leading to underestimation of the influence of these factors in the analysis.  The analysis 
identified several areas in which data reporting was sub-optimal, and the high number of exclusions due to 
missing data further highlights this problem of data reporting. Patient characteristics were reported for patients 
who were excluded from the analysis highlighting the limitations of excluding these patients. Among those 
excluded, 32% in Cohort 1 and 20% in Cohort 2 had a treatment outcome of death. There was a high level of 
missing information among excluded patients, and more than half of excluded patients were treated at 
Nyangabwe Referral Hospital (NRH). NRH is the facility that was shown to have the highest level of missing 
information also among the included patients; this further highlights the problem of data reporting and the need 
to address this nationally and specifically at this facility. Thirdly, DST results were reported in the RR-TB register, 
but the timing of specimen collection was not reported. Therefore, this analysis used a definition of resistance 
profile based on DST results available at any point during treatment and did not address when that resistance 
may have developed (before or during treatment).  Fourthly, treatment outcomes were assigned by study 
clinicians using WHO recommended definitions, but these were not verified in this research by a review of lab 
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results. Alexy, et al compared programmatic and laboratory based outcomes and reported overall good 
concordance; however, there is some discordance due to delays and incomplete access to culture144.  They 
recommend efforts to improve the accuracy of programmatically determined treatment outcomes144.  
Also a limitation of this study, several of the factors being studied appeared to be under-reported, particularly 
comorbidities. For example, diabetes was only reported among 2% of the patients in Cohort 2. However, this is 
not consistent with known rates of diabetes in the country. The prevalence of diabetes is estimated at 6% of the 
entire population, with 4% of all deaths in Botswana attributed to diabetes145. Other studies also suggest higher 
rates of diabetes among RR-TB patients: 33% in India146, 11% in Georgia147 and 27% in the Phillipines148. The 
WHO recommends collaborative care and control of diabetes and TB including screening for diabetes among TB 
patients, screening for TB among patients with diabetes and closely managing both diseases149. Diabetes is 
associated with poor treatment outcomes in drug-susceptible TB150. Recent systematic reviews suggest an 
association between diabetes and risk of developing RR-TB151, 152; one review examined the association with 
diabetes and poor treatment outcomes among RR-TB patients, and although some individual studies did report 
unsuccessful outcomes, the review did not identify a clear association152. Given the results from the individual 
studies and recommendations from the WHO, it is important to identify and control diabetes, and other 
comorbidities, among TB and RR-TB patients.  
It is important to note that there may be selection bias present in this analysis due to “survivor” effect153.  Given 
that there are low numbers of expected comorbidities (diabetes, hypertension, cancer), it is possible that those 
who survived to treatment were more resilient / healthy than those who may have died before diagnosed with 
RR-TB or being diagnosed and receiving treatment  This may affect the interpretation and generalizability of 
these results and in particular may indicate that there is an underestimation of the impact of disease severity on 
mortality in this analysis.   
Further bias can be created by censoring patients at the time point of initial outcome, as was done in this 
analysis.  Brooks, et al reports that bias can be minimized by using a predicted vital status at the end of the 
cohort period rather than at the time point of initial outcome154.  The bias inherent in the study design selected 
is acknowledged.   
The Botswana RR-TB program has achieved high treatment success in spite of many challenges. Overall, this 
analysis highlights several opportunities for improvement to decrease mortality rates. Recommendations for the 
program include increased access to new TB drugs, such as bedaquiline and delamanid, earlier diagnosis, 
improvements in data reporting, universal DST for all RR-TB patients, universal ART for HIV positive patients and 
routine monitoring for treatment failure or increased resistance throughout treatment. This analysis covered the 
time period of 2006 to 2014; since that time the country has adopted universal ART for all HIV positive persons 
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and has also begun to include the new TB drug, bedaquiline, into the second-line treatment regimen. Use of 
delamanid is included in the updated guidelines and has (as of 2019) been received in country but no patients 
have received it yet. While bedaquiline is being provided by USAID through a donation program, delamanid is 
being purchased by the government at considerable cost. However, revised guidelines which include these new 
drugs have not yet been developed and distributed. Chapter 4 described recommendations to improve case 
detection, which is also essential to ensure cases are detected and treated effectively and aren’t dying without 
having received care. Many of these recommendations are already included in national policies and guidelines, 
so emphasis on adherence to these recommendations and accountability is needed. Additionally, monitoring, 
training and financial support from the national level is necessary to ensure that all treatment facilities are well 
resourced, educated and adhering to guidelines.  
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Chapter 6: Time to treatment for rifampicin-resistant tuberculosis: a 
systematic review and meta-analysis (published) 
6.1 Chapter overview 
This chapter will describe the systematic review and meta-analysis conducted and published by the researcher. 
As well as published data, additional unpublished data will be included. Unpublished data will be identified in 
the chapter. The chapter will begin with a summary and background as published.  
6.2 Hypothesis, aim and objective 
Hypothesis 1: Time to treatment is influenced by diagnostic methods and model of care provided in various 
setting.  
Aim: To conduct a systematic review and meta-analysis assessing time to treatment for RR-TB and variability by 
diagnostic testing methods and treatment delivery approach. 
Objectives: 
To assess treatment delay in terms of DST methods, access to ambulatory treatment compared to hospital 
based treatment, and the proportion of patients who initiate treatment 
6.3 Summary 
Background: To reduce transmission and improve patient outcomes, rapid diagnosis and treatment of 
rifampicin-resistant tuberculosis (RR-TB) is required.  
Objective: We conducted a systematic review and meta-analysis assessing time to treatment for RR-TB and 
variability by diagnostic testing methods and treatment delivery approach. 
Design: Studies (2000-2015) reporting time to second-line treatment initiation were selected from PubMed and 
published conference abstracts.  
Results: From 53 studies, 83 cohorts (13,034 patients) were included. Overall weighted mean time to treatment 
from specimen collection was 81 days (95% CI 70-91), shorter with ambulatory (57 days, 95% CI 40-74) than 
hospital-based treatment (86 days, 95% CI 71-102). Time to treatment was shorter with genotypic susceptibility 
testing (38 days, 95% CI 27–49) than phenotypic (108 days, 95% CI 98–117). The mean percentage of diagnosed 
patients initiating treatment was 76% (95% CI 70-83%, range 25-100%).  
Conclusion: Time to second-line TB treatment initiation is extremely variable across studies, and often 
unnecessarily long. Reduced delays are associated with genotypic testing and ambulatory treatment settings. 
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Routine monitoring of the proportion of diagnosed patients initiating treatment and time to treatment is 
necessary to identify areas for intervention.  
6.4 Background 
Multidrug-resistant tuberculosis (MDR-TB) is a global health threat155. The World Health Organization (WHO) 
estimates that 580,000 people developed rifampicin-resistant TB (RR-TB) globally in 2015, accounting for 
250,000 deaths156. RR-TB, including MDR-TB, (defined as TB resistant to both isoniazid and rifampicin) is more 
difficult to diagnose and treat than drug-susceptible TB, requiring longer treatment courses. Globally, less than 
30% of estimated RR-TB patients are diagnosed and fewer are started on appropriate second-line treatment157.  
For the minority of RR-TB patients who are appropriately diagnosed and receive second-line treatment, delays 
to treatment initiation are often many months in some settings37, 57-61. Such delays are likely to increase 
mortality and loss to follow-up while waiting for treatment62, 63. in addition to potentially poorer treatment 
outcomes among those who do start treatment64. Long delays to treatment are also likely to contribute 
substantially to transmission, in both community and nosocomial settings65-67. Given that the majority of RR-TB 
patients in high burden settings are likely due to direct transmission,68 scale up of diagnosis and rapid initiation 
of effective treatment are required to improve patient outcomes and reduce ongoing transmission69. 
A range of health system factors may influence time from first presentation at a health service to treatment 
initiation, including access to diagnostic services, complicated referral processes, and availability of second-line 
treatment. Before the availability of genotypic drug susceptibility testing (DST), resistance testing relied on 
culture-based (phenotypic) methods, often taking months to receive results. Increased use of polymerase chain 
reaction (PCR)-based tests such as line probe assays (LPA) and Xpert MTB/RIF (Xpert) have reduced the 
laboratory time needed to reach a diagnosis of RR-TB and therefore theoretically should reduce delays in 
treatment initiation. Similarly, the provision of community-based treatment, without mandatory admission to 
hospital, as recommended by the WHO158, should both increase access to treatment and reduce delays.  
We aimed to conduct a systematic review and meta-analysis to assess time to second-line treatment among RR-
TB patients and assess delay in terms of DST methods, access to ambulatory treatment compared to hospital-
based treatment, and the proportion of patients who start treatment.  
6.5 Methods 
Search strategy 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines159. 
Using a sensitive search strategy comprised of a combination of MeSH terms and other key terms (Figure 6.1), 
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we searched PubMed (including Medline) and Scopus for relevant articles published from January 1, 2000 to July 
15, 2015, without language restrictions. We reviewed abstract books from the Union World Conference on Lung 
Health from 2010-2014 for studies that may have been completed but not yet published. Additional articles 
were identified from bibliographies of articles that underwent full text review. Study protocol is available as 
Appendix C.  
• ((((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR 
"resistant" OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND time  
• ((((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR 
"resistant" OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND delay  
•  ((((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR 
"resistant" OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND outcomes  
 
Figure 6.1. PubMed search strings (unpublished) 
Study selection 
We included studies reporting time to second-line treatment initiation for RR-TB patients, including MDR-TB and 
extensively drug-resistant (XDR)-TB. Only studies reporting mean or median times to treatment and standard 
deviations (or with available data allowing calculation of these figures) were eligible to be included in the meta-
analysis. Case reports and studies with small sample size (<10 persons) were excluded. Our intent was not to 
perform a traditional quality assessment, but to set inclusion and exclusion criteria to identify as many 
comparable studies as possible while also avoiding low quality studies. Two authors (RB, HC) independently 
reviewed titles and abstracts to identify potentially eligible articles, which then underwent full review to 
determine final eligibility status, with the same two authors dividing this effort with overlap. Any discrepancy or 
uncertainty was resolved by consensus. Abstracts and/or articles in languages other than English were 
translated. Additional articles published after the defined dates were included only if identified through 
abstracts published during the initial defined time period.  
Data extraction  
Two authors (RB, HC) extracted data for each cohort described in the included articles. The following 
information was sought: study year(s), country, sample size, study design, time to treatment definition, mean 
and median time to treatment, DST method, model of treatment provision and proportion of patients starting 
treatment. Attempts were made to contact authors of eligible or potentially eligible studies to provide missing 
data or clarifications. Study quality and potential bias were assessed by reviewing study design, primary 
outcomes and availability of adequate time to treatment data.  
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Definitions  
Studies were grouped according to definition of time to treatment. The main categories were defined as either 
time from date of specimen collected or date of diagnosis. Date of diagnosis included a range of definitions 
given, including; date of result available or received by clinician, or defined simply as date of diagnosis (unclear 
definition). Studies that used other definitions of time to treatment are listed in Table 6.1, but were not included 
in grouped analyses. Diagnostic methods were defined as phenotypic if the DST methods included liquid or solid 
culture methods and genotypic if based on any genotypic method, such as a LPA or Xpert, even if conducted 
after a positive culture. The model of treatment provision was defined as hospital-based if patients were 
hospitalized or relocated close to a hospital for initiating treatment and was defined as ambulatory if patients 
were able to receive treatment on an ambulatory basis during the full course of treatment. Weighted mean 
difference (WMD) was defined as the average value after pooling results of individual studies, where the 
contribution of each study to the mean difference is weighted by sample size.  
Data analysis 
The primary outcome was mean time to treatment. Where this was not reported, means and standard 
deviations were estimated based on methods described in Wan, et al.160. We performed both within-study, 
comparative meta-analysis as well as analyses across studies to describe the impact of varying DST methods and 
models of treatment provision. For within-study analysis, any study was eligible to be included irrespective of 
time to treatment definition used, provided they included two cohorts comparing at least one variable of 
interest. WMD and corresponding 95% confidence intervals (95%CIs) were calculated to standardize the results 
of the studies to a uniform scale and to indicate the size of the intervention effect in each study relative to the 
variability observed in that study. For the across-study analyses, pooled data were stratified by time from 
specimen collection or from diagnosis; weighted means and corresponding 95% CIs were calculated. Because 
statistical tests for heterogeneity are not reliable for pooled proportions161, heterogeneity was assessed by 
visual inspection of forest plots, with changes in mean time to treatment over time assessed through meta-
regression. All analyses were conducted using STATA version 13.0. 
6.6 Results 
From a screen of 1768 articles and 2356 conference abstracts, a total of 48 published studies and 5 abstracts 
were included in the systematic review (Figure 6.2). Many studies included more than one patient cohort; these 
are reported separately. Table 6.1 describes study characteristics, time to treatment definitions, mean and 
median time to treatment and the proportion of diagnosed patients who were treated.  
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The studies were from 21 countries and included 83 cohorts, ranging in sample size from 10 to 1063, with a total 
sample size of 13,034. Twenty-three cohorts were classified as ambulatory, and 58 were hospital-based (2 
indeterminable). Phenotypic DST was used for 53 cohorts; 29 used genotypic DST, 12 of which incorporated 
Xpert (partially or fully) (1 indeterminable). The proportion of diagnosed patients who initiated treatment was 
reported for 31 cohorts. Study design was prospective for 19 (23%) cohorts and retrospective for 64 (77%) 
cohorts. Time to treatment was a primary outcome for 26/53 (49%) studies, representing 47/83 (57%) cohorts. 
 
 
 
  
3371 references identified from 
PubMed and Scopus 
2356 abstracts identified/screened from 
Union Conference (2010-14) 
675 Duplicates removed 
2696 references screened – 
titles and abstracts 
2459 Articles removed; 
Not relevant 
2330 Abstracts 
removed; 
Not relevant 
237 references retained for 
full text review 
26 retained for review 
4 articles from 
reference lists/authors 
193 articles excluded 
180 - No data on RR TTT* 
3- Data for TTT* unclear /  
no author response 
1- Data for RR cases 
not separate 
5 -Sample size ‹ 10 
2 - Not in time frame 
2 - Duplicate data to 
another study 
21 abstracts excluded 
1- No data on RR TTT* 
19- Data for TTT* unclear/ 
undefined 
1- Sample size unclear/ 
small 
48 studies included 5 studies included 
53 TOTAL studies included 
*  TTT = Time to Treatment 
 
Figure 6.2. Study selection process flowchart  
 
83 TOTAL cohorts included 
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Author, year 
 
Year of 
cohort 
 
Location 
 
Laboratory 
Method 
 
Model of 
care 
Sample 
size (no. 
treated) 
Med-
ian 
TTT 
 
Mean 
TTT 
 
SD 
Percentage 
treated (of 
diagnosed) 
From date of specimen collection 
Brust, 2011162 2008 South Africa Phenotypic Hospital 45 74 75ǂ 47ǂ NR 
Cox, 201537 2012 South Africa Genotypic†  Ambulatory 280 12 27 47 90% 
Cox, 201537 2007 South Africa Phenotypic Ambulatory 95 76 122 196 NR 
Cox, 201537 2003 South Africa Phenotypic Hospital 158 71 147 208 NR 
Cox, 201537 2007 South Africa Genotypic  Ambulatory 699 37 51 78 86% 
Dlamini-Mvelase, 
201438 
2011 South Africa Genotypic†  Hospital 170 20 26 16ǂ 64% 
Dramowski, 2012163 2003 South Africa Phenotypic Hospital 18 70 94ǂ 133ǂ NR 
Fairlie, 201157 2008 South Africa Phenotypic Hospital 10 76 154ǂ 134ǂ 77% 
Francis, 2014164 1998 Australia Phenotypic Hospital 13 45 52 42ǂ 81% 
Gandhi, 2010165 2005 South Africa Phenotypic Hospital 46 69 72ǂ 31ǂ 37% 
Gandhi, 2010165 2005 South Africa Phenotypic Hospital 35 66 67ǂ 24ǂ 25% 
Hanrahan, 2012166 2007 South Africa Phenotypic Hospital 26 78 74ǂ 32ǂ NR 
Hanrahan, 2012166 2009 South Africa Genotypic Hospital 52 62 60ǂ 41ǂ NR 
Heller, 201058 2008 South Africa Phenotypic Ambulatory 50 84 91ǂ 32ǂ NR 
Heller, 201058 2001 South Africa Phenotypic Hospital 57 107 150ǂ 76ǂ NR 
Jacobson, 2013167 2007 South Africa Phenotypic Hospital 89 80 81ǂ 29 NR 
Jacobson, 2013167 2008 South Africa Genotypic  Hospital 108 55 57ǂ 30 NR 
Kipiani, 2014168 2009 Georgia Phenotypic Hospital 72 NR 84 38ǂ NR 
Kipiani, 2014168 2010 Georgia Genotypic  Hospital 80 NR 18 10ǂ NR 
Li, 2015169 2006 China Phenotypic Hospital 81 139 138ǂ 104ǂ 88% 
Li, 2015169 2011 China Genotypic Hospital 172 14 15ǂ 8ǂ 71% 
Loveday, 2015170 2008 South Africa Genotypic Hospital 736 72 74ǂ 32ǂ NR 
Loveday, 2015170 2008 South Africa Genotypic Hospital 813 92 94ǂ 38ǂ NR 
Mpagma, 201359 2009 Tanzania Phenotypic Hospital 61 274 301 173ǂ NR 
Munsiff, 200660 1992 USA Phenotypic NR 610 42 198ǂ 102ǂ 71% 
Naidoo, 201439 2011 South Africa Genotypic†  Ambulatory 120 17 17ǂ 6ǂ 94% 
Naidoo, 201439 2008 South Africa Genotypic  Ambulatory 375 43 43ǂ 4ǂ 91% 
Narasimooloo, 2012171 2010 South Africa Phenotypic Hospital 175 NR 87 47ǂ 94% 
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O'Riordan, 2008172 1982 UK Phenotypic Hospital 18 59 60ǂ 55ǂ 64% 
O'Riordan, 2008172 1997 UK Genotypic  Hospital 14 8 9ǂ 14ǂ 100% 
Page, 201540 2012 Swaziland Genotypic†   NR 44 12 12ǂ 8ǂ 81% 
Rodriguez, 201361 2006 Dominican 
Republic 
Phenotypic Hospital 289 222 238ǂ 177ǂ NR 
Shean, 2012*173 2000 South Africa Phenotypic Ambulatory 144 77 78 10ǂ NR 
Shean, 2012*173 2000 South Africa Phenotypic Hospital 123 62 102 7ǂ NR 
Shenoi, 2012174 2005 South Africa Phenotypic Hospital 86 88 90ǂ 9ǂ 61% 
Smith, 2013*175 2011 South Africa NR  Hospital 365 86 84ǂ 38ǂ NR 
van Kampen, 2015 41 2012 Indonesia Genotypic†  Hospital 179 16 22ǂ 24ǂ 58% 
van Kampen, 2015 41 2011 Indonesia Phenotypic Hospital 159 88 85ǂ 48ǂ 38% 
From date of diagnosis 
Charles, 2014176 2010 Haiti Genotypic†  Hospital 110 46 76 42ǂ NR 
Eliseev, 2016177 2009 Russia Genotypic Hospital 132 51 53ǂ 45ǂ NR 
Eliseev, 2016177 2007 Russia Phenotypic Hospital 163 99 114ǂ 70ǂ NR 
Farley, 201178 2000 South Africa Phenotypic Hospital 287 50 64 34ǂ NR 
Farley, 201178 2000 South Africa Phenotypic Hospital 470 54 70 36ǂ NR 
Gegia, 2013178 2009 Georgia Phenotypic Hospital 45 16 86ǂ 71ǂ NR 
Hoa, 2014179 2010 Vietnam Genotypic  Ambulatory 203 NR 2 12 NR 
Hoa, 2014179 2010 Vietnam Genotypic  Hospital 79 NR 13 47 NR 
Isaakidis, 2013180 2007 India Genotypic†  Ambulatory 16 7 8ǂ 3ǂ 100% 
Isaakidis, 2013180 2007 India Phenotypic Ambulatory 21 8 15ǂ 38ǂ 88% 
Mitnick, 2003181 1996 Peru Phenotypic Ambulatory 75 246 909ǂ 654ǂ NR 
Odendaal, 2012*182 2005 South Africa Phenotypic Hospital 224 10 13ǂ 10ǂ NR 
Odendaal, 2012*182 2005 South Africa Phenotypic Hospital 197 37 42ǂ 34ǂ NR 
Shao 2013*183 2011 Tanzania Genotypic†  Hospital 44 NR 59 97ǂ NR 
Shao, 2013*183 2011 Tanzania Phenotypic Hospital 19 NR 230 186ǂ NR 
Singla, 2009184 2002 India Phenotypic Hospital 126 NR 100 49ǂ NR 
Toshniwal, 2014*185 2009 India Phenotypic Hospital 44 NR 132 NR NR 
Toshniwal, 2014*185 2009 India Genotypic†  Hospital 71 NR 17 NR NR 
Toshniwal, 2014*185 2009 India Genotypic Hospital 157 NR 44 NR NR 
Blaya, 2014186 2006 Peru Phenotypic Ambulatory 134 88 88ǂ 73ǂ NR 
Blaya, 2014186 2005 Peru Phenotypic Ambulatory 132 77 77ǂ 68ǂ NR 
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Cavanaugh, 2012187 2002 Russia Phenotypic Hospital 198 NR 466 NR NR 
Ebonwu, 2013188 2011 South Africa Genotypic  Hospital 593 10 12ǂ 10ǂ 63% 
Gler, 2012189 2003 Philippines Phenotypic Hospital 1063 76 105ǂ 216ǂ 57% 
Hossain, 2015190 2012 Bangladesh Genotypic†  Hospital 145 5 7ǂ 10ǂ 90% 
Narita, 2001191 1994 USA Phenotypic Ambulatory 31 15 50ǂ 93ǂ 100% 
Narita, 2001191 1994 USA Phenotypic Hospital 39 177 696ǂ 568ǂ 100% 
van Kampen, 2015192  2012 Kazakhstan Genotypic†  Hospital 471 7 9ǂ 9ǂ 84% 
Other definitions of time to treatment 
Drobac, 2006193 1999 Peru Phenotypic Ambulatory 38 198 448ǂ 327ǂ NR 
Mendoza-Ticona, 
2012194 
2007 Peru Phenotypic Ambulatory 11 173 181ǂ 92ǂ NR 
Mendoza-Ticona, 
2012194 
2009 Peru Phenotypic Ambulatory 13 76 69ǂ 42ǂ NR 
Otero, 2014195 2008 Peru Phenotypic Ambulatory 37 25 31ǂ 19ǂ NR 
Belkina, 2014196 2013 Uzbekistan Genotypic†  Hospital 243 8 30 37ǂ NR 
Banerjee, 2010197 2004 USA Phenotypic Ambulatory 100 79 84ǂ 50ǂ NR 
Banerjee, 2010197 2004 USA Genotypic  Ambulatory 27 38 42ǂ 32ǂ NR 
Mirasaeidi, 2005198 2000 Iran Phenotypic Hospital 17 NR 848 638ǂ NR 
Natt, 201463  2011 India Phenotypic Hospital 67 NR 67 NR 82% 
Seddon, 2011199 2003 South Africa Phenotypic Hospital 105 91 103ǂ 86ǂ 95% 
Singla, 2014200 2009 India Phenotypic Hospital 51 157 161 56 61% 
Singla, 2014200 2009 India Genotypic Hospital 83 38 49 37 88% 
Skenders, 2011201 2003 Latvia Phenotypic Hospital 48 40 43ǂ 34ǂ NR 
Skenders, 2011201 2003 Latvia Genotypic  Hospital 23 14 14ǂ 12ǂ NR 
Otero, 2014195 2008 Peru Phenotypic Ambulatory 90 25 28ǂ 25ǂ NR 
Saravia, 2005202 1997 Peru Phenotypic Ambulatory 73 268 404ǂ 199ǂ NR 
Saravia, 2005202 1997 Peru Phenotypic Ambulatory 52 55 109ǂ 72ǂ NR 
* Union Abstract; † Includes Xpert MTB/RIF; ǂ Figures calculated based on formulas provided in Wan, et al160; UK = United Kingdom; USA = 
United States of America; NR = Not reported 
 
Table 6.1. Study characteristics and results 
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Time to treatment 
Mean time to treatment was reported for 30 cohorts and calculated for the remaining 53 cohorts. There were 
insufficient data available to calculate standard deviations for seven cohorts, listed in Table 6.1 but not included 
in analyses. Time to treatment was most commonly reported as time from specimen collection (38 cohorts), 
followed by time from diagnosis (28 cohorts) (Table 6.1).  
Mean and median times to treatment from specimen collection ranged from 9 days to 10 months and 8 days to 
9 months, respectively. Among the 38 cohorts with time to treatment measured from specimen collection, the 
weighted mean time to treatment was 81 days (95% CI 70-91, range 9-301). Among the 24 cohorts with time to 
treatment measured from diagnosis, the weighted mean time to treatment was 59 days (95% CI 50-68, range 2-
909). 
Model of treatment provision 
Five studies were included in the within-study comparison of ambulatory versus hospital-based treatment 
provision (Figure 6.3). All five studies reported faster time to treatment for patients under ambulatory 
treatment compared to hospital-based treatment; the pooled difference across all studies was significantly in 
favor of ambulatory treatment (WMD 1.26, 95% CI 0.46-2.05). 
There were seven (1,763 patients) cohorts treated under ambulatory based models of care and 29 (4,250 
patients) under hospital-based treatment with time to treatment from specimen collection. Mean time to 
treatment with ambulatory treatment was 57 days (95% CI 40-74, range 17-122) compared to 86 days (95% CI 
71–102, range 9-301).  
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        WMD = Weighted Mean Difference 
 
Figure 6.3. Time to treatment initiation by model of treatment provision 
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Drug susceptibility testing methods 
Twelve studies were included in the within-study comparison of DST methods (Figure 6.4). All studies 
consistently reported a shorter time to treatment with genotypic versus phenotypic DST; the pooled difference 
across all studies was significantly in favor of genotypic DST (WMD 1.17, 95% CI 0.83-1.51). There were 14 (3,842 
patients) cohorts using genotypic DST and 23 (2,460 patients) cohorts with phenotypic DST reporting time to 
treatment from specimen collection. Mean time to treatment was significantly lower with genotypic DST: 38 
days (95% CI 26–49, range 9-94) compared to 108 days (95% CI 98 – 117, range 52-301) for phenotypic DST. 
 
  
WMD = Weighted Mean Difference  
 
Figure 6.4. Time to treatment initiation by laboratory drug susceptibility testing methods 
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Time to treatment by year of cohort 
Among cohorts with time to treatment measured from specimen collection, the mean time to treatment 
decreased over time (β- coefficient, - 3.13, 95%CI -5.09 - 1.18, P= 0.002) (Figure 6.5). Figure 6.6 (unpublished) 
displays mean time to treatment for each cohort over time, graphed by the year each individual cohort began. 
The weighted mean time to treatment from specimen collection prior to 2010 was 98 days (95% CI 85-111, 
range 9-301), compared to 39 days (95% CI 28-50, range 12-87) for 2010 or later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Trends in mean time to treatment initiation over time 
 
 
 
Figure 6.6. Mean time to treatment (days) over time (unpublished) 
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Time to treatment by proportion initiating treatment 
The mean percentage of diagnosed patients initiating treatment (reported for 31/83 cohorts) was 76% (95%CI 
70-83%, range 25-100%) (Table 6.1). Figure 6.7 compares mean time to treatment to the proportion initiating 
treatment for the 19 cohorts reporting time to treatment from specimen collection. The upper-left shaded 
portion represents cohorts with a mean time to treatment of ≤30 days and at least 80% of diagnosed patients 
initiating treatment to represent best practice; only four cohorts37, 39, 40, 172, representing 458/3286 (14%) 
patients included in the analysis, fell into this category. All four cohorts used genotypic DST; model of treatment 
provision was ambulatory for two cohorts, hospital based for one and not reported for one.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted lines at 80% and 30 days highlight 4 cohorts with both high proportion initiating treatment and short time to 
treatment, to represent best practice37, 40, 171, 172 
 
Figure 6.7. Time to treatment initiation by proportion initiating treatment 
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Combination of Interventions (unpublished) 
The shortest weighted mean time to treatment from specimen collection was among patients diagnosed using 
genotypic DST and initiated on treatment under ambulatory models of care (Table 6.2). However, this was not 
significantly different compared to patients diagnosed using genotypic DST and initiated on treatment under 
hospital based models of care. Mean time to treatment for both of these combinations using genotypic DST is 
significantly shorter when compared to the two combinations which include phenotypic DST (Table 6.2).  
Interventions Number 
of cohorts 
Sample 
size 
Weighted mean time to 
treatment, days (95% 
CI) 
Molecular DST methods used and ambulatory 
treatment available 
4 1520 35 (17-52) 
Molecular DST methods used and hospital based 
treatment required 
9 2620 42 (22-61) 
Culture based DST methods used and ambulatory 
treatment available 
2 145 87 (73-101) 
Culture based DST methods used and hospital based 
treatment required 
18 2353 102 (93-111) 
 
Table 6.2. Combination of interventions and time to treatment initiation   
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6.7 Discussion 
Delays in initiation of second-line treatment can negatively impact clinical and public health outcomes. Even 
reductions of several weeks or months are likely to significantly impact community transmission68 and are likely 
to improve patient outcomes64, 177. This systematic review and meta-analysis has shown that time to treatment 
is extremely variable across studies and often lengthy. Overall, the average time to treatment from specimen 
collection was 2.5 months, with trend for reduction in delay in more recent years. This is consistent with 
advances in RR-TB diagnosis and treatment, and potentially reflects greater recognition of the need to initiate 
treatment sooner to improve patient outcomes and reduce ongoing transmission risk. The use of genotypic DST 
methods and provision of treatment through ambulatory based models of care both contributed to shorter 
times to treatment. While significant reductions in time to treatment are seen over time, substantial delays 
remain in recent years. 
Molecular testing methods result in more rapid laboratory turnaround times64, 203-205 and are therefore likely to 
reduce time to treatment. This was confirmed in our analysis, with genotypic testing, using LPA or Xpert, 
resulting in significantly shorter time to treatment compared to phenotypic methods reliant on culture, and our 
findings are consistent with the results of a randomized trial206 and a retrospective cohort study published after 
our search was concluded42. Xpert is of particular interest due to the feasibility of testing in peripheral 
laboratories,207, 208 potentially reducing reliance on transport and resulting in more rapid communication of 
results. Studies which have implemented faster, molecular DST show lower mortality and loss to follow-up and 
therefore a higher proportion of patients starting treatment41. Rapid DST has also been shown to reduce 
treatment failure194 and result in higher treatment success177. However, currently available genotypic methods 
are restricted by the number of drugs that can be tested, often resulting in continued reliance on phenotypic 
DST for second-line drugs. 
Ambulatory second-line treatment can result in similar treatment outcomes compared to hospital-based 
treatment,89 and can lead to higher proportions of patients initiating treatment37, 39, 180. Our review complements 
these positive findings, providing evidence that ambulatory treatment results in shorter time to treatment 
compared to hospital-based treatment. Patients receiving treatment in hospital-based setting may experience 
further delays due to the preparation needed to be admitted to the hospital; these may include referral 
processes, informing family and work, making arrangement for the care of children and other home 
responsibilities and actually traveling to the hospital.  
We identified a wide range in delay across studies, particularly among cohorts with hospital based models of 
care as well as cohorts with phenotypic DST. The authors of the main studies with lengthy times to treatment, 
refer to prolonged referral processes59 and the use of phenotypic DST methods172. Although reduced delays are 
130 
 
seen with both genotypic DST and ambulatory treatment provision, several more recent studies show times to 
treatment greater than 1.5 months.37, 58, 166 Studies report delays in reporting results to clinics and in contacting 
patients as potential contributing factors39, 167. Programmatic factors such as sample transport and results 
communication could be improved209.  
Time to initiation of second-line treatment needs to be considered in terms of the proportion of diagnosed 
patients who actually start treatment. Several studies reported relatively rapid times to treatment (less than 30 
days), but still less than 70% of diagnosed patients starting on treatment38, 41, 188. These studies highlight the 
need to assess areas of improvement along the entire diagnosis and treatment cascade for RR-TB; from 
diagnosis of TB, identification of drug resistance, treatment initiation and finally treatment success.  
Our systematic review has identified several limitations in the current evidence base. First, the definitions of 
time to treatment were not reported clearly or consistently across several studies and were grouped into 
categories described in Table 6.1 for ease of analysis. Studies reporting time to treatment from specimen 
collection can provide a clearer picture of delays caused by various elements in health care systems, including 
specimen transport, diagnostic delays, results reporting, patient notification and referral. However, there are 
several delays that could have occurred prior to sending a specimen for DST, including patient level delays in 
seeking treatment and restricted access to DST. Without universal access to DST, patients may first be treated 
for drug sensitive TB and only offered DST upon failure of treatment. Secondly, neither time to treatment nor 
the proportion of diagnosed patients initiating treatment were primary outcomes for many of the studies in this 
analysis. This contributes to unclear definitions and also uncertainty introduced through calculation of means 
and standard deviations. The inconsistency in reporting the proportion of patients initiating treatment (only 
reported for <40% cohorts) also may skew the time to treatment data. Third, there may be other factors 
influencing time to treatment that were not reported by the studies and could not be assessed in our analyses, 
including decentralized lab services, availability and accessibility of treatment services, and inclusion of 
migratory populations. Fourth, due to lack of data, authors were not able to stratify analysis by Xpert and LPA. 
Another important limitation to the conduct of this review is the limited number of databases that were 
searched. One study in this analysis is a randomized control trial, and we acknowledge that this may introduce 
bias as additional delays may be caused by the randomization process; it is important to note that this study is 
not included in the majority of analyses for this review, those that measure time to treatment from sputum 
collection and therefore, has little impact on the primary findings. Additionally, 77% of the cohorts in this review 
are from retrospective studies, and we acknowledge risk of misclassification bias with retrospective study design 
and the implication that the effect may be underestimated. Finally, as with any systematic review, there may be 
publication bias; we attempted to mitigate this bias by including abstracts. 
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The proportion of diagnosed RR-TB patients who initiate treatment and the delay to second-line treatment are 
important indicators of programmatic performance. While the proportion of the estimated global burden of RR-
TB that receives treatment is gradually increasing, there is still much room for improvement156. The WHO End TB 
Strategy calls for integrated, patient-centered care and prevention, including universal DST and treatment of all 
people with RR-TB; bold policies and supportive systems including political commitment and engagement of 
communities; and intensified research and innovation210. Such interventions and commitment should contribute 
to reducing the diagnostic and treatment gaps, and treatment delays. Routine monitoring and reporting of the 
proportion of patients initiating treatment and time to treatment, ideally measured from specimen collection to 
highlight most delays, are needed to identify gaps and areas for intervention.
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Chapter 7: Utilization of Xpert MTB/RIF (Xpert) and the impact on time to 
second-line treatment 
7.1 Chapter overview 
This chapter will include two sections. The first section will describe all Xpert testing conducted in Botswana in 
2013 and 2014. Section 1 will specifically address how patients with RR or RR indeterminate results by Xpert 
were managed in Botswana. The second section will describe a time to second-line treatment analysis using two 
cohorts: the Xpert Cohort including RR-TB patients initiating RR-TB treatment based on Xpert diagnosis, and a 
comparison cohort (the NTRL Cohort) including RR-TB patients initiating RR-TB treatment based on diagnosis 
from the National Tuberculosis Reference Laboratory (NTRL). The chapter starts with background/policy review 
and methods relevant to both sections.  
7.2 Hypotheses and aim 
Hypothesis 1: Xpert improves time to treatment as compared to DST conducted at the centralized laboratory. 
Hypothesis 2: There are gaps in confirmatory testing for patients initially tested by Xpert. 
Aim: To assess patient management and linkage to care for TB patients with RR detected or RR indeterminate 
results by Xpert in 2013 to 2014  
7.3 Background/Policy review 
At the time of this research, there was one laboratory facility in Botswana with the capacity to conduct culture 
testing and first-line phenotypic DST, the NTRL. The 2011 National TB Program Manual indicated that the 
following people should have samples submitted to the NTRL for culture and first-line DST16: 
• HIV positive individuals with presumptive TB with 2 negative sputum smear results  
• New TB patients who remain or become smear positive at month 3 of treatment  
• All previously treated TB patients regardless of reason (failure, relapse, or loss to follow-up)  
• All children with presumptive TB 
• Patients who develop TB during or after IPT  
• Symptomatic individuals at higher risk of MDR-TB: lab workers, MDR-TB contacts, health care workers 
Additionally, according to the 2009 National Guidelines for Management of DR-TB, all patients diagnosed with 
RR-TB and initiating second-line treatment should have a baseline culture and first-line DST at the NTRL48. First-
line DST at the NTRL consists of testing for at least isoniazid and rifampicin, and generally includes testing for all 
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first-line TB drugs: isoniazid, rifampicin, streptomycin, and ethambutol (and sometimes includes testing for 
pyrazinamide).  
Xpert was first introduced in Botswana in 2012 through an operational research study, the Xpert Package Rollout 
Evaluation Study (XPRES), conducted by the Centers for Disease Control (CDC) Botswana in collaboration with 
the Botswana Ministry of Health and Wellness. The study aimed to compare the sensitivity of microscopy-based 
and Xpert-based pulmonary TB diagnostic algorithms in diagnosing sputum culture-positive TB and to evaluate 
the impact of Xpert and intensified case finding on all-cause, 6-month, adult antiretroviral therapy (ART) 
mortality46. During this time, 13 Xpert devices were placed throughout the country in district laboratories or in 
TB/HIV clinics (point of care) (Figure 7.1). The study enrolled and followed up all HIV positive persons initiating 
ART with symptoms of TB seeking treatment at 22 participating TB/HIV clinics from 2012 to 2014. The devices 
were also used by the government of Botswana for routine testing of patients with presumed TB at the 
participating clinics. The analysis described in this chapter will include all tests conducted by Xpert in 2013 and 
2014, including patients tested for the study and patients tested through routine government testing.  
 
Figure 7.1. Location of Xpert devices in Botswana in 2013-201431 
After the XPRES study ended and follow-up was complete (2015), the Xpert devices were donated to the MoHW; 
the MoHW installed additional devices as well bringing the total Xpert devices in use to 34 by 2015. Xpert was 
not fully incorporated into the National TB Program in Botswana until 2016, when the diagnostic algorithm 
including Xpert (Appendix A) was finalized and distributed. While Xpert was used prior to 2016, it was not 
intended to replace routine practices in the country, described in the first paragraph. Any patient who would 
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have had a sample sent to the NTRL for testing should still have had a sample sent to the NTRL, regardless of 
Xpert result. Additionally, the government specifically released guidance to all facilities utilizing Xpert, 
instructing that any patient with an Xpert test indicating RR should have confirmatory DST conducted at the 
NTRL and should be initiated on second-line treatment while waiting on results of confirmatory culture and DST. 
Guidance also indicated that any test with an RR indeterminate result by Xpert should have a repeat Xpert test 
and follow-up testing at the NTRL if warranted based on the second test or other recommendations for routine 
testing.  
7.4 Methods 
The development of the Xpert database used in this analysis was described in Chapter 3.  
The analysis in Section 1 includes a description of all Xpert tests conducted, using proportions. This broad 
analysis includes all tests conducted. Tests run for quality assurance and training were removed, but no 
deduplication was conducted; there may be more than one test for a single patient included in this overall 
description of testing results. More specific analyses were conducted among tests for which the results were RR 
detected or RR indeterminate.  
For Xpert test results which were RR detected, tests were manually reviewed (using name and identification 
number) to identify any duplicate samples per patient. Duplications were removed, and the analysis is presented 
in terms of patients, rather than tests. Patients with a test result of RR detected were investigated for the 
following (techniques for deduplication and matching with other datasets were fully described in Chapter 3): 
• If treatment was initiated  
• Time from Xpert result to treatment initiation. The date of Xpert result is defined as the date the test 
was conducted. 
• If confirmatory DST results were available  
o Confirmatory DST results were included in the analysis if they were available (recorded in the 
LIS) within 6 months of the Xpert result. This is based on the analysis described in section 2, 
which shows it is not uncommon for DST results from the NTRL to be available up to 6 months 
after specimen collection.  
• Time from Xpert result to confirmatory DST 
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Data for patients with RR indeterminate results also underwent the same process of deduplication and matching 
that were used for the patients with RR detected results. Patients with RR indeterminate results were 
investigated for the following: 
• If a repeat Xpert test was done 
• Results of repeat tests 
• If any testing was done at the NTRL 
• Results of any the NTRL tests 
Proportions were used to describe testing, results and treatment among patients with an Xpert result of RR 
detected or RR indeterminate. Medians and interquartile ranges were used to describe time to treatment or 
confirmatory testing.  
The researcher followed up on patients that had an RR-TB diagnosis by Xpert but were not located in the RR-TB 
registry as having initiated treatment. Both the district TB coordinator and the RR-TB treatment facility which 
serves the district in which the patient was diagnosed were contacted (by phone) in 2015. The TB coordinators 
and the staff at the treatment center were asked if they were aware of the patients and if they knew why they 
were not initiated on treatment.  
The Section 2 analysis describes a comparison of time to treatment between two cohorts. The Xpert cohort 
includes any RR-TB patients with RR diagnosed by Xpert who initiated treatment. Any patient whose Xpert RR 
result was only available after treatment initiation was excluded from the time to treatment analysis. The NTRL 
cohort includes any patients diagnosed with RR at the NTRL (centralized location) who initiated treatment. Any 
patient whose DST result was only available after treatment initiation was excluded from the time to treatment 
analysis. DST results include results from MGIT testing and LPA testing, though LPA testing was limited during 
the time of this study.  
Time to treatment was measured in various ways for the two cohorts.  The specimen collection date was not 
available for the Xpert cohort; this is not recorded in the gxx. Therefore, the main comparison of time to 
treatment is defined as time from diagnosis to treatment initiation. Diagnosis is the date the result is recorded in 
the respective databases.  Additional analysis and time points were calculated based on estimates or available 
data, as described below for each cohort: 
Xpert cohort: 
• Time to treatment from diagnosis =  the date of treatment initiation in the RR-TB register MINUS based 
on the  date of the Xpert result as automatically recorded in the gxx file.  
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• Time from specimen collection to diagnosis = estimated at 10 days, per standard practice (data 
unavailable)  
NTRL cohort: 
• Time to treatment from diagnosis =  the treatment initiation date in the RR-TB register MINUS the date 
the result has been entered and reviewed at the NTRL (defined as ‘reviewed date’ in the LIS) 
• Time from specimen collection to diagnosis = the date the result has been entered and reviewed at the 
NTRL MINUS the date of specimen collection as recorded in the LIS. 
• Time from specimen collection to treatment = the treatment initiation date in the RR-TB register MINUS 
the date of specimen collection as recorded in the LIS. 
Time to treatment was measured using medians and interquartile ranges. A pairwise comparison using 
nonparametric test was used to describe the difference in medians, with .05 significance and 95% CI levels.  
All analyses were conducted using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY: IBM Corp) or Excel for basic charts and graphs.  
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7.5 Results (Section 1) 
Xpert test results 
Figure 7.2 displays the results of all Xpert tests conducted from January 1, 2013 to December 31, 2014. Of 9,086 
total tests, 1,147 (13%) had a result of MTB Detected. Of those with MTB detected, 86 (8%) had a result of RR 
detected, and 48 (4%) had a result of RR indeterminate. There was a total of 966 (11%) failed tests.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. Xpert testing results, total tests, 2013-2014 (no deduplication conducted) 
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Management of patients with RR-TB result by Xpert 
Figure 7.3 describes the management of patients with an RR detected result by Xpert. Out of the 86 tests with 
an RR detected result, this represented 75 patients after removing duplicates (same patient with multiple tests). 
Of the 75 patients, 8 (11%) did not initiate treatment. Reasons for not initiating treatment were solicited from 
the district TB coordinators and the RR-TB treatment centers. Based on feedback from the RR-TB treatment 
centers two did not initiate treatment based on clinical decision, and one died before treatment initiation; for 
five patients the RR-TB facility nor the district TB coordinator were unaware of the patients, indicating they had 
not been referred for treatment. No other information was available for these five patients. Of the two that did 
not initiate treatment based on clinical decision, one had follow-up phenotypic DST and was susceptible to all 
first-line drugs; the other had no follow-up DST and no additional information about the patient was available. 
Sixty-seven (89%) patients did initiate second-line treatment; two had initiated treatment before the Xpert 
result was available. For the 65 who initiated treatment after the Xpert result was available, the median days to 
treatment was five, and this will be further explored in section 2 of this chapter.  
Confirmatory DST was available for only 48 (64%) of the patients with an RR-detected result by Xpert, a median 
of 76 days (IQR 43-105) after the Xpert result. Confirmatory DST revealed that 42/48 (88%) were confirmed to 
be RR, with 31/42 (74%) classified as MDR and 11/42 (26%) classified as RMR. Of the 48 patients with 
confirmatory DST results, 6 (13%) were R susceptible, of which 4 were susceptible to all first-line drugs. Of all 
confirmatory DST results, 10 were from LPA testing, and 38 were from MGIT testing.  
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Figure 7.3. Management of patients with an RR result by Xpert, 2013-2014 (all data de-duplicated)  
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Management of patients with RR indeterminate result by Xpert 
Figure 7.4 describes the management of patients with an RR indeterminate result. Out of 48 tests with RR 
indeterminate, this represented 47 patients after removing duplicates. Of all patients with an RR indeterminate 
result, 20 (43%) received a second Xpert test, and none of the tests revealed RR. Out of 47 patients, 18 (38%) 
had results at the NTRL, and none revealed RR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4. Management of patients with an RR indeterminate result by Xpert, 2013-2014 (all data de-
duplicated) 
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7.6 Results (Section 2) 
Time to treatment analysis 
Of the 245 patients who initiated treatment for RR-TB in 2013-14, 128 (52%) had a diagnosis before initiating 
treatment; the remainder initiated treatment empirically and were excluded from this analysis (n=117). Sixty-
five of the 128 (51%) patients started treatment based on results from Xpert (Xpert Cohort), and sixty-three 
(49%) patients started treatment based on results from the NTRL (NTRL cohort). Patient characteristics of the 
NTRL and Xpert Cohorts are displayed in Table 7.1.  
Patient characteristics NTRL Cohort 
N=63 
Xpert Cohort 
N=65 
 n (%) n (%) 
Age, median (IQR) 33 (25-39) 37 (32-42) 
Female gender 39 (62%) 28 (43%) 
HIV positive 40 (63%) 39 (60%) 
Treatment outcomes   
Success 53 (84%) 52 (87%) 
Lost to follow-up 2 (3%) 2 (3%) 
Death 8 (13%) 6 (10%) 
 
Table 7.1. Patient characteristics of the cohorts 
 
Time from specimen collection to diagnosis 
Data on specimen collection was only available for the NTRL cohort where time from specimen collection to 
diagnosis was a median of 77 days (IQR 63-91, range 25-216) Table 7.2. Date of specimen collection was not 
reported for the Xpert Cohort. A maximum estimate of 10 days is used for comparison based on anecdotal 
reports that Xpert testing is done within 10 days of specimen collection. 
Time from diagnosis to treatment 
The time from diagnosis to treatment was a median of 22 days (IQR 14-36) for the NTRL cohort compared to 5 
days (IQR 2-10) for the Xpert cohort (Table 7.2), p-value <0.001 . Figure 7.5 below shows the proportion of 
patients who had initiated treatment by time (days) after diagnosis. By 15 days after diagnosis, 83% of the Xpert 
cohort initiated treatment, versus 33% of the NTRL cohort at this same time point. Additionally, the time to 
reach 95% of patients initiating treatment was 40 days for the Xpert cohort and 100 days for the NTRL cohort.  
Time from specimen collection to treatment 
The time from specimen collection to treatment was a median of 105 days (IQR 85-126) for the NTRL cohort 
(Table 7.2). This can be compared to approximately 15 days for the Xpert cohort, based on adding the maximum 
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time of 10 days for specimen collection to diagnosis to the 5 days from diagnosis to treatment initiation. Figure 
7.6 displays the proportion of patients who had initiated treatment by time (days) after specimen collection. The 
data for the Xpert line is estimated by using the time from diagnosis to treatment and adding the maximum 
estimate of 10 days. It is evident that there is a greater difference in time to treatment from specimen 
collection; compared to time to treatment from diagnosis, with Xpert leading to much shorter time to 
treatment. 
Time from diagnosis to confirmatory DST 
The time from diagnosis to confirmatory DST is only relevant for the Xpert cohort. The median time from 
diagnosis to confirmatory DST for this cohort is 76 days (43-105). But confirmatory testing was only available for 
64% of patients with RR detected by Xpert. 
 NTRL Xpert Median 
Difference  
median (IQR) median (IQR) p-value 
Time from specimen collection 
to diagnosis, days 
77 (64-91) NR*¥ 
 
 
Time from diagnosis to 
treatment, days 
22 (14-36) 5 (2-10) <0.001 
Time from specimen collection 
to treatment, days 
105 (85-126) NR* 
 
 
Time from diagnosis to 
confirmatory DST, days 
NA** 76 (43-105)  
* NR = not reported; ¥ Estimated at 10 days; ¥NA = not applicable 
Table 7.2. Time to diagnosis and second-line treatment, 2013-2014  
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Figure 7.5. Cumulative proportion of patients initiating second-line treatment after RR-TB result available, Xpert 
and NTRL cohorts, 2013 – 2014 (Xpert cohort N = 65, NTRL cohort N= 63) 
 
Figure 7.6. Cumulative proportion of patients initiating second-line treatment after RR-TB specimen collection, 
Xpert and NTRL cohorts, 2013 – 2014  (Xpert cohort N = 65, NTRL cohort N= 63) 
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7.7 Discussion 
During this early phase of Xpert implementation in Botswana, many patients were linked to confirmatory 
diagnosis and treatment, but gaps were identified. Among patients diagnosed with RR-TB by Xpert, 89% initiated 
second-line treatment, and 64% received confirmatory DST. Among patients with an Xpert result of RR 
indeterminate, only 43% had a second Xpert test, and 38% had samples submitted to the NTRL for culture 
testing. The use of Xpert in decentralized locations did significantly shorten time to treatment initiation for 
patients diagnosed with RR by Xpert, compared to those diagnosed at the NTRL.  
Despite Xpert implementation, many studies are continuing to report a treatment gap (defined as patients with 
RR-TB that are not making it onto treatment), and have suggested that Xpert alone is not enough to significantly 
improve this treatment gap42, 211. A nationwide analysis in South Africa reported that while Xpert reduced the 
delay to treatment for RR-TB patients, it did not reduce the treatment gap42. A study in Mozambique reported 
that of all RR-TB patients diagnosed by Xpert in 2012-2015, 53% were initiated on treatment212. In Zimbabwe, a 
study reported that 56% of RR-TB patients diagnosed by Xpert in 2014 initiated treatment213. Mnyambwa et al 
reported that only 32% of RR-TB patients diagnosed by Xpert in 2013-2016 were initiated on treatment214. This 
study further explored this treatment gap through qualitative interviews and identified several potential factors 
negatively influencing linkage to treatment, including deficiencies in the health system (lack of adherence to 
guidelines, limited training, poor communication between lab and health facilities) and patient level factors 
(superstition, stigma, limited knowledge on transmission)214. The 89% of RR-TB patients initiating treatment 
based on Xpert results in Botswana reported in this study is higher than many other settings.  
Research has also highlighted low proportions of patients with RR-TB diagnosed by Xpert receiving confirmatory 
DST (phenotypic or LPA). The current research reported confirmatory DST for 64% of RR-TB patients diagnosed 
by Xpert in Botswana. A study in South Africa reported that 50% of RR-TB patients diagnosed by Xpert received 
confirmatory DST38. In Mozambique, only 29% of RR-TB patients had confirmatory DST212. Another study from 
South Africa reported that among 1,332 patients diagnosed with RR-TB in South Africa, only 45% had second-
line DST; among those with second-line DST, 40% initiated a potentially suboptimal regimen215 Confirmatory DST 
after Xpert diagnosis is important to confirm, not only rifampicin resistance, but also to confirm resistance to 
other drugs to guide appropriate treatment. The World Health Organization (WHO) recommends that patients 
at high risk of MDR-TB with a diagnosis of RR-TB by Xpert should immediately have follow-up DST for at least 
isoniazid, fluoroquinolones and second-line injectables28. For patients at low risk of MDR-TB with a diagnosis of 
RR-TB by Xpert, the WHO recommends a second Xpert test; in the event the second test is also positive for RR, 
the WHO recommends follow-up DST to confirm rifampicin resistance as well as susceptibility testing for 
isoniazid, fluoroquinolones and second-line injectables28. 
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Discordance with rifampicin resistance between Xpert results and confirmatory DST (phenotypic or LPA) results 
has been reported by other research38, 216.The current research cannot definitively draw conclusions about 
concordance since testing with Xpert and with confirmatory DST were not from the same sample, and time 
between specimens may be up to a few weeks. However, other studies have reported on concordance using 
similar methods, and can be used as a comparison. In Botswana, this current research reported that 88% of 
patients with RR-TB by Xpert were confirmed as RR-TB by DST conducted at the NTRL; 74% of these were MDR-
TB, while 26% were RMR-TB. Dlamini-Mvelase, et al reported that, of patients with RR-TB by Xpert in South 
Africa, 91% were RR-TB by confirmatory DST; 85% of these were MDR-TB and 15% were RMR-TB38. In Zambia, 
confirmatory DST revealed confirmed rifampicin resistance for 81% of patients with RR-TB by Xpert. Reasons for 
discordant results have been addressed by other research and include factors such as mixed infections216 or a 
silent mutation on the rpoB gene217-219. This again highlights the need for confirmatory DST. This current 
research shows that confirmatory DST revealed RMR-TB among 26% of RR-TB patients in Botswana. These are 
patients who would have been denied the use of isoniazid in their treatment regimen, if they had not received 
confirmatory DST for rifampicin and other drugs and were placed on a standardized RR-TB regimen.  
As highlighted in the systematic review (Chapter 6), molecular testing methods, such as Xpert, result in more 
rapid laboratory turnaround times64, 203-205. Although the data to calculate time from specimen collection to 
diagnosis was missing for the Xpert cohort, an estimate can be made that the maximum number of days from 
specimen collection to diagnosis would be 10 days. Based on local practice in Botswana, all specimens received 
at a peripheral laboratory must be tested within 10 days or discarded. Comparing this estimate of time from 
specimen collection to diagnosis of 10 days for the Xpert cohort to the calculated median of 77 days (IQR 64-91) 
for the NTRL cohort (an estimated median difference of 67 days), it is clear that Xpert has substantially reduced 
laboratory turnaround time.  It should be noted that using the imputed value of 10 days for the Xpert cohort in 
comparison to recorded times for the NTRL cohort may overestimate the difference; while it would be more 
convincing to have had recorded values for the Xpert cohort, this data was unavailable and is a acknowledged as 
a limitation of this result.  In addition to faster laboratory turnaround time, time to second-line treatment from 
diagnosis was faster among the Xpert cohort compared to the NTRL cohort in this current research.  
It is also important to note that the observed differences in this analysis were based only on the DST method.  
However there may have been other factors contributing to the observed differences.  One factor that may have 
contributed to the observed difference is that there was a large research study (XPRES) being conducted during 
the time of this analysis, using Xpert.  Therefore, the additional attention and research staff focused on Xpert 
results may have influenced these results to be available more quickly than in a purely programmatic setting.  
However, we expect this affect is small as only 6/65 (9%) of the RR-TB patients included in this analysis were also 
participants in the XPRES study.  
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Additional bias may have been introduced in this study by excluding patients who were diagnosed but never 
initiated treatment.  Unfortunately, this data was unavailable for the NTRL cohort and therefore unable to 
include for comparison.  This is noted as a limitation of these findings, and the potential impact is that this 
analysis may have underestimated time to treatment; time to treatment would likely be longer if the excluded 
patients were added to the analysis and remained ‘at risk’ for the event of interest (treatment start).    
The benefits of Xpert have been well documented. Shortened time to treatment initiation is reported by 
numerous studies and has been addressed in this current research. Studies also report Xpert increasing case 
detection43, 44 and leading to less empiric treatment45. Boehme, et al discussed the benefits of providing access 
to early and accurate diagnosis, leading to reduced diagnostic delay, dropout and mistreatment29. Despite these 
benefits, challenges remain in ensuring all patients are linked to treatment and that they access confirmatory 
and second-line DST.  
Overall, this research highlighted that, during early implementation of Xpert in Botswana, a high proportion of 
patients were linked to treatment. Additionally Xpert led to faster time to treatment from diagnosis in this 
research. The successes seen with Xpert implementation in Botswana appear to be a result of faster time to 
diagnosis with genotypic testing methods, as well as decentralization of lab services away from the NTRL and 
closer to the point of care for patients seeking treatment.  
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Chapter 8: When policy and practice do not align: a qualitative study of 
patient and provider experiences with RR-TB diagnosis and treatment in 
Botswana.  
 
8.1 Chapter overview 
This chapter describes the analysis of qualitative data collected by interviewing RR-TB patients, health care 
providers, and national level government staff. The background and policies have been fully described in 
preceding chapters; therefore, the background will describe only any additional context as well as specific 
changes or policies, which are different for the time frame of this analysis (2017), compared to previous 
analyses.  
8.2 Hypothesis and objective 
Hypothesis 1: There are gaps in the diagnosis and treatment process in Botswana that can be identified by 
patients, providers and government staff. 
Objective: 
To identify and describe common themes through analysis of individual interviews with patients, health care 
providers, and national level government staff. 
8.3 Context and update 
Global recommendations indicate that the current focus for RR-TB management should be on improving patient 
outcomes and decreasing transmission through key interventions including early diagnosis, effective therapy 
and active contact tracing. Furthermore, as part of the End TB Strategy, the WHO includes patient centered-care 
as a core principle, focusing on ensuring universal access to TB services with increased attention to vulnerable 
and hard to reach populations. Therefore, the interviews conducted for this analysis specifically aimed to get 
first-hand in depth input from patients and providers regarding their experiences with RR-TB diagnosis, 
treatment and overall management of the RR-TB program. Furthermore, the interviews aimed to gain some 
personal insight to help understand findings from the preceding analyses.  
In order to provide context into the setting of Botswana and the expected capacity of the RR-TB program, the 
following describes key economic indicators. Botswana’s economy is classified as upper-middle income, in 
contrast to other neighboring, sub-Saharan African countries, such as Zambia (lower-middle income) and 
Zimbabwe (low income). In 2017, Botswana’s gross domestic product (GDP) was $17.41 billion USD and GDP per 
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capita was $7,595.60 USD220. Current health expenditure (CHE) in Botswana is 6% of the GDP. South Africa, 
another neighboring country, is also classified as upper-middle income and CHE is 8.2% of the GDP. CHE in all of 
Africa is 6.2% of GDP8.  
By the time these interviews took place, the TB diagnostic algorithm including Xpert (Appendix A) had been 
finalized and distributed, along with recommendations for universal testing by Xpert for all patients with signs 
and symptoms of TB. As of 2015, there were 34 Xpert machines owned and operated by the national TB 
program, placed in every health district of Botswana, with more than one in high volume districts; no additional 
Xpert machines have been added since 2015. A sixth RR-TB treatment facility was added in 2015 (in Mahalapye) 
to further decentralize care. By 2017, Botswana had begun to have limited supplies of the new TB drug, 
bedaquiline, through a donation program but only for patients who were faring very poorly on the standardized 
regimen, which still included amikacin at this time.  
8.4 Methods 
Setting 
The study took place in two (out of six total) government RR-TB treatment centers in Botswana, one in the 
capital city of Gaborone, an urban setting and the other in the rural town of Ghanzi, 670 km from Gaborone. The 
treatment centers provide both inpatient and outpatient services for patients registered for RR-TB treatment.  
Study investigators 
Several personnel were involved in the analysis described in this chapter. Rosanna Boyd (RB) is the author of this 
thesis. RB was responsible for the development of the data collection tool (questionnaire), setting up and 
leading the interviews, overseeing the transcription, and leading the data analysis. Jennifer Furin (JF) is a medical 
anthropologist, experienced in qualitative research and analysis. JF provided guidance on development of the 
analysis plan and served as a second data analyst for the study. Helen Cox (HC) provided guidance on the 
development of the research plan and data collection tool as well as in the interpretation of the findings. Lucas 
Payton (LP) served as a second interviewer in all interviews. Unami Mathebula (UM) is an experienced TB study 
nurse in Botswana, is fluent in Setswana, and served as an interpreter for the study.  
Participants 
Participants in this study included 8 patients (4 hospitalized and 4 ambulatory), 3 direct health care providers 
and 2 individuals involved in managing the RR-TB programme at the national level as part of the National TB 
Program. Patients were selected based on convenience; ie. they were physically present at the health facility 
and willing to participate on the days that the interviewers went to the facility. Patients were classified as 
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ambulatory or hospitalized based on current status at the time of interview. Providers included direct health 
care providers at treatment facilities as well as providers/consultants from the national level; all were classified 
as health care providers. Results are presented in terms of patients and providers. 
Data collection 
Data were collected between May and September 2017. Participants were informed by the interviewers of the 
purpose of the study and were asked to consent to the interview and to the use of recording devices during the 
interview. Written informed consent was obtained from all participants prior to the interview process. In-depth, 
standardized interviews were conducted by two researchers. The same two interviewers (RB and LP) were 
present at each interview. In Gaborone, a study coordinator (UM) provided translation into Setswana where 
required; in Ghanzi, the RR-TB nurse performed the translation into Setswana or Sesarwa as needed. Five of the 
eight interviews with patients required translation; all other interviews were conducted in English. Interviews 
were recorded, and all results were translated, transcribed, and saved in Word documents. For one interview, 
the patient did not consent to being recorded; this interview was conducted in English and, in this case, notes 
were taken and fully written up as a transcript immediately following the interview. 
Definitions 
Interviews included questions to describe experiences with diagnostic delays and delays with linkage to care. 
Diagnostic delays refers to any delay from the time a patient is first ill to receiving a diagnosis of RR-TB, including 
patient related delays in seeking care, as well as health system and laboratory related delays of reaching a 
diagnosis. Linkage to care delays refers to the time between a diagnosis and a patient being referred for 
treatment initiation.  
Data analysis 
To analyze the data in the study a thematic analysis was performed, as described in Vaismoradi, et al221. Two 
researchers (RB and JF) independently performed the analysis; results were compared, combined and any 
discrepancies were resolved via discussion and re-review. Interview transcripts were read through to identify 
patient and provider experiences with RR-TB treatment, themes were uncovered and transcribed on to note 
cards which included specific quotes, participant ID numbers and thematic codes. Additional review of 
transcripts was conducted to refine the themes and to identify and code subthemes. Using ArcGIS, a map was 
created to describe where patients lived in relation to treatment centers, both for ambulatory and hospitalized 
patients. The distance between village of residence and treatment centers was calculated using Google maps. 
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8.5 Results 
Patient characteristics 
Table 8.1 describes the characteristics of the interviewed patients. Of the eight patients, four were male and 
four were female, and ages ranged from 31 to 50 (median 38). One patient was married; three others reported 
cohabitating with a partner. The median number of people per household was 6.5 (range 2-13). Highest 
education levels reported for patients were primary school (1), trade school (1), secondary school (5) and college 
(1). All patients were of Motswana nationality. The distance to treatment facility from village of residence 
ranged from three to 373 kilometers (median 104). Figure 8.1 indicates the location of the home village for each 
patient in relation to the treatment facility. Providers included one doctor, one nurse, one ward supervisor and, 
at the national level, a laboratory manager from the National TB Reference Laboratory (NTRL) and the lead RR-
TB consultant/physician. 
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Gender 
 
Age 
 
Marital 
Status 
 
# in 
household 
 
Education level 
 
Occupation 
 
Nationality 
 
Patient 
status 
 
MDR 
facility 
Distance 
to MDR 
facility 
(km) 
Male 33 cohabitating 5 secondary unemployed Motswana outpatient Ghanzi 3 
Male 37 single, never married 8 
other, brigade 
trade school/junior 
secondary 
unemployed Motswana outpatient Ghanzi 373 
Male 50 married 2 Advanced /college teacher Motswana outpatient Ghanzi 373 
Female 45 single, never married 8 secondary unemployed Motswana outpatient Ghanzi 274 
Male 45 cohabitating 5 primary driver Motswana inpatient Gaborone 33.7 
Female 33 cohabitating 13 secondary security guard Motswana inpatient Gaborone 88.2 
Female 39 single, never married 13 secondary unemployed Motswana inpatient Gaborone 59.5 
Female 31 single, never married 5 secondary unemployed Motswana inpatient Gaborone 120 
 
Table 8.1. Characteristics of interviewed patients 
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Figure 8.1. Map of patient home villages in relation to RR-TB treatment facilities 
  
* Two patients receiving treatment in Ghanzi live in the same village, represented by one yellow circle, 373 
kilometers from Ghanzi 
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Thematic areas 
Six main themes relating to RR-TB treatment emerged from the data: 1) stigma and discrimination, 2) disclosure 
and contact tracing, 3) diagnostic delays, 4) overall experience with care, 5) barriers to care, and 6) RR-TB 
knowledge and education. 
Stigma and discrimination 
Stigma and discrimination from friends, family, employers and health care workers 
Among patients, there was concern about discrimination. While some reported that they were given support 
because of their place in the family, most patients (6) reported having been discriminated against, with some 
people (family, friends and health care providers) even refusing to greet or speak with them. According to many 
patients, this discrimination appeared to be based on fear: 
“They call it the strong TB in Setswana, they think when you have got MDR it’s a death sentence.” “Some 
of them (friends and family) wouldn’t even greet me when they came here to visit, they will just stand 
there but I understood it’s only that they don’t have information” 33 YEAR OLD MALE (AMBULATORY 
PATIENT) 
“When I converted I transferred to the clinic next to my house, but the nurses themselves were afraid and 
they will even say I must wait outside.” 33 YEAR OLD MALE (AMBULATORY PATIENT) 
“When you have not started treatment people are afraid of coming closer to you. They stay away from 
you and they deprive you of food” 37 YEAR OLD MALE (AMBULATORY PATIENT) 
Some patients did also report fear of job loss because of their illness and having to be away from work.  
“that is one issue that is still troubling me big time. At work they were given a letter and they accepted it 
but now they have stopped giving me the salary. I don’t know (if they will take me back) but all I know is 
that when I leave this place I am going back to them” 45 YEAR OLD MALE (HOSPITALIZED PATIENT) 
Providers were not asked specifically about stigma and discrimination in the standardized interview, but one 
provider did mention this, expressing the perception that patients are affected by discrimination/stigma and 
that this affects their health seeking behavior: 
“Yes, for people the stigma of HIV still stands. It’s still there. People are not aware of the signs and 
symptoms of TB very well. In such a way, they think that if you get sick, you are infected with HIV. Now 
for them to go consult a medical officer they’ll think that they will be exposed. So people they shun going 
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to a health center for screening for TB because they think their sickness is due to HIV” HEALTH CARE 
PROVIDER (GABORONE) 
Isolation as a form of discrimination 
Some patients expressed that they feel they are ‘made’ to stay in the hospital to receive treatment and see this 
as a form of discrimination. The patients who were currently hospitalized reported being in the hospital for two 
to three months at the time of interview. All of the ambulatory patients reported being hospitalized in the past 
for three to four months, except for the one patient with extrapulmonary RR-TB who was never hospitalized. 
One currently hospitalized patient had been previously hospitalized the year before and was now readmitted for 
what appeared to be failure of the treatment: 
“they told me that another tablet is not working, and at that time I was receiving injections in my 
treatment and that’s when they brought me back here for readmission.” 33 YEAR OLD FEMALE 
(HOSPITALIZED PATIENT) 
Patients’ perceptions of why they were hospitalized were to avoid infecting others with TB, especially children , 
which perhaps reflects what patients are told about the need to be hospitalized. The following quotes from 
patients reflect their dissatisfaction with being hospitalized, as well as their perception about the reasons for 
isolation: 
“The discrimination I see is the isolation that is being done, by bringing us here and taking us away from 
the community…… I was just told to come here, as this is the place where people are kept .I was not 
given any option to choose any place, and when I got here I was asked who I stay with at home, and they 
told me that the problem is small kids, since small kids are vulnerable to infections…. it is an 
inconvenience but the problem is that I am sick, and there is nothing I can do about it.”…. “I feel it’s ok 
because it helps me not to spread the disease to my children”…. “here, it will be all MDR patients and 
there will be no one to spread the disease to.” 45 YEAR OLD MALE (HOSPITALIZED PATIENT) 
“When it’s MDR they don’t allow you to be isolated from home at all especially if there is no spare room 
but even if there is a spare room at home they don’t allow because at home kids can’t be controlled; they 
will always come to you” 39 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
In order to address the idea of hospitalization as a perceived discrimination, we further explored what providers 
understand in relation to when and why patients are hospitalized. Providers expressed that the main reason for 
isolation is to avoid infecting others. One provider explained in detail the national policy describing the criteria 
that is to be used to determine whether or not a patient should be hospitalized for treatment initiation and their 
perception about how this policy is being implemented:  
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“So, we counsel you and then find out the infection control at home. One thing we want to know is do 
you have under 5s at home, where do you sleep in the house, so if they live in one room like this then 
automatically we would admit. But we give an option. For example, if they live in Gaborone, we say, 
what about your home village? Do you have a compound where you can go? And then in those situations 
where they have one room but they say they can go to their home village, then we make a decision and 
say ok you can go there and isolate yourself. And sometimes after counseling the patients even if they do 
have their own room, they opt to be admitted. Usually it’s for the first 2 months. But even those patients 
maybe who currently live in one room and they don’t want to go to their home village we would admit 
them. But throughout treatment if they get tired of the hospital and want to go their home village, then 
we make a decision and send them. XDR-TB – we admit. There is no criteria. So it’s all based on the 
discussion with the patient. So those patients if there is under 5s and they live in a one room we then let 
them know the reason why we have to admit. And pre-warn them that it is going to take a long time. 
Because marina [MDR ward] – we actually do say, maybe you should go see our site. It’s not like princess 
marina [general hospital wards] they get their own rooms at our site (unlike general hospital wards). So 
that’s why. And sometimes the patient may not want to be admitted but the family member wants them 
to be because they don’t want them to be at home so we often admit them because this family member 
will convince them. They say ‘ you need to be admitted’ and then they go ahead. But it’s a collective 
decision made” HEALTH CARE PROVIDER (GABORONE) 
However, there were conflicting reports about how this policy was being implemented. Three of the providers 
indicated that all or most patients are hospitalized until they ‘convert’ (become culture negative). One reported 
that most patients are not hospitalized.  
The reports from the providers that describe the purpose of hospitalization as a way to decrease risk of 
transmission matches up with the perceptions of the patients about why they are hospitalized. There is a 
widespread notion that patients with RR-TB need to be isolated when they initiate treatment and that this will 
protect the community. There appears to be little understanding that transmission will most likely have already 
occurred before the patient was diagnosed and treatment initiated. While the perception that hospitalization 
for treatment initiation will protect the community is inaccurate, it does reflect the rationale for hospitalization 
given in the national policy. 
Of the eight patients interviewed, all except the one patient with extrapulmonary RR-TB were hospitalized for 
treatment initiation.  
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Gender based discrimination 
All patients reported that they do not see gender-based discrimination in seeking care for TB, including the four 
women who were interviewed. Most patients reported that partners should allow one another to seek care and 
to support one another in seeking care. 
“And yes they have to inform their partner and I also have to accept because when one is not well, they 
are not well. Yes it’s important, you just have to tell your partner that you are going to the hospital.” 37 
YEAR OLD MALE (AMBULATORY PATIENT) 
 
“Why should you ask for a permission? As for me I think if somebody feels that he is not feeling well with 
the disease it’s his/her own choice to seek medical service, it’s just my belief” 50 YEAR OLD MALE 
(AMBULATORY PATIENT) 
Disclosure and contact tracing 
Although patients did report discrimination and reported being worried about telling others of their RR-TB 
diagnosis, all patients did report disclosing to at least some family members and friends; in some cases this was 
possibly connected to screening of close contacts. Patients did report that some of their close contacts were 
screened, often limited to household contacts. However, some patients reported that they were concerned that 
children over five were not being screened: 
“isn’t it 9 years and downwards were not checked since they said 5 years upwards have to cough out 
sputum but it’s difficult for a 6 year old child to cough out sputum…. That is what is worrying me is that 
why did they not give the test to the others who are 9 years downwards since it could help them.” 39 
YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Providers’ perceptions of screening practices varied. While some report that they routinely screen all close 
contacts, others say they do not believe that screening of contacts is done consistently. Interviews did not 
address the reasons why this is not being done consistently. 
“On paper yes. It’s partially done. The only ones that are – that you find the TB focal persons take 
consideration – is when you see more than one family member showing up with MDR-TB. There was an 
active screening group for XDR-TB, the TB program would do that themselves, but now it’s not being 
done. Contacts won’t be screened. Or they may do the first screening but not follow-ups. Unless it’s the 
family themselves that go and demand to be screened.” 33 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
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Diagnostic and linkage delays 
Patient perceptions of diagnostic delay 
Patients expressed frustration with diagnostic delays. In particular, patients noted challenges when first seeking 
care at the primary care clinic and district levels. Some patients reported having to request TB tests for 
themselves or seek care elsewhere because their illness was not being diagnosed. The following quotes comes 
from patients who felt turned away by the local clinics:  
"I sought treatment at the clinic for about one month because I had a cough, night sweats and a 
headache. The clinic said you're coming too much. And I said I’m not well" 31 YEAR OLD FEMALE 
(HOSPITALIZED PATIENT) 
“I started not feeling well for about 3 weeks, it was so strong and I kept coming to the clinic and they 
asked me to give out sputum, I told them I am not coughing. But I am feeling pains and the issue is I 
wanted them to take me for an x-ray so that at least I can clear my conscious because I had taken care of 
people who had TB. I had taken care of people with TB, and even my mother was diagnosed through X-
ray and after her death the hospital said we must be screened for TB at home and the clinic refused 
saying my mother was diagnosed through X-ray so she was not coughing and that TB is not 
transmittable.” 39 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Diagnostic delays were often long, according to patients. The one patient with extra-pulmonay RR-TB reported 
being sick and seeking care for seven months at the district hospital. After going to a private hospital in the 
capital city (at his own expense), he received the correct diagnosis and began RR-TB treatment. Another patient 
who reported his girlfriend had RR-TB, expressed concern about how long it took to diagnose him when he 
sought care: 
"I was sick for 5-6 months. They could not catch it; they did the screening, I brought the sputum but it 
took long. I was concerned because I knew that my girlfriend (had RR-TB) we were staying together in 
one house." 33 YEAR OLD MALE (AMBULATORY PATIENT) 
Several patients reported taking one or more courses of first-line treatment before being diagnosed and starting 
second-line treatment. This was expressed as a source of frustration, particularly by one patient who was on 
first-line treatment for more than one year before being diagnosed with RR-TB: 
 “I delayed because of mistreatments. I will start treatment and be told I am not healed and be started 
on another lap of treatment.” “from 2014 to September 2016. I started the first lap of 6 months and I 
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was told I am not cured, then I was started again on another 6 months lap which was extended to 9 
months and that’s when I was told I had MDR” 33 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Provider perceptions of diagnostic delay 
Providers reported that patients often delay seeking treatment thinking it’s another illness such as flu. Most 
patients reported being ill for about one month before seeking treatment. If this is the case, the diagnostic 
delays are much greater than the health care seeking delays from the patients. 
Providers also expressed concern about diagnostic delays. Their perception is that delays (after the patient 
presents for care) are caused by various factors, including laboratory closures, inconsistent availability of 
reagents, lengthy laboratory processes for culture results, and having only one culture facility for the entire 
country. Although the updated TB diagnostic algorithm recommending universal DST by Xpert had reportedly 
been implemented in 2016, providers confirmed that many patients are treated with first-line medication before 
testing for drug resistance. Some providers expressed frustration that health care workers at the primary care 
clinics do not follow the guidelines and ensure that at least high risk patients (such as previously treated 
patients) receive culture and DST at treatment initiation. The providers do acknowledge that health care 
workers likely need more training on this. The quote below describes that for a sample to be sent for culture, a 
health care worker must specifically request the test on the lab request form  
“Well the health care worker would have to request for culture. If they don’t the district lab won’t 
transfer them. If culture has been requested, they (the district lab) just package and ship them through 
the lab network to NTRL.”  
(Interviewer: If they don’t request culture does the district lab do smear testing?)  
“Yes and discard the specimen. So it’s up to the health care worker seeing the patient” HEALTH CARE 
PROVIDER (GHANZI) 
There was concern expressed by providers that the diagnostic delays / inadequacies may contribute to 
mortality.  
“the lab has not been fully functioning so maybe we are missing cases and they are dying with MDR-TB” 
HEALTH CARE PROVIDER (GABORONE) 
Impact of Xpert on diagnosis 
All providers reported that the introduction of Gene Xpert in district labs throughout the country has helped 
with diagnostic delay; they feel more comfortable having early results and starting treatment for a patient with 
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confirmed RR, rather than starting empiric treatment while waiting for DST results. The providers expressed that 
starting people on RR-TB treatment empirically used to occur much more before the introduction of Xpert. 
Providers also reported that they believe they are diagnosing cases of RR-TB that would have been missed in the 
past.  
On the other hand, providers reported many challenges with Xpert that do contribute to diagnostic delay, 
including frequent stock-outs of cartridges, modules not working and not being repaired, and machines not 
being calibrated. Furthermore, providers report that after the introduction of Xpert, providers throughout the 
country no longer routinely send samples for confirmatory testing at the NTRL; only the RR-TB treatment centers 
routinely send samples to the NTRL. The laboratory manager describes his perception of this issue: 
 "Gene Xpert has taken our job. Our sample receiving has drastically reduced by more than 75%. The 
samples that we were receiving in a month are the ones that we are receiving in a year. So, we don’t 
know what’s happening but I think it’s because of Gene Xpert people are no longer forwarding samples 
for culture. Though the algorithm says despite the Xpert result they should send the sample for TB 
culture. I think it’s not well understood" HEALTH CARE PROVIDER (GABORONE) 
 
Another provider confirms that samples are not being routinely sent to the NTRL for confirmatory testing: 
 
“The ones I have a good idea about are those ones sent from the MDR-TB sites, those patients are on 
treatment. Those they will send each time they have an encounter (with the patient). But how frequently 
from the other sites/facilities, I don’t know. It used to be better but it’s dropped. I think because of Xpert. 
I think there is just a lack of knowledge. People are just no longer sending. The lab is actually 
complaining because they are getting less samples. It’s a matter of us just training the health care 
workers.” HEALTH CARE PROVIDER (GABORONE) 
Linkage to care 
Overall delays to linkage to care were not reported. Both patients and providers reported that once a RR-TB 
diagnostic result is received, treatment is initiated very quickly (same day or within a few days). Providers felt 
that, in this instance, health care workers at the primary care level are helpful: 
“And I think what actually helps is that health care workers don’t necessarily want to develop MDR-TB so 
if there is a case, they want to send (the patient for treatment) as soon as possible” HEALTH CARE 
PROVIDER (GABORONE) 
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Overall experience with care 
Care in the hospital versus the outpatient clinic setting 
In general, patients expressed satisfaction with their providers, the waiting times and the clinic hours of 
operation (although participant 33 YEAR OLD MALE (AMBULATORY PATIENT) was an exception). Although some 
patients had expressed that being hospitalized was a form of discrimination and that they didn’t enjoy being in 
the hospital (a perception confirmed by interviewed providers), most patients did express a belief that the care 
received while in the hospital was better than care received from a local clinic. Patients explained that they 
believed the hospital staff were more available and the quality of care was better.  
 
“Here [in the hospital] it’s much better because the nurses are always available, and they also monitor 
your health and any side effects that comes with the medication” 33 YEAR OLD FEMALE (HOSPITALIZED 
PATIENT) 
In the hospital “it will be all MDR patients and there will be no one to spread the disease to. And also 
when we feel pain we are attended to immediately” 45 YEAR OLD MALE (HOSPITALIZED PATIENT) 
 
“I recognize the nurses of the hospital much more better than the clinic ones. All the assistance I needed I 
got it at the right time and they are also patient.” 45 YEAR OLD FEMALE (AMBULATORY PATIENT) 
Drug stock-outs 
All patients noted major problems with drug stock-outs and interruptions in treatment. One patient dealt with 
this by procuring his own medications. Patients expressed stress and frustration about this issue: 
"The day I arrived here I was started on treatment and took it for 7 days and then the medications got 
finished, and I stayed for the whole month of April with no medication" 39 YEAR OLD FEMALE 
(HOSPITALIZED PATIENT) 
 
"Here it is a stressful experience, the whole of April we did not have medications. We did not have the 
drip and the injection. There was nothing we were taking at all because…. You can't take the pills without 
the drip since they go hand in hand. The meds only came last week and there are some hearsay that by 
Sunday it might finish and that's a problem" 33 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Some patients indicated that they had been told the stock-out were caused by lack of funding and lack of 
prioritization given there are few RR-TB patients in Botswana. 
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“I don’t know what can be done because as for us we do try to speak out, but as we speak out they tell us 
that they do check at the pharmacies, and the government does not have money and also that MDR 
patients in Botswana are not so many and again we don’t get the same treatment. At times maybe it’s 
the suppliers who dodge around with medications looking at the fact that medications are very 
expensive but with few people taking them. For example when I got here the injection I was given is not 
the one I am getting now. Because it was out of stock for a long time. I kept talking to them till they 
switched me to this one.“ 39 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Providers confirmed that drug stock-outs have been a major problem and source of concern for them as well. 
They also confirm that treatment disruption has occurred. They indicate that stock-outs are more common now 
than in the past and that they are having to be more creative and proactive to try to manage stock-outs (sharing 
drugs between facilities). Although the patient perception was that the government does not have funding to 
buy the medications, the providers did not completely confirm this. Rather, they explain the cause as logistical 
issues of the supplier, Central Medical Stores (CMS), and how the funding is allocated and utilized. A ‘vote’ is an 
account at CMS into which the government puts funding. The vote specifies what the funding should be used 
for.  
“CMS (Central Medical Stores) say they used to have a vote (account) for MDR-TB drugs. Now since last 
year they didn’t, so they were just batching up with all the other drugs they were buying. In the vote they 
had for every other drug. So that proved to be a huge challenge. We had so much stock-outs, something 
we never used to be able to see. And now I think we were treating more patients than what we are 
now.” 
Interviewer: Will this be addressed in the next financial year? 
“I don’t know” HEALTH CARE PROVIDER (GABORONE)  
“Just because I heard the information from the CMS. It’s the issue of funds and the changing of suppliers 
and signing of contracts that delay the supply of these drugs” HEALTH CARE PROVIDER (GHANZI) 
One provider explains their efforts to avoid stock-outs when possible.  
“For instance when we didn’t have augmentin, we got augmentin from Mahalapye. So we will call the 
sites. Francistown will call us and say we don’t have moxifloxacin and so we will find out does Gaborone 
have enough moxifloxacin. Can they share? And they will call around all the MDR-TB sites. And if they 
have enough, they will share.” HEALTH CARE PROVIDER (GABORONE) 
Some providers at the treatment center expressed frustration but seemed unsure of the cause of stock-outs: 
162 
 
"Yes we (currently) have drugs available to treat MDR-TB. The facility has experienced shortages of MDR-
TB drugs in the past for 1 to 2 months. The stock-out came from CMS (Central Medical Stores). I don’t 
know why. We order the drugs but they don’t show up here.” HEALTH CARE PROVIDER (GHANZI) 
Adverse events 
All patients reported concerns about adverse events and side effects including high blood pressure, mobility 
problems, nausea/vomiting, loss of appetite and dizziness. The largest concern for patients was hearing loss, and 
one patient who was approached for interview could not participate because they had hearing loss due to use of 
the second-line injectable drug. The following quote describes the patients’ frustration and fears about hearing 
loss: 
“You are told (by providers), it all depends on luck, that there is a possibility of you losing your hearing 
and all those discussions you have. And when you tell them (providers) that to lose hearing is very painful 
if you have ever heard before they will tell you is it not better to be crippled and be alive than death. And 
the painful thing is that if you lose your hearing it is not treatable or give you hearing aid to help you or 
when you tell them that you feel you are losing your hearing, I don’t know if there is any action that they 
take or they reduce the treatment dosage to avoid hearing lose, but most of us we lose our hearing 
because of this treatment…… The only thing is that they should be serious about these drugs because 
there are too strong and also the issue of injections because that is what makes me so worried above all 
things. Because to hear and then later lose your hearing it’s a problem, you can’t do anything for yourself 
let alone to walk alone and again I don’t think the government will give us jobs because we lost our 
hearing while on treatment, it will be our own problem.” 39 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
Providers also reported that patients are particularly worried about hearing loss and report that they are 
working to get access to better tolerated medications.  
"What they (patients) do remember is the side effects, the hearing loss. They will tell you before they 
start that they don't want the injection" HEALTH CARE PROVIDER (GABORONE) 
“One, bedaquiline, one of the new drugs, USAID is offering it as a compassionate drug. So countries are 
requested to apply for that. They’ve paid for that through the WHO but there’s certain requirements you 
have to meet before you do that and then you have to estimate the amount you need in a year. So 
ministry of health were in the process of doing that and submitting those documents to USAID. Once 
that’s done the bedaquiline is available.” HEALTH CARE PROVIDER (GABORONE) 
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Barriers to care 
Transport 
In general, transportation was reported as a concern and barrier to care by both patients and providers. 
However, it was noted by all participants that the government provided transportation and this was 
appreciated. Overall, transportation is free and is provided; the concerns are with consistency and timeliness.  
“They provide transport, it’s only that they come late so that’s why I normally walk” 33 YEAR OLD MALE 
(AMBULATORY PATIENT) 
 
“We have one day allocated each month for MDR-TB patients. If for some reason a patient is unable to 
come we call the clinic and re-book. They usually miss because of transport” HEALTH CARE PROVIDER 
(GABORONE) 
 
“I guess the issue may be transport. If the facility doesn’t have transport to bring them to the clinic 
(monthly check up) then they have to change it. But at least the facility will call and say we don’t have 
transport today, can we change it to another day?” HEALTH CARE PROVIDER (GABORONE) 
Access to Food 
Participants also discussed that access to food was a problem and should be provided to mitigate adverse 
events. Even when hospitalized and food was provided, many complain about the quality and quantity of food.  
 “The challenge here (hospitalized) is that we don’t eat properly. Sometimes there is only bread in the 
morning and again in the evening. Sometimes there is not enough soup to go with the rice we are given. 
It is less than what we can get at home” 31 YEAR OLD FEMALE (HOSPITALIZED PATIENT) 
 
“what we (ambulatory patients) always emphasize is that we should be provided with lunch like now we 
don’t have money where are we going to get food now. So that at least if you take these tablets without 
eating obviously you are going to vomit they should always provide lunch for us.” 50 YEAR OLD MALE 
(AMBULATORY PATIENT) 
Providers agree that access to food is a problem and a concern for patients. They do report that they advocate 
for food baskets for patients but that this is not always successful; the decision for this food support is made by 
social workers who are available at each treatment facility. One provider did indicate that the 2017 updated 
national guidelines for management of drug-resistant TB (still in draft, 2019) include a policy to provide food 
baskets for all RR-TB patients, but these updated guidelines are not yet finalized, approved and distributed. 
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These new policies will require additional funding support from the national level and are waiting for approval 
from the Ministry of Health and Wellness. 
“And mainly the main thing that they tend to want is food. It’s very difficult but we do refer them. Some 
will get food, some won’t. So this is something we are trying to advocate for from the ministry of health 
that can this be something that all of them can get now that they’re MDR can they just get it.” HEALTH 
CARE PROVIDER (GABORONE) 
“Then the other thing is trying to help those patients to cope with taking those treatment trying to 
involve the social workers so that they give them food baskets because most of our patient here are not 
working so they need that support. Now have a big problem because when we refer them to the social 
workers they will just tell them no, you are not eligible for those food basket, but it was an issue that was 
discussed so that the social workers can be informed that automatically whenever a patient is diagnosed 
with MDR should be given food basket until the end of their treatment. For now I will think it’s not the 
issue of money it’s the problem of communications between the ministry and the social work 
department.” HEALTH CARE PROVIDER (GABORONE) 
Directly observed therapy 
For ambulatory patients, a majority of patients reported receiving a supply of medications as opposed to taking 
them daily at the clinic (although one went to the clinic and took them daily). They report that receiving the 
supply is based on trust the providers have in them. People also reported that they preferred to take 
medications at home because they wanted to take them with food. Treatment support, for taking medications 
at home, was usually provided by females in the lives of the participants (mother, sister or wife). Hospitalized 
patients noted as a positive that nurses remind them to take medications at the right times and that they do 
receive food with medication (even though there are some complaints about food). 
Funding 
Providers reported concerns about decreased lab capacity for a variety of reasons, including stock-outs of 
laboratory reagents and Xpert cartridges and closures of the NTRL, making it difficult not only to diagnose 
patients but also to manage them properly. Providers do report that funding support is not adequate and leads 
to these problems. 
“From 2010 until now that we stopped (conducting second-line DST). I think it had to do with money. So 
there was a gap of no second-line DST. And then they trained and then the lab closed (2014). So that’s 
how many years, 6-7 years, with no second-line DST. It is a big deal especially when our doctors in 2008 
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showed we have high new infections so there is high transmission.” HEALTH CARE PROVIDER 
(GABORONE) 
“We (NTRL) run out of reagents which will disrupt the testing of the patients, diagnosis of the patients, 
monitoring of the patients so we don’t know exactly if we are where we are supposed to be there…. We 
are (currently) using the solid method but the quickest and the best way is to use the liquid method. But 
we don’t have the reagents for the liquid method now but we are using the solid method. It’s slower, 
cumbersome… Whoever has the say about the financial support of the lab thinks treating the patient will 
be cheaper than buying the reagents which is not the way. They think it is better to have the infection 
spreading then we will treat the patient which is not the way. So I think it is a matter of prioritizing the 
funding itself” HEALTH CARE PROVIDER (GABORONE) 
"The program has a very good plan and strategies for MDR treatment but unfortunately I think it's to do 
with financial support. The program does not have enough funds for the support for the proposals they 
have raised. We always have strategies that are put in place but they do not take over because of 
financial constraints." HEALTH CARE PROVIDER (GABORONE) 
Missing cases  
Providers felt that, as a consequence of decreased lab capacity and decreased utilization of lab services, patients 
with RR-TB are being missed/undiagnosed. 
“At the moment I think we should be seeing more MDR cases. If we truly used Xpert I think we should 
be picking up more cases. But since 2011 our MDR-TB cases have dropped because of the lab 
support.” HEALTH CARE PROVIDER (GABORONE) 
"We usually diagnose about 1 or 2 cases of MDR-TB per month. This past year, we have only 
diagnosed 1 patients. There have been no cartridges for Xpert so maybe our diagnosis is down" 
HEALTH CARE PROVIDER (GHANZI) 
Knowledge and education 
This theme explores TB knowledge and beliefs among patients and, for providers, examines access to and 
adequacy of training and guidance.  
Patient knowledge and education 
Providers and patients both report that education about RR-TB is provided to patients, and accompanying family 
members, at the time of treatment initiation. This education includes information about the medications, the 
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side effects and infection control. Prior to initiation of RR-TB treatment, most patients had heard of TB but not 
RR-TB or MDR-TB, and reported receiving health information from a mix of health providers, friends/family, 
community events and television. Those that had previously heard of RR-TB, had limited information: 
“I had heard that there is a big TB which is stubborn” 37 YEAR OLD MALE (AMBULATORY PATIENT)  
It appears that the education provided at treatment initiation is not sufficient for all patients. It is possible that 
the information provided is sufficient but that it is not retained or completely comprehended. While some 
patients appeared to have good knowledge about RR-TB during the interview, others expressed limited 
knowledge, and some expressed an interest in finding out more about TB:  
 “Can I ask you something, this word ‘culture’ what does it look like?” 33 YEAR OLD FEMALE 
(HOSPITALIZED PATIENT) 
Regarding side effects: “this hearing thing when it changes, what are the signs?” 39 YEAR OLD FEMALE 
(HOSPITALIZED PATIENT) 
When asked how they think they got RR-TB, one patient reported that his girlfriend had MDR-TB; others 
speculated reasons such as working a dusty environment or that it may have been transmitted sexually, and 
some did not know: 
“I don’t know how I got it, I just found myself sick” 45 YEAR OLD FEMALE (AMBULATORY PATIENT) 
Provider access to training 
Overall, interviewed providers reported being satisfied with their training. Three of the providers received 
training provided by the International Union Against Tuberculosis and Lung Disease (IUATLD); these providers 
then provide training for others in the program. The interviewed nurse from Ghanzi, for example, reported 
receiving hands on training at the Gaborone treatment facility (the doctors and specialists at this treatment 
facility have received IUATLD training). Providers did indicate that there is a lack of training for staff at primary 
care levels and that this influences many aspects of RR-TB management. Only one interviewed provider (the 
laboratory manager) reported their training as being inadequate: 
“The training will never be enough. There are always new things coming up and we can’t say it’s enough. 
We don’t know how far we can reach and we cannot give ourselves boundaries” HEALTH CARE 
PROVIDER (GABORONE) 
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Provider access to guidance and expert consultation 
Providers reported good access to experts for consultation. All providers reported that they frequently consult 
with the lead RR-TB physician and that she is readily available. This lead physician also has access to a TB expert 
at the Union and reports that he is “always happy to consult”.  
One area in which providers expressed some dissatisfaction was the availability of updated RR-TB management 
guidelines. All providers reported that guidelines were available in the facilities but that they are not up to date; 
all reported having access to the version from 2009. Providers reported that a newer version has been in 
development but that there is a delay:  
“Well, the guidelines they have changed but they’re still not in the facility. The last guidelines that were 
in the facility were in 2009. A lot has changed since 2009. They’ve been revised since last year but they 
waited for endorsement from the Permanent Secretary because it requires budget changes. Like the new 
drugs and they’ve also put in this part of MDR-TB patients getting food baskets so she needs to approve 
it before it goes out.” HEALTH CARE PROVIDER (GABORONE) 
Understanding of TB transmission among providers and patients 
Although patients reported receiving education about RR-TB and providers report overall satisfaction with 
training, there does appear to be some misconceptions among both patients and providers about TB 
transmission. None of the patients mentioned airborne transmission when asked how they think they acquired 
TB, and others mentioned different modes of transmission (sex, environment). Furthermore, the idea of 
hospitalization because of transmission risk was mentioned by both patients and providers, and reflects and 
misunderstanding about the low risk of transmission once on treatment. No one mentioned that most 
transmission would have occurred prior to treatment initiation, therefore negating this as a reason for 
hospitalization.  
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8.6 Discussion 
This is the first qualitative study of a cohort of RR-TB patients and providers in Botswana. This study provides a 
wide variety of insights about the successes and challenges of RR-TB management in Botswana based on patient 
and provider experiences.  
There are several areas in which the program appears to be succeeding. The interviewed providers involved 
directly in RR-TB patient care (those at RR treatment facilities and those that provide support from national 
level) showed compassion and support for patients; patients reported being satisfied with the care they 
received in the RR-TB treatment centers. This research indicated that patients do not experience gender based 
discrimination in Botswana. Although delays in diagnosis were reported, linkage to care once patients were 
diagnosed was reported to be rapid. Providers felt they have adequate training and good access to experts for 
consultation as needed, though some of the challenges and misunderstandings identified in this research call 
into question whether or not the training available is actually adequate.  
Overall, Botswana has good policies in place that are in line with global recommendations; however, these are 
not implemented consistently, and this creates many challenges in the program. One major area of 
misunderstanding is with the policy for hospitalization. Providers view hospitalization as one of the main ways to 
reduce transmission and a great deal of effort is placed on ensuring patients are hospitalized and on managing 
patients in the hospital. While it is a common perception that isolating patients is needed to reduce 
transmission86, 222, it is not in line with current the WHO recommendations. Research has shown that with 
effective treatment, RR-TB patients quickly become noninfectious223.  The focus on isolating patients can also 
create a false sense of security whereby health care workers and communities believe that they are not at risk 
when ‘infectious’ patients are removed from the community; but this fails to take into account the numerous 
patients who are undiagnosed and are still in the community with the possibility of transmission69. Furthermore, 
even settings which recommend hospital based care for RR-TB patients recognize the limitations. Oladimeji et al. 
reports the usefulness of hospitalization in Nigeria but also notes that less than 5% of estimated cases initiated 
treatment, and surmises that with the expected scale-up of RR-TB care, the hospitalized model would be hard to 
sustain86. Additionally, systematic reviews suggest that hospitalization is not associated with better outcomes 
than ambulatory treatment89, 90. In the current research, one provider in Botswana reported that, in line with 
national policy, most patients are not hospitalized for treatment initiation. However, other providers reported 
that most patients are hospitalized until culture conversion and all patients interviewed, with the exception of 
one extrapulmonary RR-TB patient, reported being hospitalized for several months. This indicates a 
misunderstanding of the policy and of the main factors contributing to transmission. While so much effort is 
placed on hospitalization, other important factors are ignored.   
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Early diagnosis of drug resistance is one of the most important factors to reduce transmission, and Botswana did 
implement an updated TB diagnostic algorithm including universal DST in 2016. However, the diagnostic 
algorithm is not consistently adhered to leading to lengthy delays in diagnosis, in turn contributing to increased 
transmission. Several factors contribute to non-adherence to the algorithm. There appears to be 
misunderstanding and a lack of training at the primary care level where patients are first seen; health care 
workers at this level often request only smear testing, and even when Xpert testing is requested, a follow-up 
confirmatory DST is often not requested. As a result, diagnosis of drug resistance is delayed. Once samples arrive 
at the NTRL, a process including reflex testing is followed whereby any culture positive test automatically 
triggers first-line DST. However this same concept of reflex testing is not followed at the peripheral labs. 
Peripheral labs will not automatically forward specimens to the NTRL unless they are accompanied by a form 
which specifically requests culture and/or DST. Additionally, challenges with maintenance of Xpert instruments 
and stock-outs of testing reagents, both Xpert cartridges at the district level and laboratory reagents at the 
national level, lead to inability to adhere to the diagnostic algorithm as well. Other settings have reported similar 
challenges. Sikhondze et al reported that in the Xpert rollout in Swaziland, the lack of government budget to 
support maintenance, calibration, and module replacement contributed to the number of unsuccessful tests33. A 
study in Nepal also reported barriers to successful implementation of Xpert including timely supply of cartridges, 
replacement of damaged modules and machine maintenance34. The study recommends the following to 
improve Xpert implementation: evaluation of workload and provision of adequate human resources, 
comprehensive training to staff of Xpert testing locations, and co-operation between Xpert users and suppliers 
to minimize delay of supply and maintenance34. A key element that is relevant in Botswana, and likely other 
settings, is the importance of adequate funding and logistics to support the supply of cartridges/maintenance. 
A systematic review224 showed that contact investigation for drug-resistant tuberculosis patients is a high-yield 
intervention for detection of drug-resistant tuberculosis. While Botswana national policy indicates that contact 
tracing should be conducted for all close contacts of RR-TB patients, there were conflicting reports from 
providers about this being done consistently. Additionally, some patients reported concern that not all of their 
contacts were screened, and one patient reported having to request screening even after his girlfriend had been 
diagnosed and treated for RR-TB. As has been shown in previous chapters describing the RR-TB cohort in 
Botswana, the number of children diagnosed is low; children are often detected through screening225 and may 
be missed due to inconsistent screening practices in Botswana. Inconsistent screening practices also contribute 
to diagnostic delay.  
The delays in diagnosis can lead to ineffective treatment and continued transmission. Most patients report 
receiving first-line treatment before being diagnosed with RR-TB, with some patients receiving multiple courses 
of first-line treatment before diagnosis of drug resistance. Studies report that treatment failure can be 
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determined early and that among those whose treatment has failed, multi-drug resistance is common and 
therefore important to monitor; Pachas et al reported that smear positivity at 2 months of first-line treatment 
was strongly associated with failure of treatment, and approximately 75% of those with DST had MDR-TB226. 
Additionally influencing the ability of the program to provide effective treatment are drug stock-outs, which was 
an area of concern for both patients and providers reporting frequent and lengthy treatment interruption. This 
same challenge is seen in other settings. A qualitative study in South Africa reported challenges with access to 
important medicines caused by inefficiencies at the central level including delays in awarding pharmaceutical 
tenders, absence of contracts for certain medicines and suppliers’ inability to provide medications due to stock-
outs at multiple levels227. Bam et al. conducted a comprehensive evaluation of supply chain issues for second-
line TB drugs in South Africa and has produced guidelines to cost-effectively reduce stock-outs by implementing 
supply chain policies which and take into account lead times from drug suppliers, as well as include maintaining 
safety stock of medications at a central distributor228.  
At the time of this research, Botswana was using a standardized long course regimen including amikacin. 
National policy does state that individualized regimens are provided based on DST results, but it is not clear how 
consistently this is done48. As shown in other chapters, many patients in Botswana initiate treatment empirically 
on the standardized regimen and some patients never receive DST to guide treatment regimens; they remain 
classified as presumptive RR-TB throughout treatment. The WHO recommends use of treatment regimens in 
which drugs are likely to effective based on DST, and research has also shown the importance of basing 
treatment regimens on known drug resistance profiles13. The Preserving Effective Tuberculosis Treatment Study 
(PETTS) showed that patients who received six potentially effective drugs (based on DST) had a 36% greater 
likelihood of culture conversion than patients who received less than six potentially effective drugs229.  
National policy had not officially addressed shorter treatment regimens and the use of medications with less 
side effects; however, plans to incorporate these into policy had begun according to interviewed providers. 
Given the strong concerns and complaints about side effects with the current treatment reported by both 
patients and providers, it is important to incorporate alternative treatment options. Chapter 5 confirmed that 
concern regarding hearing loss was warranted, given that 44% of the patients in the studied cohort reported 
hearing loss, and a publication from another cohort in Botswana reported hearing loss in more than 60% of the 
patients receiving treatment110. As a follow-up to determine if there have been any changes in treatment 
regimen since the time of this research, the Botswana National TB Program Manager was contacted by the 
researcher. This follow-up communication (December 2018) revealed that the program has mostly switched 
from amikacin to capreomycin or bedaquiline containing regimens11. Bedaquiline is being provided by USAID as 
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part of a donation program. Amikacin is still available for individual regimens. The program is still using the long 
treatment duration as of 2018.  
There were several other challenges identified in this analysis, all of which should be considered in this 
recommended shift of priorities and attention to ensuring policies are adequately implemented. These include 
challenges with transport being provided consistently, inadequate food support for patients, and a need for 
opportunity for continued counselling and education of patients throughout treatment. The cost of these 
supportive interventions is low in contrast to the cost of second-line medications; the WHO reported the median 
cost of RR-TB treatment per patient was over $7000 USD in 201713.  
While it has been determined that Botswana policies are in line with global recommendations in many 
important areas, adherence to the policies is problematic. National program manuals and guidelines are not 
updated regularly and contribute to this non-adherence. The most recent TB program manual was developed in 
2011, and the most recent guidelines for management of drug-resistant TB was developed in 2009. This is a 
major challenge, given the rapidly changing WHO guidance on RR-TB management. Furthermore, important 
updates have been made and implemented in Botswana, such as the updated diagnostic algorithm including 
universal DST through Xpert; however, this update has not been incorporated into the relevant national 
program manual or guidelines. Botswana produced an updated draft of the guidelines for management of drug-
resistant TB in 201792; however, this has remained in draft form waiting for approval at the national level. One 
interviewed provider did report that the approval and distribution of these guidelines is delayed because the 
update calls for increased commitment from the government (in the form of new drugs, food support for 
patients, etc.), so this is pending approval from the Minister of Health. Recent communication (December 2018) 
with the program revealed that these guidelines have still not been approved and distributed104, indicating lack 
of support at the high levels of the Ministry of Health and Wellness.  
There are limitations of the study. There were few patients interviewed, but the interviews were very lengthy 
and in depth. Additionally, there were few providers interviewed and this was limited to providers at the 
national level and at two of the six RR-TB treatment facilities; this analysis did not include providers from the 
primary care level. The same translator was not used at each site; due to limited funding, the translator could 
not travel to Ghanzi, and the RR-TB nurse provided the translation in Ghanzi. The nurse was educated to 
translate the interviewers’ words verbatim, and the transcriptions, which were all performed by the same 
person, confirmed this was done.  
These findings highlight the need to focus attention away from less crucial and more expensive TB control 
practices such as hospitalization and prioritize case finding and safe, effective treatment without interruption. 
While the providers interviewed demonstrated strong work ethic and dedication to the successful management 
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of RR-TB, there is a larger system level problem. Stock-outs of testing reagents and medications, non-adherence 
to the diagnostic algorithm, inconsistent contact tracing and treatment regimens with serious side effects are 
evidence of larger system issues. Botswana is an upper-middle income country and should be able to support an 
effective RR-TB control program including adequate laboratory capacity; however, this is not the case evidenced 
by the many gaps that have been identified in this analysis. National level support is needed to shift priorities, 
provide adequate funding, improve communication and training to reverse misunderstandings and to integrate 
services across all levels of care.  
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Chapter 9: Conclusions 
9.1 Chapter overview 
This chapter will summarize the key findings and implications of this research, as well as overall 
recommendations.   
9.2 Key findings and implications 
Inadequate RR-TB case detection 
There is considerable variation in RR-TB patient numbers diagnosed per year in Botswana suggesting 
inconsistent case detection. Based on current WHO estimates, it would be expected that 266 (13%) of the 2053 
previoulsy treated TB patients notified in 2013 and 2014 would have RR-TB; however the monitoring efforts 
described in this analysis only identified 36 patients.  It is possible that some of these ‘missed’ patients might 
have been identified later in their treatment, but this is a missed opportunity for early detection of drug 
resistance. To explore factors that may contribute to poor case detection and under-diagnosis, this research 
assessed monitoring for drug resistance among previously treated TB patients, a group at risk of RR-TB, notified 
in 2013 and 2014. Overall, there was a low rate of monitoring for drug resistance among previously treated TB 
patients in Botswana; only 42% of patients had samples submitted for culture and fewer still (19%) had DST 
conducted. Notably, only 43% of patients who had previous first-line TB treatment which failed had samples 
submitted for testing, and these patients may have been initiating a second round of ineffective treatment. 
Factors which were associated with lower monitoring for drug resistance included not having a smear test at the 
diagnosing facility, living in a rural area and having a treatment category of previous treatment success. A wide 
variation in sample submission rates was seen among health districts. However, spatial and district analysis 
unfortunately did not provide clarity into this variation among districts, and it appears that this is mainly 
affected by poor compliance with guidelines.  Although the focus of this analysis was on previously treated 
patients, the implications for failed case detection very likely expand to other at risk patients as well. 
While WHO recommends universal DST for all patients with signs and symptoms of TB, this is not implemented 
consistently in Botswana. The program has reported that they do now recommend universal DST with Xpert. 
However, the policy remains unclear and based on the most recent reports from WHO this is not yet being 
accomplished. The most recent 2017 TB country profile for Botswana indicated that only 5% of previously 
treated patients were monitored for RR-TB. Furthermore, many patients (interviewed in 2017) reported 
receiving one or more courses of first-line treatment before receiving any TB diagnostic tests including for drug 
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resistance, indicating this high-risk group (previously treated patients) are still not being screened early for drug 
resistance. 
There were frequent laboratory closures during the time of this analysis, and the qualitative interviews revealed 
this is an ongoing problem. Although the laboratory reopened in 2016, interviewed providers reported 
continuing challenges with reagent availability. Xpert capacity was also highlighted as a major challenge. 
Interviewed providers reported frequent stock-outs of testing cartridges and machines, which have not been 
calibrated.  
As a result of inadequate monitoring, TB patients with drug resistance are likely to remain undiagnosed. These 
patients may be detected with TB drug resistance during subsequent TB treatment episodes, but in the 
meantime they are likely to develop more severe disease, and remain infectious for longer117 possibly 
transmitting drug-resistant tuberculosis in the community and at the health centers where they are seeking 
care. However, many patients, particularly those with HIV infection are likely to die during TB treatment if their 
TB drug resistance remains undiagnosed.  
Poor confirmation of first- and second-line drug resistance patterns among patients initiating RR-TB treatment 
It is clear that Botswana is missing many patients due to inadequate monitoring.  For the patients who are 
identified, it is crucial to confirm the drug resistance profile to ensure effective treatment. This research 
assessed confirmation of drug resistance among the cohort of RR-TB patients registered between 2006 and 
2014. For patients initiating RR-TB treatment, the first-line drug resistance profile was confirmed for 85%, and 
this has remained consistent over time. There were 120 patients who received second-line treatment with no 
information about resistance available at any point during treatment. Second-line DST was available for few 
patients (24%) and has been impacted by changing practices (not sending samples to South Africa for testing) 
and no in-country laboratory capacity. Among those who were eventually diagnosed by laboratory tests to have 
Pre-XDR or XDR- TB, these confirmatory results were available a median of 118 days after treatment initiation, 
with a delay of more than one year for some patients.  
These findings further highlighted the effect of interrupted laboratory services and the inconsistencies in the 
national guidance about testing recommendations. The qualitative interviews identified concerns among 
providers that the introduction of Xpert had actually created an even larger gap in patients receiving culture 
testing and confirmatory DST. They reported that many fewer samples were now being sent to the NTRL for 
testing and that it appeared that the primary health care facilities were relying solely on Xpert and not seeking 
confirmatory testing as recommended.  
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As a result of inadequate monitoring among patients initiating second-line treatment in Botswana, many 
patients may have received ineffective second-line treatment, and patients with Pre-XDR or XDR-TB may have 
not been identified. For the patients who were identified with Pre-XDR or XDR-TB, the delay in diagnosis is 
concerning. Furthermore, because the specimen collection date was not available in the RR-TB registry, it is 
difficult to discern whether second-line resistance was present at treatment start or developed during 
treatment.  
Mortality during RR-TB treatment 
This research explored risk factors for mortality among patients on RR-TB treatment. Botswana has high 
treatment success but also has consistently high mortality during treatment. The analysis among patients 
initiating treatment between 2006 and 2014 in Botswana revealed independent factors associated with 
mortality, including older age, HIV positivity and not on ART at treatment initiation, unknown HIV status, smear 
positivity at treatment initiation, baseline radiology not recorded, registration category not recorded, unknown 
drug resistance profile (presumptive RR-TB), Pre-XDR or XDR-TB, treatment at Princess Marina Hospital or 
Sekgoma Memorial Hospital, and treatment between 2009-2011. The analysis of the 3 year subset (2012-2014) 
for which chart reviews were conducted also revealed associations with disease severity and risk of mortality.  
The results of the mortality analysis are related to the earlier findings about inadequate monitoring. Of all 
patients initiating second-line treatment described in the mortality analysis, 83% were reported as having had a 
result of treatment failure from previous first-line TB treatment. Many of these patients likely belonged to one 
of the high-risk groups (such as previously treated TB patients) and should have had monitoring for drug 
resistance sooner (before failing first-line treatment).  Patients on RR-TB treatment with an unknown drug 
resistance profile (presumptive RR-TB) were shown to have a higher risk of mortality. They are likely to have 
been diagnosed and started on second-line treatment after first-line treatment failure, indicating late diagnosis 
and possibly more severe disease; others may have been diagnosed as contacts of other RR-TB patients. 
Regardless, these are patients who did not have DST results available to guide treatment and may have received 
ineffective treatment. Additional factors associated with mortality pointed to potential poor clinical care, 
including missing clinical information (radiology, smear, etc.). 
Reducing delays to treatment initiation and treatment gap with decentralized testing using Xpert 
A systematic review and meta-analysis of time to treatment for RR-TB was conducted. This analysis showed that 
molecular testing methods (Xpert and LPA) led to faster time to treatment. Furthermore, ambulatory care has 
been shown to be effective and leads to similar treatment outcomes as compared to hospital-based treatment; 
this analysis reported shorter time to treatment among cohorts with ambulatory treatment, compared to 
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hospital-based treatment. The studies included in this systematic review did reveal that treatment delay is 
common, particularly among cohorts with hospital-based models of care as well as cohorts with phenotypic DST. 
While initiating treatment quickly is important, it is also important to ensure all diagnosed patients actually do 
make it on to treatment. In this analysis, several studies reported relatively rapid times to treatment (less than 
30 days), but still less than 70% of diagnosed patients starting treatment, a large treatment gap. 
Building upon this systematic review, this research also described Xpert use in Botswana in 2013-2014 and 
examined the impact of Xpert use on time to treatment. In regards to the treatment gap described in the 
systematic review, this analysis indicated that among patients diagnosed with RR-TB by Xpert in Botswana, 89% 
initiated second-line treatment. Xpert did reduce the time from diagnosis to treatment (median 5 days, IQR 2-
10), when compared to the NTRL cohort (patients initiating treatment based on testing conducted at the 
centralized laboratory, which was mainly using phenotypic DST) (median 22 days, IQR 14-36). Although the time 
from diagnosis to treatment is shorter for the Xpert cohort, neither cohort had extremely long delays in linkage 
to care once a diagnosis was available. This finding was confirmed in the qualitative interviews in which patients 
reported starting treatment quickly once they were diagnosed with RR-TB. The time from specimen collection to 
treatment was substantially shorter for the Xpert cohort (median ~15 days) compared to the NTRL cohort 
(median 105 days, IQR 85-126), using estimated times for the Xpert cohort as the specimen collection dates 
were not available. In regards to follow-up testing of RR-TB patients diagnosed by Xpert, 64% received 
confirmatory DST, which revealed that 26% of these patients with DST had RMR-TB. Confirmatory DST after 
Xpert diagnosis is important to confirm, not only rifampicin resistance, but also to confirm resistance to other 
drugs to guide appropriate treatment. Patients with RMR-TB are denied the use of isoniazid in their treatment 
regimen if they are placed on a standardized regimen.  
It is concerning that providers reported in the qualitative interviews that confirmatory testing has been 
decreasing in the country, attributed to sole reliance on Xpert. It is also disappointing that the successes shown 
in this research appear to not be maintained in subsequent years, given the most recent WHO report that few 
TB patients are being tested for rifampicin resistance. The qualitative interviews also revealed challenges with 
inconsistent Xpert capacity due to cartridge stock-outs and lack of calibration/maintenance for machines.  
Patient and provider experiences with RR-TB diagnosis and treatment 
It is unfortunately rare that patients are asked about their experiences with the care they receive, despite the 
recommendations to provide patient centered care. Patient perceptions and experiences should be an integral 
part of how programs operate. Both patients and providers were interviewed as part of this research to gain 
further insight into their personal experiences and in an attempt to understand some of the other findings in this 
research. This analysis highlighted some successes of the RR-TB program in Botswana. The providers interviewed 
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all showed compassion and care for the patients, and the patients confirmed this in their responses about their 
satisfaction with the care they received. There were no reports of gender-based discrimination. National policies 
are generally in line with global recommendations, and providers reported being satisfied with the support and 
training they receive.  
Despite these successes, many challenges were revealed. Although National policies are in line with global 
recommendations, there are issues with adherence to National guidelines. Furthermore, guidelines were not up 
to date and did not incorporate important new recommendations related to RR-TB care. A key finding of this 
analysis is that many patients are being hospitalized in Botswana for treatment initiation, up to three or four 
months; there appear to be misconceptions about transmission and need for hospitalization among both 
providers and patients. This analysis also confirmed delays to diagnosis, which had been highlighted or 
speculated about in other chapters. Some patients reported more than one course of first-line treatment failing 
before being tested for drug resistance. Patients reported seeking care multiple times and at multiple locations 
before being tested, and there were concerns from patients that contact tracing was not done consistently. The 
analysis also highlighted misunderstandings and likely lack of training at the primary care level, with health care 
workers not requesting appropriate diagnostic tests for patients. This analysis revealed a very concerning finding 
that drug stock-outs had been common; all patients and providers reported interrupted treatment for weeks 
due to drug stock-outs. Patients were also very concerned about side effects of medications, particularly hearing 
loss, and the results about side effects reported along with the mortality analysis (44% of patients with hearing 
loss) confirm this is a valid concern. Many challenges were identified, and patients and providers indicated that 
they think many of these challenges are due to lack of funding. 
The findings from this analysis highlight the need to focus attention away from less crucial and more expensive 
TB control practices such as hospitalization and prioritize case finding and safe, effective treatment without 
interruption. It is also crucial that guidelines are updated to reflect changing recommendations. It is a concern 
that the national guidelines are not up to date, and this potentially represents a lack of support from the 
leadership at the MoHW; updated guidelines for the management of drug-resistant tuberculosis have been 
drafted since 2017, but these have not yet been released because they have not yet been approved by MoHW 
leadership. The program is currently operating with guidelines produced in 2009, which do not include 
important updated global recommendations.  
Summary of key findings: 
• The impact of interrupted laboratory capacity is clearly highlighted in these analyses, affecting case 
detection and confirmation of drug resistance pattern. 
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• Factors contributing to mortality point to poor clinical care and/or misclassification of disease / 
exposure from missing information. 
• One particular problem in Botswana is high empiric second-line TB treatment and then a gap in those 
who received confirmatory drug resistance testing.  This is peculiar to this setting, and this data shows a 
deviation from national guidelines.  Of concern is that those without confirmed drug resistance profile 
appear to be at a higher risk of mortality.   
• A systematic review of factors influencing time to treatment provided a detailed overview of literature 
to date on the topic, providing new and complementary evidence that molecular diagnostic methods 
and ambulatory treatment/care models lead to faster time to treatment.   
• Inconsistent adherence to guidelines is highlighted in multiple analyses, impacting case detection, 
diagnostic confirmation and rapid linkage to care. 
• Xpert has been shown to reduce time to treatment in Botswana, as in other settings.  Challenges of 
effective Xpert implementation were clearly reflected in the qualitative findings (funding constraints, 
supply chain issues, lack of adherence to guidelines). 
• Qualitative findings further highlighted important and modifiable barriers to effective RR-TB diagnosis 
and treatment:  drug stock outs, inconsistent adherence to guidelines, unnecessary hospitalizations due 
to misperceptions among health care workers, and health system factors contributing to treatment 
delay (including patients with multiple first line treatment failures before being tested for drug 
resistance).   
9.3 Recommendations 
Before providing recommendations, it is important to recognize the successes of this program.  Among RR-TB 
patients who initiate treatment in Botswana, the success rate is very high (78%), especially for a country with a 
high HIV burden.  Furthermore, the lost to follow-up and treatment failure rates are impressively low (2% each) 
compared to other countries. The program has compassionate health care providers and national level staff who 
are very dedicated to the program and the RR-TB patients.    
It is a global priority to accelerate efforts to reach the goals set forth in WHO’s End TB Strategy, and a key area 
for action is multisectoral accountability. Important elements of multisectoral accountability include: 1) 
attention to TB at the level of Heads of State, at global and national levels; 2) engagement from ministers across 
government and beyond the Ministry of Health; 3) strong process for review and feedback on progress of a 
program; 4) engagement of civil society and media; 5) strengthened legislative framework; and 6) TB service 
delivery focused on the “three As”: affordability, availability and accessibility230. In this context, it’s extremely 
important to consider Botswana’s potential, the areas for needed improvement and what the country should be 
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accountable for. Given the country’s high economic standing as an upper middle-income country, Botswana 
should be able to address some of the challenges identified in this research. To accomplish this, it will be 
important to focus on all of the aforementioned elements, particularly the attention to TB at higher levels of 
government and across government, which appears to be lacking in Botswana currently.  
Many of the challenges revealed in this research were caused by lack of adherence to recommended guidelines. 
The research also highlighted inconsistencies in available guidelines, which were drastically out of date. It would 
be advisable for the program to develop more effective procedures for revising and endorsing guidelines. Global 
recommendations are currently updated much more frequently than they have been in the past, and Botswana 
should be able to quickly respond to innovation. Two examples of this are with the introduction of Xpert and 
with the use of new drugs. Xpert was first used in Botswana in 2012 through a pilot implementation study, and 
was also used for routine testing starting in 2012; however, the updated algorithm to include Xpert was not 
finalized and distributed until 2016. The use of Xpert has still not been incorporated into the available national 
guidelines (the 2011 TB Program Manual and the 2009 National Guidelines for Management of DR-TB). There 
have also been a number of new drugs and treatment recommendations since these national guidelines were 
developed. The country has actually moved away from routine use of amikacin, and most patents now receive 
capreomycin or bedaquiline instead of amikacin, but this is not reflected in current guidelines. Amikacin is still 
available for use in individualized regimens. It is important to not only respond to change quickly but also to 
translate that change into guidance to ensure this is implemented effectively in practice. The frequent updates 
will also require routine and repeated training to ensure adherence to guidelines.  
Another major challenge in this research is the frequent interruption in laboratory capacity. Not only have there 
been frequent closures at the central laboratory for renovations and stock-outs of reagents, Xpert use has also 
been interrupted due to stock-outs of cartridges and machines which are not calibrated or maintained. The 
successes of Xpert implementation highlighted in this research (reduced delays to treatment and a high 
proportion of diagnosed patients initiating treatment) do not seem to be maintained as of more recently. Given 
the most recent WHO report that only 5% of previously treated patients received testing for rifampicin 
resistance, it is unfortunately clear that Xpert is not being implemented effectively in Botswana.  
Challenges highlighted in this research include inadequate monitoring for drug resistance, low case detection, 
high mortality rates, delays to diagnosis and treatment and continued practices that are not patient centered 
such as hospitalization. Additional challenges included issues with missing important information about patients 
on treatment. Limitations in this research included missing important information needed for the analyses such 
as specimen collection dates. And more importantly, there was missing clinical information in the RR-TB register 
(radiology results, smear results, and information about monthly monitoring of patients on treatment). The 
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missing information may be a marker of poor clinical care. While the qualitative interviews did report that 
providers do have compassion and care for patients, they may be inadvertently providing poor clinical care by 
not adhering to recommended guidelines (of which they may not be aware since national guidelines are not 
updated).   
It is clear from this research that RR-TB case detection is low, and many patients do not make it onto treatment 
or suffer long delays before initiating treatment. The full scale of the problem is hard to estimate because there 
has not been a recent drug resistance survey in the country; the last survey is from 2008. It is advisable that the 
program conduct more frequent surveys to better understand the situation of RR-TB in the country, or this could 
be accomplished through universal DST, in turn providing ongoing resistance surveillance. Recommendations for 
the program include increased access to new TB drugs, earlier diagnosis, improvements in data reporting, 
universal DST for all TB patients, and routine monitoring for treatment failure and resistance acquisition during 
treatment. All of these recommendations will require disseminating updated guidance, clear education and 
routine monitoring and support to health facilities at all levels (from hospitals to mobile posts). None of this will 
be possible without increased national level support to shift priorities, to provide adequate funding, to improve 
communication and training to reverse misunderstandings and to integrate services across all levels of care. The 
time has come for Botswana to have a TB program commensurate with its positive standing in the global 
economic community.  
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Appendix A: BNTP Diagnositic Algorithm (2016) 
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Appendix B: Qualitative Questionnaires and Consents 
Questionnaire – MDR-TB Patients 
 
 Date of interview DD MM YY 
      
Interview location  
Interviewer name  Participant  ID number  
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Informed Consent – MDR-TB Patients (Flesch Kincaid Grade Level = 5.7) 
 Hello.  My name is                            ,  and I am working on a study to learn about and improve health care for MDR-TB patients.  Would you prefer conducting this interview in English or Setswana?  
Why is this study being done? We are doing this study to learn more about how people in Botswana find out if they have MDR-TB.  We also want to learn more about how people get the care they need when they have MDR-TB.  This study has been approved by research ethics committees at the Botswana Ministry of Health, the University of Cape Town in South Africa and the Centers for Disease Control (CDC).  All of these groups are involved in the study.    
Why are you being asked to take part in this study? You are being asked to take part in this study because you are a patient.  You have important information about how you found out that you have MDR-TB and how your care has been.  This information will help us learn about the health care issues for patients in Botswana.    
How many people will take part in this study? We will talk to 10-20 patients and will also talk to doctors and government workers.  
What will happen if you decide to take part in this study? We will ask you some questions about being a patient.  This will take about 30-45 minutes.  You do not have to answer every question.  If there are any questions that you do not want to answer, that is ok.  After we finish this survey, your participation will be finished.  We will not contact you again to answer more questions for this study.  
What are the risks of taking part in this study? You may find some of the questions hard to answer.  If any of the questions upset you, we will give you the names and phone numbers of people that you can talk to about this.   Also, it is possible that someone outside the study could see this data, but we will be very careful not to let this happen.  Your name will not be kept in the same place with this data, and all documents will be kept in locked areas at all times.  
Who will see the information that you provide during the study? First of all, we will not put your name on the survey so no one will know that you are the person giving these answers.  Also, only the people involved in the study will be able to see your answers.  These study staff have been trained to make sure the information is kept confidential.  We will keep this survey in a locked office and in a locked cabinet.  The consent form with your signature will not be kept with the survey so that no one can link you to your answers.   
Are there any benefits for being in the study? 
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There are no direct benefits from participating in this study.  The main benefit of participating is this study is that we will use what we learn to improve health care for people in Botswana.  So this may benefit you and would also benefit other patients in the future.  
What other choices do you have? If you do not want to be in the study, that is ok.  Participating in the study is voluntary. You can say no, and we will not ask you again.  Your choice will have no effect on the care that you receive.  If you say no, you will receive the same care.  
Who do you speak to (or contact) if you have questions or concerns about the study? This study is being done by people at the University of Cape Town in South Africa, the Botswana Ministry of Health and the Centers for Disease Control Botswana (CDC Botswana).   You can contact any of the following people for questions about the study or to discuss withdrawing from the study:  
1. Helen Cox, PhD      
       Lead Researcher           
       University of Cape Town          
       +27(0)21 650 1860            
 
2. Rosanna Boyd 
Local Researcher 
CDC Botswana 
367-2432 
 
You can contact the following people for questions about your rights as a participant in this study: 
 
3. Health Research Development Committee (HRDC) 
       Botswana Ministry of Health 
       363-2000 
 
4. Health Research Ethics Committee (HREC) 
       University of Cape Town 
       +27 (0) 21 406 6338  
What are the next steps? Please take your time to think about this and ask any questions you have.  You can ask as many questions as you like.   
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 The information that we get from this survey will be very important and useful.  We would like to tape record your answers to make sure that we do not miss anything that you say. We will keep your responses confidential by (1) not sharing this information with anyone not involved in the study (e.g., the media) and (2) not having your name mentioned on the recording (e.g. using a Participant ID Number). If you do not want for this to be recorded, we can do the interview without recording, it will just take more time so that no information is missed. 
 Do you agree to participate in this survey?       Yes        _No 
 Do you agree to have this interview recorded?        Yes        _No  Signature of participant: _______________________________________ (Please note this page with your signature will not be kept in the same place with your answers to the questions).     
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Patient Information: 1. Gender:   _____ Male         ______Female 2. Age:       ___________________ 3. Marital Status:   _______Single never married _______Single divorced _______Married _______Cohabitating _______Other: ________________________________________ 4. Number of people you live with:       _______ 5. Education level: _______ Advanced/college _______Primary _______Secondary _______No formal education _______Other: ________________________________________ 6. Occupation:_________________________________________ 7. Village: ____________________________________________ 8. Nationality: _________________________________________ 9. Patient status: _______ Inpatient _______Outpatient  
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Patient Knowledge/Attitude: 10. How do you think you got MDR-TB?  Probes: Before you got sick, did you know anyone else who had been sick or had TB?  11. Are people with MDR-TB discriminated against in the community?  Probes: Should people tell others?  Are certain people discriminated against more (i.e. men vs women)? b) Does anything worry you about having MDR-TB? Probes: Fear of job loss? Is your job waiting for you afterwards?  12. How did you feel when you found out you had MDR-TB? Probes:  Did you inform friends/family? Any relationships change?   Do you have children?  Were children or other family / friends screened for TB?  Outcome?  For inpatients:  Do any of your family or friends visit you here? 13. Women:  Do you need permission from husband, boyfriend or family to access health services?  Men:  Do women in the community need permission from husband, boyfriend or family to access health services?   
Access to MDR-TB Diagnosis and Treatment: 14. a) Do you have any challenges accessing / coming to this health facility? Probes: Distance, Transport availability and cost?, Easy to get an appointment? b) Do you ever use a different facility for getting treatment or care? Experience? Challenges? Probes: Distance, Transport availability and cost?, Easy to get an appointment? 15. a) Have you ever been hospitalized for MDR-TB? For how long? b) How do you compare receiving care in the hospital versus in the community/local clinic? Probes: Why?  Any challenges? 16. Please describe the process for your receiving and taking MDR-TB medication. What was the difference between taking your medication during hospitalization and when you come to the clinic? Probes: Where do you receive medication?  Meds always available? If no, explain. Who helps you remember to take meds? Any challenges?   
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Health Seeking Behavior: 17. Have you had TB before?   Probes: If yes, when? List all TB episodes. Please describe treatment (any problems, were you able to complete treatment?).   18. How long were you sick this time before seeking treatment? Probes:  What symptoms did you have?  If there was delay: Why? 
Estimation of delays: 19. How long (weeks or months) after seeking treatment did you hear that you have MDR-TB? Where (facility) did you hear you had MDR-TB? After hearing you had MDR-TB, how long (weeks or months) did it take to start treatment?  How could these delays be reduced, in your opinion? 
Sources of information: 20. Where do you receive most of your health information? Do you receive any health information from family/friends? Probe:  Had you heard about MDR-TB before you were diagnosed?  If yes, where/how 
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Patient Satisfaction/Feedback on Providers: 21. Please use the provided scale to answer the following questions: 
(Likert scale below to be provided on a separate card to patients) 
 
a 
Are the health care providers at the hospital supportive 
and respectful of people who have MDR-TB? 
1       2      3      4        5 
 
b 
If not, in your opinion, why not? 
 
 
 
c Are the health care providers at your local clinic 
supportive and respectful of people who have MDR-TB? 
1       2      3      4        5 
d If not, in your opinion, why not? 
 
 
 
 
 
 
e 
Before coming for diagnosis/ treatment, did you expect 
that the providers would be supportive and respectful of 
people who have MDR-TB? 
1       2      3      4        5 
 
f 
Have health care workers at this facility answered all of 
your questions concerning MDR-TB? 
1       2      3      4        5 
g 1) Are you satisfied with the schedule at the hospital? 1       2      3      4        5 
g 2) Are you satisfied with the schedule at your local clinic? 1       2      3      4        5 
h 1) Are you satisfied with the waiting time at the hospital? 1       2      3      4        5 
h 2) Are you satisfied with the waiting time at your local clinic? 1       2      3      4        5 
 
i 1) 
Are you satisfied with the availability of drugs at the 
hospital? 
1       2      3      4        5 
 
i 2) 
Are you satisfied with the availability of drugs at your local 
clinic? 
1       2      3      4        5 
 
j 1) 
Are you satisfied with your treatment partner/ DOTS 
supporter at the hospital? 
1       2      3      4        5 
 
j 2) 
Are you satisfied with your treatment partner/ DOTS 
supporter at your local clinic? 
1       2      3      4        5 
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         Questionnaire – Health Clinic Staff (Health Care Providers) 
 
 Date of interview DD MM YY       Interview location  Job Title/ Position  ID no.  
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Informed Consent – Health Clinic Staff (Health Care Providers) (Flesch-Kincaid Grade Level = 5.7) 
 Hello.  My name is                            ,  and I am working on a study to learn about and improve health care for MDR-TB patients.    
Why is this study being done? We are doing this study to learn more about how people in Botswana find out if they have MDR-TB.  We also want to learn more about how people get the care they need when they have MDR-TB.  This study has been approved by research ethics committees at the Botswana Ministry of Health, the University of Cape Town in South Africa and the Centers for Disease Control (CDC).  All of these groups are involved in the study.    
Why are you being asked to take part in this study? You are being asked to take part in this study because you are a health care provider.  You have important information about how people find out they have MDR-TB and about the linkage to health care.  This information will help us learn about the MDR-TB health care system in Botswana.  
How many people will take part in this study? We will talk to 5-10 health care providers and will also talk to patients and government workers.  
What will happen if you decide to take part in this study? We will ask you some questions about being a health care provider.  This will take about 30-45 minutes.  You do not have to answer every question.  If there are any questions that you do not want to answer, that is ok.  After we finish this survey, your participation will be finished.  We will not contact you again to answer more questions for this study.  
What are the risks of taking part in this study? You may find some of the questions hard to answer.  If any of the questions upset you, we will give you the names and phone numbers of people that you can talk to about this.  Also, it is possible that someone outside the study could see this data, but we will be very careful not to let this happen.  Your name will not be kept in the same place with this data, and all documents will be kept in locked areas at all times.   
Who will see the information that you provide during the study? First of all, we will not put your name on the survey so no one will know that you are the person giving these answers.  Also, only the people involved in the study will be able to see your answers.  These study staff have been trained to make sure the information is kept confidential.  We will keep this survey in a locked office and in a locked cabinet.  The consent form with your signature will not be kept with the survey so that no one can link you to your answers.   
Are there any benefits for being in the study? 
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There are no direct benefits from participating in this study.  The main benefit of participating is this study is that we will share what we learn with the Ministry of Health.  So this may benefit you by increasing understanding of the issues and improving health care services.  
What other choices do you have? If you do not want to be in the study, that is ok.  Participating in the study is voluntary. You can say no, and we will not ask you again.  Your choice will have no effect on your job.  Your employer will not know if you have participated or not.    
Who do you speak to (or contact) if you have questions or concerns about the study? This study is being done by people at the University of Cape Town in South Africa, the Botswana Ministry of Health and the Centers for Disease Control Botswana (CDC Botswana).   You can contact any of the following people for questions about the study or to discuss withdrawing from the study:  
1. Helen Cox, PhD      
       Lead Researcher           
       University of Cape Town          
       +27(0)21 650 1860            
 
2. Rosanna Boyd 
Local Researcher 
CDC Botswana/University of Cape Town 
367-2432 
 
You can contact the following people for questions about your rights as a participant in this study: 
 
3. Health Research Development Committee (HRDC) 
       Botswana Ministry of Health 
       363-2000 
 
4. Health Research Ethics Committee (HREC) 
       University of Cape Town 
       +27 (0) 21 406 6338  
What are the next steps? Please take your time to think about this and ask any questions you have.  You can ask as many questions as you like.   
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 The information that we get from this survey will be very important and useful.  We would like to tape record your answers to make sure that we do not miss anything that you say. We will keep your responses confidential by (1) not sharing this information with anyone not involved in the study (e.g., the media) and (2) not having your name mentioned on the recording (e.g. using a Participant ID Number). If you do not want for this to be recorded, we can do the interview without recording, it will just take more time so that no information is missed. 
  Do you agree to participate in this survey?       Yes        _No 
 Do you agree to have this interview recorded?        Yes        _No  Signature of participant: _______________________________________ (Please note this page with your signature will not be kept in the same place with your answers to the questions). 
  
195 
 
Health Clinic – General 
 
1. What is the average distance that people travel to come to this facility? 
Probes:  What is the furthest distance people travel?  How do people travel? 
 
 
2. What days of the week is the clinic open and seeing confirmed or presumptive TB/MDR-TB patients? 
 
 
3.  How many cases of MDR-TB are diagnosed per month at the clinic?  How many are currently on 
treatment at the clinic? (Hospital vs Ambulatory) 
 
 
4. Do you think that people in this district have good access to MDR-TB services?  Do you think overall in the 
country that people have good access to MDR-TB services.   Please explain. 
 
 
 
Capacity Building 
 
5. Do you treat patients with MDR-TB? 
Probe:  If yes, did you receive any training on MDR-TB?  If yes, how often?  Adequate? 
 
 
6. Do you have guidelines on the management of MDR-TB available in the facility? 
Probe:  If you have questions about a case, who do you call? 
 
7. Do you have a TB focal person in the facility? 
 
 
Diagnosis and Treatment (Access, Delays) 
 
8. Is this facility a reference center for MDR-TB suspects?  If yes, from where do you receive referrals?   
 
 
9. On average, how long are MDR-TB patients symptomatic before they present to the clinic to be 
screened? (days, weeks, months) 
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10. On average, how long does it take to diagnose a symptomatic patient with MDR-TB in this facility?  (days, 
weeks, months) 
Probe: Where are samples sent?  How do you receive the results? 
 
a) How long does it take to have AFB culture results? 
 
b) How long does it take to have DST results? 
 
c) How long does it take to have Gene Xpert results (if applicable) 
11. Do you think there are overall delays for MDR patients to start treatment?  Is it common for patients to 
experience delays?  What do you think are the main reasons for delay?   
 
12. How often are samples sent from the health facility to the NTRL for testing?   
Probes:  are specimen refrigerated if collection takes more than 24 hours?  Any challenges? 
 
 
13. When was Xpert installed in the district?  How is it going?  Any interruption in use of the machine?  What 
is done when you receive a RR+ from Xpert? 
 
 
14. What do you think are the effects of using Xpert in the districts? 
Probes:  Numbers of people diagnosed, time to diagnosis, time to treatment?  Any concerns?  Reagent 
availability?   
 
 
15. In your opinion, are lab services in the districts adequate?  What is needed? 
 
   
16. What is the average time taken from getting MDR-TB diagnostic results to starting patient on treatment?  
(days, weeks, months).   
Probe:  How are patients notified of results?   
 
 
17. When is empiric treatment given?  How often?  Who makes that decision?   
 
 
18. Do you have second line drugs available to treat MDR-TB?   
Probe:  Has the facility/district experienced any shortages of MDR-TB drugs in the past year?  If yes, for 
how long?  Why?  Did it result in treatment interruption? 
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19. Where do most patients receive MDR-TB treatment throughout course of treatment (hospital vs. home)?  
Any challenges? 
 
 
20. Do you ever receive results for patients that are diagnosed with MDR-TB and then they do not start 
treatments?  How often (per month)?  What are the reasons for that?  (able to contact, refusal) 
 
 
 
 
21. Who do you think is most vulnerable for MDR-TB?  Are vulnerable groups for MDR-TB being identified? 
Probe: Are the groups being actively approached for TB/MDR-TB screening?  Describe. 
 
 
22. Is active case finding conducted for MDR-TB diagnosis?  In which circumstances is active case finding 
conducted?  Please describe.  Are family members of diagnosed patients routinely screened?  Describe 
this process?  Is it done consistently per recommendations?   
 
 
 
23. In general, what are the major challenges in diagnosing and treating TB? 
 
 
 
 
Patient education and support 
 
 
24. Does this facility offer education and counseling for MDR-TB patients?   
 
Probe: If yes, please describe.  What topics are covered?  Who provides these services? 
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25. When most MDR-TB patients first come to the facility, do they have knowledge about MDR-TB? 
Probe:  Is the knowledge complete/correct?   
 
 
 
 
26. Are there support groups for MDR-TB patients?  If yes, please describe. 
 
 
 
 
27. Are MDR-TB services free of charge for all patients? 
Do MDR-TB patients receive food/nutrition support? 
Do MDR-TB patients receive transportation or financial support for transportation? 
 
 
 
 
28.  Overall, do you think that there is anything that can be done to improve MDR-TB diagnosis and 
treatment in Botswana?  Explain.   
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Appendix C:  Systematic Review Protocol and Study Screening Form 
Protocol: Systematic review and meta-analysis, time to treatment for RR-TB patients 
Primary objective:  
• To assess and summarize studies that report on time to treatment for patients diagnosed with 
rifampicin-resistant tuberculosis in resource limited settings between 2000 – 2015. 
Potential secondary objectives: 
• To describe common factors influencing time to treatment 
• To describe different diagnostic methods’ effect on time to treatment (culture, Xpert, etc) 
Types of studies:  
All study types will be considered; case reports of less than 10 patients will be excluded. Study design will be 
recorded for sub-analysis. 
Inclusion criteria: 
• Any studies that report time from diagnosis (however defined) to treatment initiation 
Exclusion criteria: 
• Case reports 
• Studies whose quality of data is deemed unacceptable (see quality assessment section) 
• Studies with small sample size (less than 10 persons) 
Search strategy: 
A standardized search strategy will be designed to generate a comprehensive list of relevant literature from 
PUBMED. The search will include a combination of key words: 
1. Tuberculosis 
2. drug-resistant  
3. multidrug-resistant 
4. rifampicin-resistance 
5. rifampin-resistance 
6. MDR-TB 
7. treatment 
8. time 
9. delay 
10. outcomes 
Search strings:  
 
• ((((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR "resistant" 
OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND time  
• ((((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR "resistant" 
OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND delay   
• (((("tuberculosis" OR "TB"))) AND (("MDR" OR "drug-resistant" OR "multidrug-resistant" OR "resistant" 
OR "rifampicin resistant" OR "rifampin resistant"))) AND treatment) AND outcomes  
 
Secondary references from selected studies will be reviewed to identify publications not captured by the 
electronic search. Additionally, authors of selected publications may be contacted for clarification or to further 
stratify already reported data.  
Two independent searches will be conducted by two reviewers, each evaluating titles, abstracts and full text 
articles. Both reviewers will review all titles and abstracts, using the study selection form (Appendix A). The full 
text articles will be reviewed for all potentially eligible articles based on the initial review of titles and abstracts. 
The reviewers will divide the full text articles, each reviewing 60% for 10% overlap.  
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Data extraction:  
Data abstraction forms will be used during the initial review of titles and abstracts for eligibility. For the full text 
review, a database will be developed to capture all relevant variables. Each reviewer will complete the data 
abstraction forms and database individually and then comparisons will be made and data will be combined for 
final analysis.  
Quality Assessment:  
Study quality will be assessed by reviewing the study methodology, availability of adequate data for inclusion 
and primary outcome of the study.   
Data analysis:  
Data will be combined, cleaned and analyzed using Microsoft Excel and SAS, STATA and/or SPSS. The objectives 
will each be analyzed separately.  
Variables: 
List of potential variables to be captured: 
• Title 
• Author 
• Publication Year 
• Study Year(s) 
• Country 
• Study Design 
o Prospective or retrospective or both 
o Routine setting or research setting 
o Cohort , Case series, Case control, Randomized control studies… 
• Sampling method 
• Sample size 
• Study population / Patient Characteristics 
o Age 
o Gender 
o HIV status 
o MDR classification (for example if they are only looking at previously treated cases, etc. – 
probably unlikely) 
o DR profile 
o Special population (prisoners, etc.) 
• Diagnostic testing method (s) 
• Patient outcomes 
o Time to culture conversion 
o Treatment success 
o Death rate 
• How the study calculated time to treatment (from first patient visit, from date of sputum collection, 
from date of result received) 
• MDR rate/burden in the study setting 
• Model of care for DR-TB treatment in setting (ie. centralized, specialist hospital vs ambulatory, 
decentralized) 
• Laboratory setting (TB/MDR diagnosis centralized or decentralized) 
• Eligible study (Yes or No) 
• Time from diagnosis (however defined) to treatment start (median, mean, range, IQR) 
• Treatment regimen (standardized or individualized) 
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Study Screening Form 
 
First Author’s last name ____________________________________ 
Journal ______________________________________________   
Publication Year _________  Volume_____    Issue_______   Pages___________ 
Step One: 
Determine whether the article meets all of the eligibility criteria. Circle the response. 
1. Does the study population include RR-TB patients?       YES      NO 
 
2. Does the study report on time to treatment initiation?    YES   NO 
 
3. Is the study population 10 persons or more?     YES   NO 
 
If the study did not meet all three study criteria (if you answered no to 1 or more questions above) STOP HERE. 
If the study did meet all three study criteria (if you answered yes to ALL questions above) please proceed to the 
full text review using the Systematic Review Database Excel form.  
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